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ABSTRACT 
Schizophrenia is a common, complex disease with a substantial genetic component and 
an estimated heritability of 80%. The molecular pathology underpinning its genetic 
susceptibility is largely unknown. The recent genome-wide association studies (GWAS) 
have revealed common and rare genetic polymorphisms robustly associated with 
schizophrenia, giving a great boost to the field. A major challenge, which is essential for 
these findings to be translated into novel treatments, is to elucidate the biological 
mechanisms by which these genetic variants alter gene function and biological networks, 
the downstream effects on brain function and in turn disease risk. The main aim of this 
thesis was to characterize the molecular and cellular mechanisms by which genetic 
variation in the loci containing the transcription factor 4 (TCF4) and vaccinia-related 
kinase 2 (VRK2) genes confer susceptibility to schizophrenia. The work presented in this 
thesis can be divided into three main modules: i) a bioinformatic module used to gather 
information from public database to complement our current knowledge and highlight 
areas of interest for further investigation; ii) knockdown of VRK2 and TCF4 mRNA in a 
neuronal progenitor cell line; and iii) assay of relative allelic expression of VRK2. 
 
The findings presented in this thesis provide experimental evidence for the biological 
effect of TCF4 and VRK2 on cell proliferation in human neural progenitor cells in vitro, 
indicating this as a possible mechanism underlying the influence of these genetic variants 
on the pathology of schizophrenia. Additionally, allelic expression analyses revealed an 
effect of genotype at rs2312147 on VRK2 allelic expression in foetal samples suggesting 
a molecular risk mechanism for schizophrenia operating during early brain development, 
long before the evident appearance of the disease. 
 
The result presented in this thesis support the idea that schizophrenia is in part a 
neurodevelopmental disorder and provides new insight for molecular mechanism 
underlying the pathology of the disease. 
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Chapter 1  General Introduction 
 
1.1 Introduction 
Schizophrenia is a complex disease with a strong genetic component. Recent genome-
wide genetic association (GWA) studies have revealed a number of discrete genomic 
regions harbouring common, low risk schizophrenia susceptibility alleles. However, these 
susceptibility alleles so far only explain a relatively small proportion of the population risk 
and its genetic component, although this is expected to change as samples sizes and 
power increase. A number of rare susceptibility variants of moderate effect, including 
copy number variants and point mutations, have also been identified. In order to translate 
these genetic findings into clinical practice, disease susceptibility alleles have to be 
understood in terms of the biological mechanisms mediating their risk. This is currently 
the greatest challenge faced after identifying a disease locus. Although a great effort 
have been made in trying to understand the epidemiology and neuropsychology of 
schizophrenia, there is still little knowledge about the molecular pathology underlying the 
disease. 
 
My project started from two loci with compelling statistical evidence of association with 
schizophrenia from GWA studies and I sought to use molecular and cellular biology to 
further our biological understanding of the associated genetic variants and their putative 
effector genes. The project focused on loci containing transcription factor 4 (TCF4) and 
vaccinia-related kinase 2 (VRK2) genes. Here I describe two pieces of evidence. Firstly, 
the cis-regulatory effect of the risk allele on the expression of VRK2, and, secondly, the 
cellular phenotype produced upon knockdown of VRK2 or TCF4 on neuronal progenitor 
cells. My results show that both genes are involved in regulating neuronal progenitor cell 
proliferation and that VRK2 has complex cis-regulatory effects involving genetic variants 
in addition to the risk allele. These results, especially those related to cell proliferation, 
bear important implications to our understanding of schizophrenia, which I discuss 
throughout my thesis. 
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1.2 Schizophrenia 
Schizophrenia (MIM 181500) is a severe, long-term and common psychiatric disorder 
which is ranked in the top 10 causes of disability worldwide (Whiteford et al., 2013). The 
onset of symptoms typically occurs in early adulthood before the age of 25 (Lewis and 
Lieberman, 2000). The incidence rate of schizophrenia varies (Dixon et al., 2007a) 
between 7.7 and 43.0 per 100,000 (McGrath et al., 2008), incidence in England from 
1950-2009 was 15 people per 100 000 per year (Kirkbride et al., 2012), with a lifetime 
prevalence of schizophrenia estimated to be 0.4% (Saha et al., 2005). 
 
Schizophrenia imposes a large financial cost to the health system and to society, due to 
its early onset, severity and chronic nature. Individuals with schizophrenia have a life 
expectancy 12 to 15 years shorter as a result of higher suicide rate and ill physical health 
(Crump et al., 2013; van Os and Kapur, 2009). Common comorbidity with other 
psychiatric disorders includes depression, anxiety and substance abuse, the latter with a 
lifetime occurrence of 50% (Buckley et al., 2009). 
 
Due to the absence of physical biomarkers the diagnosis of schizophrenia is based on 
the presence of behavioural symptoms and is made by reference to the criteria in the 
fourth edition of the American Psychiatric Association’s Diagnostic and Statistical Manual 
(DSM-IV) (A.P. Association, 2000) and the International Classification of disease (ICD-
10).  
 
The disease is characterised by a range of psychological symptoms that are commonly 
divided into three main categories: i) psychotic or ‘positive’ symptoms such as auditory 
hallucinations, delusions, and thought disorder; ii) deficit or ‘negative’ symptoms including 
severe disturbances in social interactions and expression of affect, loss of motivation, 
inability to experience pleasure, poverty of speech and lack of interest and initiative; iii) 
cognitive dysfunction affecting attention, working memory, and executive and intellectual 
function (Andreasen, 1995; Tamminga and Holcomb, 2005). 
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The main treatments for schizophrenia are antipsychotic drugs, which have affinity for a 
number of neurotransmitter receptors in the brain. The common mechanism of action is 
blockade of Dopamine D2 receptors (Creese et al., 1976; Seeman et al., 1975), which 
remain sufficient and necessary for antipsychotic efficacy. Although, antipsychotic are 
largely effective in treating the positive symptoms, they are unsuccessful for treating 
negative and cognitive symptoms, which are more persistent. Additionally, antipsychotics 
drugs have undesirable side effects, such as motor symptoms and weight gain.  
 
A better understanding of the aetiology and molecular pathophysiology of schizophrenia 
has the potential to enable the development of better treatments that address the 
underlying neurobiology of schizophrenia. 
 
1.3 The neurobiology of schizophrenia 
The aetiology and pathophysiology of schizophrenia remain largely elusive. However 
there is evidence for neuropathological, neurochemical as well as structural and 
functional disturbances in the brain of schizophrenic patients.  
 
Several findings from neuroimaging, neuropathology and neurochemistry studies have 
reproducibly showed association with the disease.  
 
1.3.1 Neuroimaging 
Structural neuroimaging studies have shown structural brain abnormalities in 
schizophrenia patients compared with controls, including enlarged ventricles and an 
overall reduction by ~3% of the whole brain volume, with more pronounced reductions in 
the temporal lobe (Shepherd et al., 2012). The presence of these abnormalities at the 
onset of the disease is consistent with the neurodevelopmental hypothesis of the disease 
(Weinberger, 1987). 
 
Functional imaging studies have been used to study brain regions that may be 
dysfunctional in schizophrenic patients. These studies are used to measure the activity of 
Chapter 1: General Introduction 
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the brain under different conditions; for example, comparing patients and controls at rest 
or during cognitive tasks, or correlating brain activity with psychiatric symptoms across 
patients or within a patient over time (Fu and McGuire, 1999). A reduced activation of the 
prefrontal cortex and temporal lobe appears to be the most consistent finding in 
schizophrenia (Ragland et al., 2007). The many studies conducted in this area to date 
suggest that the observed abnormal function observed in schizophrenic is related to 
abnormal function in a network of brain regions and might be correlated with structural 
abnormalities, regional connectivity and symptoms clusters (Niznikiewicz, 2003). 
 
1.3.2 Neuropathology 
Neuropathological studies conducted in post-mortem brain from schizophrenic patients 
have identified subtle cytoarchitectural alterations in the prefrontal cortex and 
hippocampus (Harrison, 1999). Selemon and colleagues (Selemon and Goldman-Rakic, 
1999) described an increased density of pyramidal cells in the prefrontal cortex without 
neuronal loss. This alteration could be attributable to a reduction in the neuropil 
(interneural space) or to a decrease in somal volume and in dendritic spines observed in 
schizophrenic patients (Black et al., 2004; Guidotti et al., 2000; Lewis et al., 2003b; 
Selemon and Goldman-Rakic, 1999). 
 
Additionally, studies have shown that the numbers of GABAergic cortical interneurons are 
reduced in schizophrenia (Benes, 1993). This correlates with findings showing reduced 
levels of mRNA and protein of glutamic acid decarboxylase (GAD) 67; the principal 
synthesizing enzyme for GABA in the cortex (Akbarian et al., 1995; Guidotti et al., 2000; 
Volk et al., 2000). The reduction of GAD67 is also associated with decreased levels of 
mRNA of other genes expressed in GABA neurons such as reelin (Impagnatiello et al., 
1998) and parvalbumin (Beasley and Reynolds, 1997). Alteration in the GABA system 
might explain the abnormal activity observed in the frontal cortex in neuroimaging studies 
of schizophrenia patients as well as the neuronal connectivity impairment associated with 
schizophrenia. 
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Additional neuropathological studies have shown an abnormal expression of genes 
associated with process of myelination (Hakak et al., 2001) and a reduction in the number 
of oligodendrocytes in schizophrenia (Byne et al., 2006; Vostrikov et al., 2007). 
Neuropathological findings have promoted the view of schizophrenia as a disorder of 
connectivity and of the synapse as well as supporting the neurodevelopmental hypothesis 
of schizophrenia (see section 1.4) 
 
1.3.3 Neurochemistry 
The neurochemical hypotheses of schizophrenia spawned from observations that some 
psychotropic drugs, such as amphetamine, phencyclidine or lysergic acid diethylamide 
(LSD), have the ability to induce or mimic in normal individuals the psychotic symptoms 
observed in schizophrenic patients, while antipsychotic drugs ameliorate these 
symptoms. These observations lead to the investigation of altered neurotransmitter 
systems in schizophrenia.  
 
The dopamine hypothesis postulates that psychotic symptoms of schizophrenia are due 
to a hyperactivity of the dopaminergic system (Howes and Kapur, 2009). This hypothesis 
originated from observations that antipsychotic drugs are dopamine (D2) receptors 
antagonists (Creese et al., 1976; Seeman et al., 1975) and that psychotic symptoms can 
be generated by dopamine releasing agents such as amphetamines (P.H., 1958). 
Evidence from positron-emission tomography (PET) studies have shown an elevated 
density of D2 receptors in the striatum in schizophrenic patients as well as elevated 
DOPA decarboxylase activity (Joyce and Meador-Woodruff, 1997; Laruelle, 1998). These 
studies have also shown elevated sub-cortical dopamine release in schizophrenia and 
confirmed the blockade of D2 receptors by antipsychotics drugs (Breier et al., 1997; 
Frankle and Laruelle, 2002; Laruelle, 1998; Laruelle et al., 1996).  
 
The glutamate hypothesis was driven by findings showing antagonists of the NMDA (N-
methyl-D-aspartate) receptor, such as phencyclidine and ketamine, are capable of 
inducing psychotic-like symptoms similar to those observed in schizophrenic patients 
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(Halberstadt, 1995; Javitt and Zukin, 1991; Lahti et al., 1995; Olney et al., 1999). 
Glutamatergic anomalies such as altered expression of glutamate receptor subunits and 
binding sites have been detected in post-mortem brain of schizophrenics patients 
(Beneyto et al., 2007; Eastwood and Harrison, 2010; Oni-Orisan et al., 2008) suggesting 
a role for glutamatergic pathways in schizophrenia pathology.  
 
There is evidence for abnormalities involving a wide variety of additional neurochemical 
systems, for example GABA, serotonin or norepinephrine. Those together with the above 
described form complex circuits that converge in neurochemical pathways involved the 
neuropathology of schizophrenia (Carlsson et al., 2001; Lieberman and Koreen, 1993; 
Tost and Meyer-Lindenberg, 2011).  
 
 
1.4 The neurodevelopmental hypothesis of schizophrenia 
The neurodevelopmental hypothesis of schizophrenia postulates that this disorder owes 
its origins to pathological processes happening early in life before the onset of the 
disease (Weinberger, 1987). Neurodevelopmental hypotheses centre on two potential 
susceptibility periods: the prenatal period and adolescence/early adulthood. In both 
periods, important developmental brain processes and maturation of areas functionally 
associated with the disease are occurring. The neurodevelopmental hypothesis is 
supported by several pieces of evidence provided by neuropathological, epidemiological 
and clinical studies (Fatemi and Folsom, 2009). As stated in section 1.3.1, the presence 
of neuroanatomical deviations at the onset of the disorder is considered to be a key piece 
of evidence in favour of the neurodevelopmental hypothesis. In addition, cytoarchitectural 
features such as reduced synaptic markers as well as the lack of classic 
neurodegenerative changes in the brains of patients with schizophrenia are consistent 
with a neurodevelopmental origin to the disorder (Harrison, 1997). Epidemiological 
studies have provided indirect evidence for association between obstetric complication, 
such as gestational diabetes, preeclampsia, abnormal fetal growth and development and 
complications of delivery, with an increased risk of schizophrenia (Clarke et al., 2006). 
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Furthermore, maternal malnutrition and infection during pregnancy is also associated with 
an increased risk of schizophrenia in offspring (Brown and Patterson, 2011; Brown et al., 
1996). Other studies have found that adults who become schizophrenic have a high 
incidence of deficits in cognition, motor skill, attention, and verbal memory as children 
(Chua and Murray, 1996; Erlenmeyer-Kimling et al., 2000; Walker et al., 1996). 
Schizophrenic patients also show an increased occurrence of minor physical and cerebral 
anomalies, suggesting disturbed intrauterine developments (Lawrie, 2001). Recently, 
neurons derived from induced pluripotent stem cells (iPSCs) of patients with 
schizophrenia have been shown to display altered development of synaptic connections 
(Brennand et al., 2011).   
 
 
1.5 Genetics of schizophrenia 
Genetic epidemiology studies have consistently shown a strong genetic component with 
an estimated heritability around 80% (Cardno et al., 2002; van Os and Kapur, 2009). 
Family studies have found a higher risk for schizophrenia in first-degree relatives of 
individuals with the disorder (3-15%) than in the general population (0.5-1%) (Shih et al., 
2004). The concordance rate for schizophrenia in monozygotic twins is estimated at 45-
75% and 4-15% for dizygotic twins (Lichtermann et al., 2000). However, our knowledge of 
the underlying aetiology and the precise genetic architecture of the disorder, which gives 
rise to these high heritability estimates, remain very incomplete. Schizophrenia is thought 
to be a complex disorder which involves multiple genetic variants, including common 
polymorphisms of small effect-size and rare mutations of moderate to large effects 
(Figure 1.1), environmental and epigenetics factors (Cannon et al., 2002; McGrath et al., 
2010; Pidsley and Mill, 2011; Rujescu and Collier, 2009; St Clair et al., 2005).  
 
The first attempts to identify risk alleles for schizophrenia were through linkage analyses 
in multiple affected families or affected sibling pairs. Linkage studies are powerful tools to 
detect loci which have high penetrance, especially those following Mendelian inheritance, 
and were very successful in identifying genes for diseases such as Huntington’s and 
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cystic fibrosis. However, they have low statistical power to detect genetic variants of small 
effect-sizes, which have very low penetrance and are therefore often transmitted between 
unaffected individuals (Risch and Merikangas, 1996). The second parallel approach 
involved candidate gene association studies. They focused on analysing genetic variation 
within and around genes proposed as good candidates based on their known biological 
function. This study design is better in identifying common variants with small to large 
effect sizes (depending on sample size used). Both strategies produced many putative 
disease loci but few had robust evidence for replication, suggesting that large effect 
variants exists but are largely private to individual families, presence of allelic 
heterogeneity (multiple risk alleles on same gene) and the absence of common variants 
of large effect (leading to false positives in small sample size studies). 
 
Due to technological advancements in the field of genetics (the systematic identification 
of genome-wide genetic variation) and the development of new microarray technologies 
allowing large scale, low cost genotyping, systematic genome-wide association studies 
(GWAS) of common genetic variation in large cohorts became possible. GWAS has shed 
more light on the role of common variation in the genetic architecture of schizophrenia 
and have provided robust evidence for association with multiple loci. It has consistently 
shown that common variants conferring risk to schizophrenia do not have large effects 
and that large sample sizes, in the order of tens or hundred of thousands of individuals, 
are needed to identify risk loci robustly. Genetic studies in families or large population 
cohorts have also shown that rare variation can have large effects and represents a 
major part of genetic susceptibility to schizophrenia. Currently, large scale studies based 
on DNA sequencing studies are being performed to better quantify the effects of rare 
variation.  
 
I will briefly review the main findings from linkage, candidate genes and GWAS. This 
does not aim to be a comprehensive review but to summarise the most important 
genetics findings to date in schizophrenia. 
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control samples and, of vital importance, follow-up
analyses in even larger samples. GWAs incorporate the
merits of the association design (power to detect small
effects) with those of the positional genetics design (no
requirement for specific knowledge of pathogenesis). For
many common diseases, GWAs have transformed our
knowledge of genetic susceptibility by identifying com-
mon alleles (minor allele frequency>0.01) of small effect
(OR < 1.3) [7] (Figure 1). Early GWAs of schizophrenia
suggest similar gains might accrue and these studies are
the first focus of this review.
The success of GWAs is based upon the assumption that
risk of disease depends, at least in part, on alleles which are
sufficiently common to be detected indirectly by linkage
disequilibrium with neighbouring markers, the so-called
common-disease-common-variant (CDCV) hypothesis. As
we have seen, it is likely that risk of common disease,
including psychiatric disorders, reflects both the CDCV
and the operation of some rarer variants with relatively
higher penetrance. Whilst the success of linkage-based
approaches to common diseases was limited in detecting
alleles of this latter kind, probably because of non-allelic
heterogeneity, the advent of new array-based technology
has allowed researchers to conduct genome-wide studies of
at least oneclass of relatively uncommonvariant, submicro-
scopic chromosomal abnormalities often referred to as copy
number variations (CNVs), and to obtainevidence that that
these confer high risk of psychiatric disorders (Figure 1).
These studies are the second focus of this review.
Genome-wide association studies
There have been six published GWAs of schizophrenia,
three of which were based upon genotyping pooled DNA
samples including one which was limited to non-synon-
ymous SNPs. In the first study based on individual
genotyping (178 cases and 144 controls), the authors
reported only the strongest result (P = 3.7 ! 10"7) which
was located equidistant (#350 kb) from two genes, colony
stimulating factor 2 receptor alpha (CSF2RA) and short
stature homeobox isoform b (SHOX) [9]. CSF2RA is a sub-
unit of a cytokine receptor which regulates granulocytes
and macrophages whilst SHOX is a putative transcription
factor deleted in some people with short stature. The
authors targeted for sequencing CSF2RA and the neigh-
bouring interleukin 3 receptor alpha (IL3RA) in a second
small sample (71 cases and 31 controls). A number of
significant associations were observed across the two
genes, but to what extent these relate to the findings
from the GWAs stage is unclear. A priori, replication in
such a small sample would seem extremely unlikely
unless the effect sizes are much larger that in a typical
complex disease locus.
The second GWAs with individual genotypes [10] was
larger (738 cases/733 controls) but none of the findings
achieved genome-wide significance (P = 5 ! 10"8) [11]
and in the absence of follow-up data it is impossible to
draw conclusions regarding any specific locus. It may be
relevant that the sample was ethnically heterogeneous,
which may have adversely impacted upon power.
The only other study published with individual geno-
types [12$$] was based upon initial GWAs of 479 UK
cases and 2937 UK controls, with sequential follow-up of
loci surpassing a threshold P < 10"5 in up to 6829 cases
and 9897 controls. Of 12 loci followed up, strong support
(P < 5 ! 10"4) was observed for three, whilst another
Schizophrenia Owen, O’Donovan and Michael J 267
Figure 1
The frequency and penetrance of risk alleles determines whether they can be detected by current genetic studies. Uncommon and rare mutations will
become increasing tractable as high-throughput sequencing become more available, with limits imposed by the size of available samples, risk allele
frequency and penetrance.
www.sciencedirect.com Current Opinion in Genetics & Development 2009, 19:266–270
 
Figure 1.1 Schematic representat on of current genetic findings in schizophrenia. 
The frequency and penetrance of risk alleles determine which methodology can be used to detect 
them. Common variants with small effect size associated with schizophrenia have been identified 
through GWAS studies, while uncommon and rare mutations of large effect such as CNVs, can be 
identified by sequenci g (taken from Owe  et al., (Owen e  al., 2009)). 
 
 
1.5.1 Genetics studies  
1.5.1.1 Linkage 
In linkage studies, families with at least two affected individuals are analysed to identify 
the co-segregation of a chromosomal region with the disease phenotype (Lander and 
Schork, 1994). The linkage study design provides statistical power to detect risk allel s of 
large effect, usually associated with Mendelian disorders or M ndelian forms of complex 
traits (Lander and S hork, 1994) (Figure 1.1). Linkag  regions can be many megabases 
in sizes and contain dozens of genes, making difficult the identification of the gene or 
genes responsible for the phenotype (Altshuler et al., 2008; Lander and Schork, 1994). 
Mapping is dependent on the identification of recombination events within linkage 
regions, which can narrow the candidate region to a smaller number of genes which can 
then be sequenced to identify causative mutations. 
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Linkage results in schizophrenia have shown poor replication success. To date, over 20 
genome-wide linkage studies have been completed, implicating a large number of 
putative schizophrenia susceptibility loci. Three meta-analyses have been performed 
showing evidence for linkage on chromosomes 1q, 2q, 3p, 4q, 5q, 6p, 8p, 11q, 13q, 14p, 
20q and 22q (Badner and Gershon, 2002; Lewis et al., 2003a; Ng et al., 2009). Notably 
between the three studies, there is only agreement for a single locus on chromosome 8p. 
As noted above, linkage analysis identifying broad regions, of millions of centimorgans, 
but unlike Mendelian disorders, fully penetrant disease variants have not been found for 
schizophrenia and thus recombination events cannot be used to fine map loci as 
susceptibility variants for complex disorders have low penetrance. Stefansson et al. 
attempted to map the linkage signal for schizophrenia on chromosome 8p using linkage 
disequilibrium – this led the identification of a schizophrenia-associated haplotype within 
the neuregulin 1 gene (NRG1) (Stefansson et al., 2002) which remains controversial.  
 
One of the strongest evidence for schizophrenia reported by linkage studies came from a 
family study reporting a reciprocal translocation between 1q42 and 11q14.3 that co-
segregates with schizophrenia, bipolar disorder and major depression (St Clair et al., 
1990). This translocation affects disrupted in schizophrenia 1 and 2 (DISC1 and DISC2). 
DISC1 is to date one of the most studied risk genes for schizophrenia. It is associated 
with cellular process such as cell division and signal transduction and has been 




1.5.1.2 Candidate gene association studies 
Association studies assess differences in allele frequencies between affected and non-
affected individuals, organized as cases and controls for dichotomous traits (McGuffin et 
al., 2003). One advantage of this strategy is greater power to detect alleles of smaller 
effect-size than linkage studies (Risch and Merikangas, 1996) (Figure 1.1). Candidate 
genes association studies are carried out on genes within chromosomal regions 
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implicated through linkage studies (positional candidates) (Collins, 1995) or plausible 
genes based on their known function (functional candidates) (McGuffin et al., 2003). 
Candidate gene studies are limited due to our poor understanding of the pathophysiology 
of schizophrenia, and have led to a high number of false positives due to population 
stratification, multiple testing and the small sample sizes used (Altshuler et al., 2008). 
Hundreds of genes have been tested for association with schizophrenia (see 
www.schizophreniaforum.org/res/sczgene for an updated list), the most cited candidates 
include DRD2, DTNBP1, NRG1, DISC1, and COMT (Muir et al., 2008; Pawel et al., 2010; 
Walker et al., 2010; Wirgenes et al., 2010). Currently candidate gene studies are less 
common and their evidence considered weaker than that of GWAS unless they are done 
on large sample sizes. Most popular candidate genes do not show evidence of 
association in large GWAS, suggesting that the candidate genes approach is not 
necessarily an effective way to identify schizophrenia susceptibility loci.  
 
 
1.5.1.3 GWAS for common variation  
Genome-wide association studies compare the frequencies of single nucleotide 
polymorphisms (SNPs) spanning the whole genome between cases and unaffected 
control individuals for a disease to identify loci associated with disease susceptibility 
(Corvin et al., 2010). GWAS provides a powerful tool to identify alleles associated with 
complex disorders. Hundreds of associations with many traits have been identified using 
GWAS (see a compendium at NIHGRI GWAS Catalogue, www.genome.gov/gwastudies). 
A review of the NIHGRI GWAS Catalogue (visited on 20th of April 2014) shows 31 GWAS 
for schizophrenia, referring to more than 60 SNPs suspected to be involved in the 
pathogenesis of schizophrenia at an association p-value of <5 x 10-8 (as per Dudbridge 
and Gusnanto, (Dudbridge and Gusnanto, 2008)), and pointing to more than 100 genes. 
However, the biological mechanism linking these genetic variations to the pathology of 
schizophrenia is still unknown. Table 1.1 summarize GWAS study finding for 
schizophrenia and genes/loci significantly associated with risk at P values < 5x10-8. 
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Several genomic loci showing association contain plausible candidates for schizophrenia 
pathology, for example, ZNF804A, TCF4, MIR137, CACNA1C, NRGN and the MHC 
region, which includes a large region of strong linkage disequilibrium (LD) with signals 
from HLA, histone genes and possibly others non-immune system genes such as 
NOTCH4 (International Schizophrenia et al., 2009; Stefansson et al., 2009). Biological 
functions reported for these genes support their plausible role in schizophrenia 
susceptibility, such as calcium signalling pathways, neuronal plasticity, synaptogenesis 
and neurodevelopment (Giegling et al., 2010; Melom and Littleton, 2011; Silber et al., 
2008; Smrt et al., 2010).  
 
Table 1.1 Schizophrenia genome-wide association studies and genes/loci significantly 
associated with risk at P value < 5x10-8. 
Reference Region Reported Gene(s) Strongest 
SNP-Risk 
Allele 





6p21.32 MHC, NOTCH4 rs3131296-G 2E-10 1.19 
6p22.1 MHC, PRSS16 rs6932590-T 1E-12 1.16 
11q24.2 NRGN rs12807809-T 2E-9 1.15 
18q21.2 TCF4 rs9960767-C 4E-9 1.23 
(Shi et al., 2009) 6p21.32 HLA-DQA1 rs9272219-G 7E-8 1.14 
6p22.1 SLC17A1, SLC17A3, BTN3A2, 
BTN2A2, BTN3A1, HIST1H2AG, 
HIST1H2BJ, PRSS16, POM121L2, 
ZNF184 










18q21.2 CCDC68 rs12966547-G 3E-8 1.40 
10q24.32 CNNM2 rs7914558-G 2E-8 1.22 
8p23.2 CSMD1 rs10503253-A 2E-8 1.16 
3p21.1 ITIH3, ITIH4 rs2239547-? 6E-8 1.10 
1p21.3 MIR137 rs1625579-T 2E-11 1.12 
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1q43 NR rs6703335-? 5E-8 1.09 
10q24.33 NT5C2 rs11191580-T 3E-8 1.20 
2q32.3 PCGEM1 rs17662626-A 5E-8 1.20 
6p22.1 TRIM26 rs2021722-C 2E-12 1.15 
(Yue et al., 2011) 6p22.1 NKAPL rs1635-? 7E-12 1.28 
11p11.2 TSPAN18 rs11038167-? 1E-11 1.29 
(Shi et al., 2011) 1q24.2 BRP44, DCAF6 rs10489202-A 1E-8 1.23 
8p11.23 LSM1, WHSC1L1 rs16887244-? 1E-10 1.19 
(Bergen et al., 
2012) 
2q37.2 CENTG2 rs13025591-? 8E-8 1.11 
5q12.1 Intergenic rs7709645-? 4E-8 1.11 
7p22.3 MAD1L1, SNX8, NUDT1, FTSJ2 rs12666575-? 2E-9 1.12 
6p22.1 MHC rs17693963-? 3E-11 1.24 
8q21.3 MMP16 rs7004633-? 6E-8 1.15 







6p22.1 MHC, TRIM26 rs2523722-G 1E-16 1.25 
(Betcheva et al., 
2013) 
1q32.2 HHAT rs7527939-C 6E-9 2.63 
(Aberg et al., 
2013) 
18q21.2 TCF4 rs1261117-T 3E-10 1.60 
(Ripke et al., 
2013)  
1q43 AKT3, CEP170 rs14403-C 2E-8 1.10 
10q24.32 C10orf32, AS3MT, CALHM1, CALHM2, 
CALHM3, 
CNNM2, CYP17A1, INA, MIR1307, 
NT5C2, PCGF6, PDCD11, SFXN2, 
ST13P13, TAF5, USMG5, WBP1L 
rs7085104-A 4E-13 1.11 
12q24.31 C12orf65, ABCB9, ARL6IP4, 
CDK2AP1, MIR4304, MPHOSPH9, 
OGFOD2, PITPNM2, RILPL2, SBNO1, 
rs11532322-A 2E-8 1.09 
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SETD8 
2q37.1 C2orf82, GIGYF2, KCNJ13, NGEF rs778371-G 2E-8 1.09 
12p13.33 CACNA1C rs1006737-A 5E-12 1.10 
10p12.31 CACNB2, NSUN6 rs17691888-G 1E-10 1.16 
2q33.1 FONG, C2orf47, C2orf69, SPATS2L, 
TYW5 
rs2949006-T 1E-8 1.10 




(Ripke et al., 
2013) 
1p31.1 Intergenic rs10789369-A 4E-10 1.10 
5q33.1 Intergenic rs2910032-C 4E-8 1.08 
2q32.1 Intergenic rs4380187-A 6E-8 1.08 
17p13.3 Intergenic rs4523957-T 6E-8 1.08 
3p22.2 Intergenic rs6550435-G 6E-8 1.08 
3p21.1 ITIH3, ALAS1, ALDOAP1, BAP1, 
C3orf78, DNAH1, GLT8D1, GLYCTK, 
GNL3, ITIH1, ITIH4, MIR135A1, 
MIRLET7G, MUSTN1, NEK4, NISCH, 
NT5DC2, PBRM1, PHF7, PPM1M, 
RFT1, SEMA3G, SFMBT1, SPCS1, 
STAB1, TLR9, TMEM110, TNNC1, 
TWF2, WDR82 
rs4687552-T 1E-8 1.09 
7p22.3 MAD1L1, FTSJ2, NUDT1, SNX8 rs6461049-T 6E-13 1.11 
19p13.11 MAU2, CILP2, GATAD2A, GMIP, 
HAPLN4, LPAR2, MIR640, NCAN, 
NDUFA13, PBX4, SUGP1, TM6SF2, 
TSSK6, YJEFN3 
rs2905424-T 3E-9 1.09 
1p21.3 MIR137, DPYD rs1198588-T 2E-12 1.12 
8q21.3 MMP16 rs11995572-T 3E-8 1.12 
2p22.2 QPCT, C2orf56, CEBPZ, PRKD3, 
SULT6B1 
rs2373000-T 7E-9 1.09 
1q43 SDCCAG8 rs1538774-G 3E-8 1.09 
5q21.1 SLCO6A1 rs6878284-C 9E-9 1.09 
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11q25 SNX19 rs7940866-T 2E-9 1.09 
18q21.2 TCF4 rs4801131-C 1E-8 1.08 
8q24.3 TSNARE1 rs4129585-A 2E-10 1.09 
2q22.3 ZEB2 rs12991836-C 1E-8 1.08 
5q12.1 ZSWIM6, C5orf43 rs171748-A 4E-8 1.08 
(Wong et al., 
2013) 




1.5.1.4 Copy Number Variation 
Genomic variants (deletions or duplications of segments of the genome) have traditionally 
been identified by cytogenetic using chromosome staining and light microscopy. In the 
more modern terminology, copy number variants (CNVs) usually refer to submicroscopic 
(i.e., not detected by traditional cytogenetic tools) deletions and duplications of about 500 
kb to 1 kb (Conrad et al., 2010; Hastings et al., 2009). CNV constitute a common form of 
genetic variation and the vast majority of CNVs are inherited (Conrad et al., 2010), 
however, de novo CNVs can also occur, and these have been strongly implicated in the 
disease. The consequences of CNVs can be a disruption of gene expression and have 
been associated with a number of traits, especially neurodevelopmental and metabolic 
disorders (Hurles et al., 2008; Malhotra and Sebat, 2012). 
 
Several CNVs have been associated with susceptibility to schizophrenia; these findings 
are presented in Table 1.2. The strongest evidence is for a greater burden of rare de 
novo CNVs affecting genes (International Schizophrenia, 2008; Xu et al., 2008). Several 
studies have shown that these CNVs are enriched for genes with high expression or 
known role at the synapse and other brain associated cellular functions (for example 
Stefansson et al., (Stefansson et al., 2008) and Kirov et al., (Kirov et al., 2012)). GWAS 
technologies can also detect rare copy number variants (CNVs). Stefansson et al. 
(Stefansson et al., 2008) also showed CNVs are under negative selection, suggesting a 
significant effect on fitness. 
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Table 1.2 Summary of CNVs identified in schizophrenia. 
Locus Type Genes References 
1q21.1 Deletion 11 (Ikeda et al., 2010; International Schizophrenia, 2008; 
Levinson et al., 2011; Need et al., 2009; Walsh et al., 
2008). 
1p36.33 Duplication 5 (Rees et al., 2014) 
2p16.3 Exonic deletion NRXN1 (Ikeda et al., 2010; Kirov et al., 2009b; Levinson et al., 
2011; Magri et al., 2010; Need et al., 2009; Rujescu et 
al., 2009; Walsh et al., 2008). 
3q29 Deletion/duplication 21 (Kirov et al., 2012; Levinson et al., 2011; Magri et al., 
2010; Mulle et al., 2010; Vacic et al., 2011). 
7q36.3 Exonic deletion VIPR2 (International Schizophrenia, 2008; Levinson et al., 
2011). 
15q11.2 Deletion 4 (Kirov et al., 2009a; Kirov et al., 2012; Magri et al., 
2010; Stefansson et al., 2008). 
15q13.3 Deletion 8 (International Schizophrenia, 2008; Kirov et al., 2012; 
Levinson et al., 2011; Stefansson et al., 2008; Vacic et 
al., 2011). 
16p11.2 Duplication 26 (Glessner et al., 2010; Kirov et al., 2012; Levinson et 
al., 2011; McCarthy et al., 2009; Vacic et al., 2011; 
Walsh et al., 2008).    
16p12.1 Deletion 7 (Rees et al., 2014) 
16p13.1 Duplication 11 (Ikeda et al., 2010; Ingason et al., 2011; Kirov et al., 
2009a; Magri et al., 2010). 
17q12 Deletion 15 (Kirov et al., 2009a; Magri et al., 2010; Moreno-De-
Luca et al., 2010).  
22q11.21 Deletion 29-43 (Glessner et al., 2010; International Schizophrenia, 
2008; Stefansson et al., 2008; Vacic et al., 2011).    
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1.5.1.5 Exome sequencing   
Recent studies conducted using exome-sequencing technology, have shown that genes 
previously associated with schizophrenia are enriched for rare variants and de novo 
mutations (Fromer et al., 2014; Purcell et al., 2014). In addition, these studies show that 
genes with known prominent functions on the synapse and brain are also enriched for 
rare risk alleles. These gene sets include the voltage-gated calcium ion channels and 
genes involved in synaptic process, such as NMDAR (N-methyl-D-aspartate receptor), 
ARC (activity-regulated cytoskeleton-associated) and PSD-95 (postsynaptic density-95) 
as well as FMRP (fragile X mental retardation protein) targets. These genes sets have 
been associated with other neurodevelopmental disorders such as autism and intellectual 
disability and the authors show that they have high postnatal brain expression (Cross-
Disorder Group of the Psychiatric Genomics and Genetic Risk Outcome of Psychosis, 
2013; Kirov et al., 2012).   
 
These studies provide further evidence for an implication of synaptic disruption as a 
pathogenic mechanism in schizophrenia. Furthermore, they support the idea of a shared 
disease mechanism between other neurodevelopmental disorders and schizophrenia and 
demonstrate a polygenic burden increasing risk for schizophrenia, comprising rare 
nonsense and de novo mutations distributed across many genes. Interestingly, these 
studies do not support the idea of rare variation with large effects on schizophrenia 
susceptibility (Figure 1.1) and suggest that large sample sizes will also be needed to 
identify association with rare variants. 
 
 
1.6 Molecular biology studies for schizophrenia GWAS loci 
Genetic studies have provided a robust lead to help uncover the biological processes 
underlying schizophrenia aetiology. The current challenge is to interpret the biological 
meaning of these findings to inform projects for the development of new treatments for 
schizophrenia.  Molecular studies focusing on genes pointed to by GWAS of 
schizophrenia have shown that these genes participate in several cellular functions 
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relevant to the pathology of the disease such as neuronal proliferation, neurogenesis, 
neuronal differentiation and maturation as well as other cell regulation processes such as 
circadian cycle (see Table 1.3 present a representative selection of these studies). 
Furthermore, some of these studies have also shown using animal models that 
manipulation of these genes impact on behaviour and cognitive functions. This evidence 
is helping us to delineate the molecular pathways by which genetic variation influencing 
these genes can have an effect and in turn to highlight which traits they might be 
modifying. For example, a transgenic mouse moderately overexpressing TCF4 shows 
cognitive deficit, a phenotype well described in patients with schizophrenia (Brzózka et 
al., 2010). This suggests that the molecular pathways in which TCF4 is involved modulate 
cognitive function in mice, and potentially in humans (human knock-out of TCF4 have 
profound cognitive phenotype, see section 1.7). Therefore, identifying these molecular 
pathways and their effect on neuronal and brain systems can point to potential targets to 
develop therapies oriented to improve or avoid cognitive deficit. 
 
The present thesis focuses on two putative effector genes for schizophrenia - TCF4 and 
VRK2 - as there is very little known about their role in the brain, making them attractive 
for molecular studies. I now present a brief description of these two genes. A more 
detailed characterisation will be presented through the thesis. 
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Table 1.3 Examples of molecular studies for schizophrenia genes. 




TCF4 Transgenic mice 
overexpressing 
Tcf4 postnatally 
in the forebrain 
-Tcf4 transgenic mice 
present cognitive and 
sensorimotor deficit. 
- TCF4 interact with 
neurogenic bHLH 
factors NEUROD and 




neuronal bHLH factors 





- Reporter gene 





- Microarray and 
qRT-PCR 
Circadian cycle (Brzózka et 
al., 2010). 





knockdown has a 
significant effect on the 
expression of genes 
involved in cell 
adhesion. Suggesting 
a role for ZNF804A in 
processes such as 
neural migration, 
neurite outgrowth and 
synapse formation. 
 
- RNAi knowdown 
- Microarray 




- Pathway analysis 
Cell adhesion (Hill and 
Bray, 2012). 









in association with 
miR137 
overexpression are 




and inhibition of 
miR-137 using a 
mirVanaTM miRNA 






(Illumina HT-12 v4 
BeadChip array) 
- qRT-PCR 
- Pathway analysis 
Neuronal 
differentiation 
(Hill et al., 
2014). 












development both in 
brain and cultured 
primary neurons. 
miR-137 targets the 
- Relative 
quantification of 




miR-137 in new- 
born cells of the 





(Smrt et al., 
2010)  
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 Mind bomb one (Mib1) 







- Overexpression of 
miR-137 in 
neuroprogenitor 
cells using lentivirus 
- 3’-untranslated 
region dual 











development and in 
the adult dentate 
gyrus. 





DISC1 knockdown in 





- DISC1 expression 
knockdown in vivo 
and in vitro using 
shRNA lentivirus. 
- In utero BrdU 
labeling 
- Cell proliferation 
assays 
- Luciferase assays 
in vitro binding and 
kinase assays to 
test DISC1 inhibition 






(Mao et al., 
2009)  
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1.7 TCF4 
TCF4 (transcription factor 4) encodes a basic helix-turn-helix Ephrussi-box transcription 
factor located at chromosome 18q21.2. It is widely expressed in human tissues and 
appears to be involved in multiple biological functions in a variety of cell types (Cisse et 
al., 2008; Engel and Murre, 2001; Muir et al., 2006; Quong et al., 2002; Sobrado et al., 
2009; Wikstrom et al., 2008). Additionally, TCF4 is likely to play a major role in 
neurodevelopment, especially as its haploinsufficiency has been associated with a rare 
form of syndromic mental retardation, Pitt-Hopkins syndrome (MIM #610954) (Pitt and 
Hopkins, 1978). However, there is a paucity of information on its roles in the human CNS. 
It is known to interact with three proteins involved in neurodevelopment, MATH1 (Flora et 
al., 2007; Gohlke et al., 2008; Ross et al., 2003), HASH1 (Persson et al., 2000) and 
NEUROD2 (Ravanpay and Olson, 2008). TCF4’s interactions with these transcription 
factors suggest it is involved in an intricate combinatorial regulatory circuit during CNS 
development.  
 
Three common variants within or close to TCF4 have been shown to confer risk to 
schizophrenia in GWAS studies: rs9960767 (Stefansson et al., 2009), rs4309482 
(Steinberg et al., 2011), and rs12966547 (Ripke et al., 2011). Both rs4309482 and 
rs12966547 lie approximately equidistant from CCDC68 (coiled-coil domain containing 
68, aka cutaneous T-cell lymphoma associated antigen, CTLC SE57-1) a gene with an 
unknown function, and TCF4 (in addition to a lincRNA (ENST00000507267; AC091103.1) 
gene which overlaps with TCF4) and it is unclear which gene they affect. However, 
because mutations in TCF4 are known to cause intellectual disability (Brockschmidt et al., 
2007), it is a plausible hypothesis that all three variants affect TCF4 in some way. 
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rs9636107, incl. replication (P = 3.34e−12)
chr18_52749216_D, incl. replication (P = 8.03e−11)
rs78322266, incl. replication (P = 1.32e−08)
rs66791238, incl. replication (P = 1.19e−07)




Figure 1.2 Association signals between the TCF4 markers. Figure obtained from PGC 
schizophrenia analysis (broadinstitute.org/mpg/ricopilli/) 
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1.8 VRK2 
VRK2 is a member of the vaccinia-related kinase (VRK) family of serine/threonine 
kinases located at chromosome 2p16.1. Two splice variants generate isoforms A and B 
of 508 and 397 amino acids, respectively. VRK2A is localised in the cytoplasm with a 
hydrophobic tail in the C-terminal region that anchors the protein to the membrane of the 
endoplasmic reticulum and mitochondria (Blanco et al., 2006). VRK2B is shorter and is 
localised to the nucleus as well as the cytosol (Blanco et al., 2006). 
 
One common variant within VRK2 has been shown to confer risk to schizophrenia in 
GWAS (Figure 1.3). The association at rs2312147 was initially reported by Stefansson et 
al. (Stefansson et al., 2009) with a P value not reaching reach genome-wide significance. 
A follow up study now provides genome-wide evidence of association with rs2312147 
(OR = 1.10, P = 5.4x10-10) (Steinberg et al., 2011) rs2312147 is located within the first 
intron of the long isoform of VRK2 and upstream of the short isoform.  
 
A microdeletion syndrome involving chromosome 2p15-p16.1 has recently been reported 
in six individuals. They share similar clinical neurodevelopmental and cognitive 
phenotypes including mental disability and autism as well as facial dysmorphism 
(Chabchoub et al., 2008; de Leeuw et al., 2008; Felix et al., 2010; Liang et al., 2009; 
Rajcan-Separovic et al., 2007). Three of the six individuals have microdeletions affecting 
VRK2, but only two presented intellectual disability and autistic features, thus the gene 
cannot be exclusively responsible for these phenotypes.  
 
Downstream of VRK2 is FANCL (Fanconi anemia, complementation group L), which is 
known to be involved in Fanconi anemia (MIM ID #227650). Fanconi anemia is a 
genetically heterogeneous recessive disorder characterised by cytogenetic instability, 
hypersensitivity to DNA cross-linking agents, increased chromosomal breakage, and 
defective DNA repair. FANCL deficient mice are less fertile and have defective 
proliferation of germ cells (Zhao et al., 2005). Functionally, FANCL is a weaker candidate 
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for schizophrenia, and the index SNPs in VRK2 are not in LD with genetic variation within 
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Figure 1.3 Association signals between the VRK2 markers. Figure obtained from PGC 
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1.9 Aims of this thesis 
This PhD thesis aims to characterise the biological mechanisms through which two 
schizophrenia susceptibility loci identified through GWAS operate using molecular and 
cell biology tools. Thus I aim to provide a better understanding of the underlying biology 
of schizophrenia, especially that related to TCF4 and VRK2, which could point to future 
avenues for improvements of its diagnosis, management or treatment. 
 
Specific Objectives: 
A. In silico characterisation of TCF4 through extensive bioinformatic analyses and 
data mining. This is presented in Chapter 2. 
B. Test whether manipulation of the endogenous expression of TCF4 has an effect 
on the proliferation of human neural progenitor cells. This is presented in Chapter 
3.  
C. Test whether VRK2 expression in the neonatal and adult human brain is 
influenced by the schizophrenia risk allele (rs2312147 allele G, Steinberg et al., 
2011) and other common cis-regulatory variation. This is presented in Chapter 4.  
D. Assess the effect of VRK2 knockdown on the transcriptome and proliferation of 
human neural progenitor cells. This is presented in Chapter 5.  
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The present chapter is a modified version of the work published in: Navarrete K, Pedroso 
I, De Jong S, Stefansson H, Steinberg S, Stefansson K, Ophoff RA, Schalkwyk LC, 
Collier DA. 2013. TCF4 (e2-2; ITF2): A schizophrenia-associated gene with pleiotropic 
effects on human disease. Am J Med Genet Part B 162B: 1–16. The published version of 
this article and its supplementary material is attached in Appendix 1. I made the major 
contribution to this published work; I performed all the bioinformatics analysis and 
contributed to the majority of the writing. The only part of this published work that was not 
performed by me was the expression analysis of TCF4 in lymphocytes from 
schizophrenia patients and controls. This experimental work was performed at Dr Roel 
Ophoff’s Lab by his MSc student Simone de Jong. 




The TCF4 gene on chromosome 18q21.2 (Entrez Gene ID 6925; ensemble 
ENSG00000196628) encodes a basic helix-turn-helix (bHLH) Ephrussi-box (‘‘E-box’’ or 
E-) protein transcription factor. The gene spans 437 kb and has 41 exons. It has multiple 
aliases in addition to the official HUGO name TCF4 and is also known as E2-2, ITF2, 
PTHS, SEF2, SEF2-1, SEF2-1A, SEF2-1B, bHLHb19, MGC149723, and MGC149724. 
The pleiotropic disease associations of TCF4 include rare non-synonymous mutations 
and gene deletions in Pitt-Hopkins syndrome (PHS), and common risk variants for Fuch’s 
corneal dystrophy (FCD) and schizophrenia, which are genetically distinct from each 
other. It should not be confused with TCF7L2 (transcription factor 7-like 2), another 
transcription factor mapping to a different locus on chromosome 10q25-25.3, that plays a 
key role in the Wnt-signaling pathway, which has also been called TCF4, and has been 
associated with schizophrenia (Alkelai et al., 2012; Hansen et al., 2011). 
 
In the present chapter, I performed a systematic literature search for publications 
describing the TCF4 protein, using the terms E2-2, ITF2, PTHS, SEF2, SEF2-1, SEF2-
1A, SEF2-1B, bHLHb19, PHS, and FCD. The literature search was updated up until July 
9, 2012, and references collated (see Appendix 1 for full list of references identified for 
the study). Papers referring to TCF7L2 (but which used the term TCF4) were manually 
excluded from the list after reading the text to determine this. Several papers whose 
subject was TCF4 (e2-2) were incorrectly indexed with the term TCF7L2, including the 
original paper describing the cloning of TCF4 (e2-2). These were retained in the list. 
Bioinformatic analysis was performed up until April 2012. 
 
2.1.1 The aim of the present study 
The aim of this chapter was to characterize TCF4 in silico through extensive 
bioinformatics analyses and data mining and to collect information about TCF4 through a 
systematic literature review. 
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2.2 TCF4 and human disease 
2.2.1 Pitt-Hopkins Syndrome 
Non-synonymous mutations and deletions in the TCF4 gene are a cause of PHS (MIM 
#610954), a rare autosomal dominant encephalopathy caused largely by de novo 
mutations (Whalen et al., 2012). PHS was originally described in 1978 in two unrelated 
patients with mental retardation, recurrent episodes of hyperventilation, and a wide mouth 
(Pitt and Hopkins, 1978). A series of additional cases helped to refine the clinical 
features, which are severe psychomotor delay, epilepsy, and daily bouts of diurnal 
hyperventilation starting in infancy; mild postnatal growth retardation, postnatal 
microcephaly and distinctive facial features (de Pontual et al., 2009; Orrico et al., 2001; 
Peippo et al., 2006; Singh, 1993; Van Balkom et al., 2012). Families describe their 
children with PHS as creative and joyful (pitthopkins.org). Clinical study finds that most 
have a smiling appearance, as well as anxiety, stereotypic movements, particularly of the 
arms, wrists, and fingers, and hyperventilation that may be triggered by emotional 
situations (Whalen et al., 2012). Constipation is common, and there is co-morbidity for the 
developmental disorder Hirschsprung disease in PHS, a neurocristopathy characterized 
by the absence of enteric ganglia along a variable length of the intestine. 
 
Using systematic genome-wide BAC-array screening, de novo microdeletions on 
chromosome 18q21.1, which include the TCF4 gene, were identified in PHS (Amiel et al., 
2007; Brockschmidt et al., 2007; Gustavsson et al., 1999; Zweier et al., 2007) and fine 
mapping of the deleted region led to the identification of heterozygous TCF4 mutations in 
non-deleted cases (Amiel et al., 2007; de Pontual et al., 2009), including null alleles 
created by splice site, frameshift, nonsense mutations, and missense mutations which 
change highly conserved residues. Almost all mutations are de novo and private. Point 
mutations account for 40% of these, mostly causing premature stop codons, indels 30%, 
and de novo gene deletions 30%. Missense mutations are generally within the bHLH 
domain, a mutational hotspot. There may also be attenuated loss of function with a less 
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severe phenotype: one parent carried a mosaic mutation and suffered from depression 
and epilepsy (de Pontual et al., 2009). 
 
Analysis of the effects of TCF4 mutations in PHS is consistent with loss of function, with 
activation of a reporter construct significantly and similarly impaired for nonsense, 
frameshift, and missense TCF4 mutants when co-transfected with achaete-scute complex 
homolog 1 (HASH1; ASCL1) cDNA (de Pontual et al., 2009), a cofactor involved in 
activation of TCF4 DNA binding (Persson et al., 2000). The causative mutations in TCF4 
(that is, hemizygous deletions and inactivating mutations) indicate that PHS is caused by 
haploinsufficiency of the gene and that is it is highly dosage-sensitive. 
 
While TCF4 mutations are confirmed as the cause of PHS, autosomal recessive 
disorders resembling PHS (Pitt-Hopkins- like syndrome) are caused by mutations in 
NRXN1 and CNTNAP2 (Blake et al., 2010; Zweier et al., 2009). Copy number variants 
(CNVs) in both of these genes are also associated with schizophrenia and other 
neurodevelopmental disorders (Friedman et al., 2008; Rujescu and Collier, 2009). 
 
2.2.2 Schizophrenia 
Genetic epidemiology studies of schizophrenia have consistently shown a strong genetic 
component, with estimates of heritability at up to 80% (Cardno et al., 2002; van Os and 
Kapur, 2009). Multiple genetic variants have been implicated in risk, including common 
single nucleotide polymorphisms (SNPs) from genome-wide association with small effect-
size and rare CNVs of moderate to large effects (Rujescu and Collier, 2009), as well as 
environmental and epigenetics factors (Pidsley and Mill, 2011). To date, two independent 
genetic loci in near TCF4 have been implicated in schizophrenia, one in intron three of 
the gene and one between the distal end of TCF4 and the gene CCDC8, providing robust 
GWAS evidence for association (Ripke et al., 2011; Stefansson et al., 2009; Steinberg et 
al., 2011). 
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The initial association between TCF4 and schizophrenia was with the SNP rs9960767, in 
intron three of the gene (P = 4.1 X 10-9; OR 1.23) (Stefansson et al., 2009). A second 
variant (rs4309482) downstream of the TCF4 gene reached a genome-wide significance 
level in a follow-up study (P = 7.8 X 10-9; OR 1.09) (Steinberg et al., 2011), and a third 
variant (rs12966547) was significantly associated with schizophrenia in a GWAS mega-
analysis from the psychiatric GWAS consortium (P = 2.60 X 10-10; OR 1.09) (Ripke et al., 
2011). A fourth variant, rs17512836, has also been associated with schizophrenia from 
the PGC schizophrenia analysis (P = 2.35 X 10-8); after follow-up this gave a combined P 
value of 1.05 X 10-6 (OR 1.23) (Ripke et al., (Ripke et al., 2011); 
broadinstitute.org/mpg/ricopili/). 
 
The TCF4 gene, the location of GWAS associated SNPs, and their linkage disequilibrium 
(LD) with other SNPs at the locus is shown in Figure 2.1. rs12966547 is physically (1.5 
kb) very close to rs4309482 and is in complete LD (r2 = 1), so is effectively the same 
marker. rs4309482 and rs12966547 are in very weak LD with rs9960767 in the 
Caucasian population (D’ = 0.05, r2 = 0), that is they are showing independent association 
signals with schizophrenia. rs17512836 is likewise in very low LD with rs4309482 and 
rs12966547 (D’ = 0.02, r2 = 0), but in moderate LD with rs9960767 (D’ = 1, r2 = 0.52), 
indicating the association signal there is not independent. 
 





Figure 2.1 Association signals between the TCF4 markers rs4309482, rs12966547, 




Both rs4309482 and rs12966547 lie approximately equidistant from three genes: 
CCDC68 (coiled-coil domain containing 68, aka cutaneous T-cell lymphoma associated 
antigen, CTLC SE57-1), a gene with unknown function; a long intergenic non-coding RNA 
(ENST00000507267 or AC091103.1) overlapping TCF4 in the opposite strand; and TCF4 
itself. Therefore, in contrast with PHS mutations, it is less certain from the GWAS results 
which gene(s) these variants affect, as they are not obviously functional. However, a 
parsimonious association with TCF4 can be hypothesized given that (i) rs9960767 is in 
an intron of the TCF4 gene and is in low LD with the other two TCF4 associated markers, 
(ii) mutations in TCF4 are known to cause severe mental illness, and (iii) TCF4 is target 
of micro-RNA 137, which has also been associated with schizophrenia (Kwon et al., 
2013; Ripke et al., 2011). Therefore, it is reasonable that the gene mediating the genetic 
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risk conferred by these variants is TCF4 and that the GWAS-associated variants are 
tagging two independent TCF4 loci which have a functional effect on the gene in some 
way. 
 
However, these SNPs do not show any association with bipolar affective disorder 
((Psychiatric, 2011); http://www.broadinstitute.org/mpg/ ricopili/), making them unusual in 
that many genome-wide significant susceptibility loci for schizophrenia and bipolar 
disorder reported to date cross traditional diagnostic boundaries (Williams et al., 2011a). 
It is also interesting that both common and rare variants affect the same gene and confer 
susceptibility to brain disorders of varying severity, as it has been shown for other traits 
(Johansen et al., 2010; Zaghloul and Katsanis, 2010). 
 
Two earlier genetic studies, before the advent of GWAS, examined this locus in 
schizophrenia: one study examined an unstable CTG repeat (CTG18.1) in an intron of 
TCF4 (McInnis et al., 2000) which did not show association, and a second, cytogenetic, 
study of families with schizophrenia or bipolar disorder found independent pericentric 
inversions on chromosome 18 close to the TCF4 gene (inv[18][p11.31;q21.2] and 
inv[18][p11.31;q21.1]) which could conceivably affect gene function (Pickard et al., 2005). 
 
Consistent with its involvement in schizophrenia pathogenesis, blood TCF4 levels were 
found to be reduced during psychotic states (Kurian et al., 2011), and a small study of 
post-mortem cerebellar cortices of 14 schizophrenia patients and six controls also 
highlighted TCF4, but found up-regulation of expression in patients (Mudge et al., 2008). 
However, post-mortem brain mRNA-level analyses of three adult brain regions, the 
dorsolateral prefrontal cortex (DLPFC; Brodmann area BA46) (Narayan et al., 2008), the 
lateral and caudal superior temporal gyrus (BA22) (Barnes et al., 2011) and the 
frontopolar prefrontal cortex (BA10) (Maycox et al., 2009), found no association between 
schizophrenia and TCF4. These discrepancies may well be explained by differences in 
expression patterns among tissues and cell type. Nonetheless, it remains unclear if 
mRNA expression changes are part of the schizophrenia pathology. In order to gather 
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additional evidence, colleagues at Dr Roel Ophoff’s Lab examined TCF4 relative mRNA 
levels experimentally in lymphocytes from cases with schizophrenia (n = 106) and 
controls (n = 96), and found approximately 20% lower expression in patients (fold change 
= 0.84 and P-value = 2.13 10-7, see section 2.9 for details). Williams et al., (Williams et 
al., 2011b) examined TCF4 cis-regulated variation in gene expression for correlation with 
one of the associated SNPs, rs9960767, using an assay to detect differential allelic 
expression. They found no evidence for cis-regulated mRNA expression in adult cerebral 
cortex related to genotype at the schizophrenia associated SNP. However, they could not 
rule out temporal- or tissue-specific effects on expression. Future studies on larger 
sample sizes looking at specific brain regions across development will be needed to 
clarify the role of mRNA-level changes of TCF4 in schizophrenia risk. 
 
2.2.3 Fuch’s Corneal Dystrophy 
Genetic variation within TCF4 has also been associated with FCD (Baratz et al., 2010; 
Kuot et al., 2012; Li et al., 2011), a common eye disease affecting about 5% of the 
population, and the leading cause of corneal transplant (accounting for 10% of all corneal 
dystrophies) (Lang and Naumann, 1987); 80% of those affected are female. FCD is 
characterized by the development of collagen-free regions, which may be caused by cell 
death (Meek et al., 2003). Baratz et al., (Baratz et al., 2010), in a GWAS study, showed 
that SNPs at the TCF4 locus were strongly associated with typical FCD, with an odds 
ratio of 30 for homozygotes for the disease variants. While many markers showed 
association, the SNPs rs17595731 and rs613872, intronic for TCF4, and rs9954153 and 
rs2286812, upstream of TCF4, demonstrated independent signals across the gene and 
gave the best case–control discrimination. rs613872 showed the strongest evidence for 
association (P =1 X 10-18). 
 
The FCD-associated variants appear partly independent of schizophrenia associations, 
even though the FCD index SNP rs613872 maps to the same intron of the gene as some 
of the schizophrenia associations. rs613872 shows weak to moderate LD with 
rs17512836 (D’ = 1, r2 = 0.25) and rs9960767 (D’ = 0.65, 1, r2 = 0.20) but negligible LD 
Chapter 2: Bioinformatic analysis of TCF4 
 47 
with rs4309482 (D’ = 0.07, r2 = 0) and rs12966547 (D’ = 0.07, r2 = 0). Given that 
schizophrenia and FCD are common in the population (about 1%) and may partially 
share some genetic risk, it will be worth determining whether there is any co-morbidity 
between these two disorders. However, there is no evidence of this from the literature. 
 
2.3 The TCF4 gene 
TCF4 (immunoglobulin transcription factor 2; ITF2; SEF2; OMIM *602272) was initially 
identified in 1990 through cloning and sequencing of the cDNA, identified as encoding a 
HLH transcription factor binding to Ephrussi, or E box elements (the mu-E5 motif of the 
immunoglobulin heavy chain enhancer and the kappa-E2 motif of the light chain 
enhancer) (Henthorn et al., 1990). TCF4 was independently identified by Corneliussen et 
al. (Corneliussen et al., 1991), who characterized a protein family with homology to other 
bHLH transcription factors through their binding to glucocorticoid response element E-box 
motifs in the in the murine leukemia virus SL3-3 enhancer. Corneliussen et al., 
(Corneliussen et al., 1991) called the new protein family SEF2, for ‘‘SL3-3 enhancer 
factors’’; TCF4 was named SEF2-1B (667 amino acids). They also identified multiple 
splice variants. Pscherer et al., (Pscherer et al., 1996) identified the murine homologue of 
TCF4 (SEF2-1B; mouse Sef2) through its binding to the E box of the somatostatin 
receptor (SSTR2) initiator element, where it can recruit the basal transcription factor 
TFIIB through physical interaction with SEF2. 
 
2.3.1 Comparative Genomics of TCF4 
Comparative genomic analyses on 14 representative vertebrates showed that the length 
of the TCF4 gene greatly differs even between closely related species, for example 
medaka and fugu and mouse and rat, probably as a result of the extent of repeats. A 
tendency towards increase in the size of the gene is detected from fish (36.2 kb) to 
human (437 kb), which could be explained under neutral evolution (Lynch, 2007). The 
length of deduced human proteins from alternative TCF4 transcripts based on the 
Ensembl annotation is between 511 and 773 amino acids. Although the length of the 
deduced protein differs across species there is high sequence identity of the primary 
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Supplementary Figure 1 (Appendix 1) shows an alignment of TCF4 protein sequences of 
14 vertebrate species. The bHLH domain is conserved among these species as well as 
an element reported to play an important role the activity of the protein (Herbst and 
Kolligs, 2008). Only the Ensembl database annotates a longer N-terminal region that 
includes a signal peptide region in a human (ENSP00000381382) and chimpanzee 
(ENSPTRP00000040814) isoforms (amino acids position 1–31). Bioinformatic analyses 
were with a suite of tools, as described by Emanuelsson et al. (Emanuelsson et al., 2007) 
to predict the function of this N-terminal region and the subcellular localization of TCF4 in 
human and chimpanzee. I confirmed that both the human (amino acids position 1–31) 
and chimpanzee (amino acids position 1–27) sequences have predicted signal peptides 
(Supplementary Table I; Supplementary Figures 2–4; see Appendix 1). For the human 
protein, a leucine-rich nuclear export signal (amino acid position 14) was also predicted 
by the software NetNES (la Cour et al., 2004). Proteins having this signal can shuttle 
back and forth between the nuclear and cytoplasmic compartments many times during 
their life cycle (Pemberton and Paschal, 2005). In a recent study by Sepp et al. (Sepp et 
al., 2011) experimental evidence demonstrated TFC4 in fact does shuttle from the 
nucleus to the cytoplasm. They showed that full-length TCF4 isoforms that have longer 
N-termini were restricted to cell nucleus whereas other isoforms localized to both the 
nucleus and the cytoplasm, and found a nuclear localization signal in the protein in exons 
8–9. 
 
In addition to protein motifs, non-coding sequence nearby genes can have important 
regulatory functions, such as driving expression or modulating splicing, and represent an 
important source of information to understand gene function. These regulatory sequences 
can be identified by cross species DNA alignments. I used the VISTA genome browser 
(Frazer et al., 2004) and identified 365 ECRs (evolutionarily conserved sequences) 
between human and mouse with an average identity of approximately 75% 
(Supplementary Table II, Appendix 1). When more genetically distant species (human, 
dog, mouse, and opossum) were employed in a cross-species sequence comparison, all 
exons appear highly conserved but only a few non-exonic ECRs are present 
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(Supplementary Figure 5, Appendix 1). Four ECRs conserved between the human and 
mouse genome sequences have been tested as part of the vista enhancer project (Visel 
et al., 2007) (Supplementary Table III, Appendix 1). The human element hs376 
(chr18:51,240,623–51,242,077 on human genome assembly hg19) is located in intron 5 
of TCF4 and was shown to drive expression of a reporter gene in the nervous system 
during mouse development, including the hindbrain (rhombencephalon), mid-brain 
(mesencephalon), and neural tube (Supplementary Figure 6, Appendix 1). Interestingly, I 
found reported genetic variation within this regulatory element (Supplementary Table IV, 
Appendix 1) and several predicted transcription factor binding sites (Supplementary 
Figure 7, Appendix 1) for CREB1, ZEB1, and CUX1 among others. Interestingly, CUX1 
binding to the TCF4 gene promoter has been proved experimentally by Harada et al. 
(Harada et al., 2008) where chromatin affinity experiments were performed in HEK293 
cell line. I also found four experimentally identified transcription factors binding sites from 
the ENCODE Chip-seq data: REST (NRSF), NFKB1, SPI1 (PU.1), and POU2F2 
(Euskirchen et al., 2007; Robertson et al., 2007; Rozowsky et al., 2009)  (Supplementary 
Figure 7, Appendix 1). Some of these transcription factors are known to be important in 
neurogenesis and neuronal plasticity, like REST and CREB1 (Dworkin and 
Mantamadiotis, 2010; Gao et al., 2011; Merz et al., 2011; Rossbach, 2011). Further study 
of these ECRs and the potential regulatory links revealed by growing functional genomics 
information might shed light on the regulation of TCF4 expression and its function in the 
central nervous system (CNS). 
 
2.4 The TCF4 protein 
E-proteins comprise a family of class I bHLH transcription factors homologous to the 
drosophila protein ‘‘daughterless’’ (Lazorchak et al., 2005; Murre, 2005) and include E12 
and E47 (encoded by a single gene, E2a), HEB and TCF4 (E2-2) which form 
homodimers or heterodimers with other proteins in order to enable DNA binding. They 
have no known DNA binding activity as monomers. Class I bHLH transcription factors are 
expressed in a ubiquitous pattern and are able to dimerize efficiently with tissue-restricted 
class II factors to activate gene expression (Murre et al., 1989). They recognize a 
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palindromic binding site (‘‘CANNTG’’), first identified in immunoglobulin enhancers, and 
have a preference for C or G in the central bases. Because each partner contributes a 
specific DNA recognition half-site, different class I and class II heterodimers can provide 
distinct E box binding specificities. 
 
Multiple alternatively spliced transcript variants that encode different TCF4 proteins have 
been described, with two main isoforms, E2-2A and E2-2B. E2-2B is a transcriptional 
repressor and a downstream target of the TCF/β-catenin complex (Kolligs et al., 2002; 
Petropoulos and Skerjanc, 2000) whereas E2-2A is a transcriptional regulator with 
diminished or absent repressor capacity (Furumura et al., 2001; Skerjanc et al., 1996). 
For example, the E2-2B isoform can repress the brain-specific FGF1 (fibroblast growth 
factor 1) by binding to an imperfect E-box in the promoter (Liu et al., 1998) while the E2-
2A isoform has no activity. Likewise, interaction of E2-2B protein with MyoD can inhibit its 
activity by forming an inactive heterodimer (Skerjanc et al., 1996). 
 
 
2.5 Biological functions and interactions of TCF4 
TCF4 is widely expressed in human tissues and appears to be involved in multiple 
biological processes, including plasmacytoid dendritic cell development (Cisse et al., 
2008; Ghosh et al., 2010; Watowich and Liu, 2010), sertoli cell development (Muir et al., 
2006), B and T lymphocyte development (Bergqvist et al., 2000; de Pooter and Kee, 
2010; Engel and Murre, 2001; Quong et al., 2002), thymocyte development (Wikstrom et 
al., 2008), the epithelial-mesenchymal transition (EMT) (Sobrado et al., 2009), the 
maintenance of the properties of corneal epithelial stem cells during corneal epithelial 
development (Bian et al., 2010; Lu et al., 2012), and brain development (see below). 
 
In EMT, a process that allows cell migration during embryonic development and tumor 
invasion, TCF4 can act as an E-cadherin repressor. Functional loss of the cell–cell 
adhesion molecule E-cadherin is an essential event in EMT and transcriptional repression 
has emerged as the main regulatory mechanism. E-cadherin repression mediated by 
Chapter 2: Bioinformatic analysis of TCF4 
 53 
TCF4 is indirect and independent of proximal E-boxes of the promoter (Sobrado et al., 
2009). Because of the potential role of TCF4 in tumor invasion, TCF4 has been examined 
in cancer, including estrogen receptor negative breast cancer (Appaiah et al., 2010; 
Brody and Witkiewicz, 2010) and is activated in human cancers with beta-catenin deficits 
(Kolligs et al., 2002). 
 
TCF4 (E2-2.1) is also an essential molecular regulator of the plasmacytoid dendritic cell 
(PDC) lineage (Cisse et al., 2008; Esashi and Watowich, 2009; Nagasawa et al., 2008), 
cells which play a central role in the defense against viruses through rapidly producing 
interferon I (Cervantes-Barragan et al., 2012). TCF4 shows high expression in PDCs 
relative to other immune cells and regulates terminal development and interferon 
production by controlling PDC-related genes. Impairment of TCF4 (E2-1.1) leads to a 
reduced number and abnormal cell surface of PDCs, which is thought to be the basis for 
persistent respiratory infection in patients with PHS. 
 
TCF4 may also be involved in regulation of calcium signaling in cells through its 
interaction with calmodulin. TCF4 along with the E2A proteins E12 and E47 bind 
calmodulin in vitro at physiologically relevant calmodulin concentrations (Corneliussen et 
al., 1994) in an interaction modulated by sequences directly N-terminal to the basic 
domain. This results in inhibition of DNA binding in vitro. Increased intracellular Ca2+ 
concentration potently inhibits the transcriptional activity of TCF4 on an E-box containing 
reporter plasmid, as does calmodulin overexpression. Thus Ca2+ signaling may inhibit the 
transcriptional activity of E-proteins, including TCF4, by establishing an E-protein-
calmodulin complex that prevents the E-protein from interaction with its target DNA 
(Saarikettu et al., 2004). 
 
TCF4 expression in the brain is likely to play a major role in neurodevelopment, 
especially as haploinsufficiency has been associated with PHS and common variants in 
or near the gene confer risk of schizophrenia. However, there is a paucity of information 
on the role of TCF4 in the CNS. TCF4 is known to be important in the differentiation of 
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glial cells, especially the maturation of oligodendrocyte progenitors. In the postnatal 
spinal cord TCF4 expression is exclusive to oligodendrocyte lineage cells and decreases 
as myelination proceeds, whereas in the brain, TCF4 is also expressed in neurons, 
especially in the thalamus (Fu et al., 2009).  
 
TCF4 is known to interact with several class II bHLH transcription factor genes involved in 
neurodevelopment: Math1, a proneural protein expressed in the differentiating 
neuroepithelium (Flora et al., 2007; Gohlke et al., 2008; Ross et al., 2003); HASH1, a 
protein necessary for the formation of distinct neuronal circuits within the CNS, especially 
the telencephalon (Persson et al., 2000); neuroD2, which plays important roles in 
neuronal differentiation and survival (Ravanpay and Olson, 2008); and Id1, a homologue 
of the drosophila daughterless and emc loci, which are required for correct patterning in 
neurogenesis (Einarson and Chao, 1995). TCF4 is also the only transcription factor 
showing complete co-expression with Olig2 (Fu et al., 2009), an essential regulator of 
ventral neuroectodermal progenitor cell fate and a requirement for oligodendrocyte and 
motor neuron development (Othman et al., 2011; Panman et al., 2011). Taken together, 
these data suggest that TCF4 is involved in an intricate combinatorial regulatory circuit 
during CNS development. Ravasi et al., (Ravasi et al., 2010) support a model in which 
the combinatorial nature of transcription factors rather than their expression in isolation is 
the main determinant of tissue specificity and the functionality of transcription factors 
complexes is associated with their conservation across species. Ravasi et al., (Ravasi et 
al., 2010) show that TCF4 is part of a conserved transcription factor complex of proteins 
co-expressed in cerebellum in human and mouse. 
 
Math1 is highly expressed in proliferating progenitors of the rhombic lip, a specialized 
neuroepithelium in the developing dorsal hindbrain (Akazawa et al., 1995; Ben-Arie et al., 
1996), and is also required for the differentiation of most cerebellar and pre-cerebellar 
structures (Ben-Arie et al., 1997; Wang et al., 2005)—for example, Math1 knockout mice 
lack all cerebellar granule neurons. It is important to note that cerebellar expression of 
TCF4 is very high (Sepp et al., 2011) and could relate to Math1. TCF4 also forms a 
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functional complex with HASH-1, and thus appears to be involved in the development of 
specific parts of the central and peripheral nervous systems (Persson et al., 2000). The 
HASH-1/TCF4 complex binds an E-box (CACCTG) in vitro and is one of the major HASH-
1 interacting proteins in extracts from neuroblastoma cells. HASH-1 (MASH-1 in mouse) 
is a transcription factor homologous to the drosophila ‘‘achaete-scute homolog-1’’ and is 
essential for correct development of olfactory and most peripheral autonomic neurons, 
and for the formation of distinct neuronal circuits within the CNS (Persson et al., 2000). 
 
The E proteins E12, HEB, and TCF4 all interact with neuroD2, and heterodimers bind a 
neuroD2 preferred E-box. These complexes have a comparable ability to induce 
neurogenesis, indicating a similar baseline biological activity (Ravanpay and Olson, 
2008). NeuroD2 has been reported to play a critical role in the induction of neuronal 
differentiation, the promotion of neuronal survival, and development of thalamocortical 
communication (Farah et al., 2000; Ince-Dunn et al., 2006; Lin et al., 2006; Noda et al., 
2006; Olson et al., 2001). 
 
Brockschmidt et al., (Brockschmidt et al., 2011) performed knockdown of TCF4 in 
zebrafish embryos, which resulted in developmental delay or defects in terminal 
differentiation of brain and eyes. The authors conclude that TCF4-knockdown in zebrafish 
embryos did not seem to affect early neural patterning and regionalization of the 
forebrain, but may be involved in later aspects of neurogenesis and differentiation. 
 
2.6 Human TCF4 expression 
Inspection of public databases showed that TCF4 is expressed at detectable levels 
across many tissues (Supplementary Figures 8 and 9, Appendix 1). However, its 
expression is high in prefrontal cortex, foetal brain, and BDCA4+ dendritic cells. I 
explored the Human Brain Transcriptome dataset, which has expression data of TCF4 
across several brain regions and developmental stages (Kang et al., 2011), and also 
examined the Sestan Lab Human Brain Atlas Microarrays dataset (Johnson et al., 2009) 
to explore the expression pattern of TCF4 in human brain. I found that TCF4 has higher 
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expression in neocortex and hippocampus compared with striatum, thalamus, and 
cerebellum and that its expression seems to be higher at early stages of development 
(Figure 2.2; Supplementary Table V, Appendix 1). These brain areas have been 
implicated with schizophrenia by neuropsychological neuroimaging and post mortem 
histology and neurochemical studies (Boyer et al., 2007; Casanova et al., 2008; Harrison, 
2004; Heckers, 1997; Lewis and Gonzalez-Burgos, 2008; Zierhut et al., 2010). 
 
de Pontual et al. (de Pontual et al., 2009) found that TCF4 is highly expressed throughout 
human CNS development and the sclerotomal component of the somites from Carnegie 
stage C13 28–32 days postfertilization (dpf). TCF4 expression continues into adult life, 
expressed in lymphocytes, fibroblasts, gut, muscle, but not the heart. Sepp et al. (Sepp et 
al., 2011) used RT-PCR to detect TCF4 transcripts and also found widespread 
expression, including testis, placenta, prostate, and in postmortem adult human brain, 
where they found particularly high expression, especially in the cerebellum. 
 
 
Figure 2.2 Expression of TCF4 across several brain regions and developmental stages. 
Data obtained from the Human Brain Transcriptome dataset and the Sestan Lab Human Brain Atlas 
Microarray dataset. TCF4 has higher expression in neocortex and hippocampus compared with 
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2.6.1 TCF4 RNA Transcripts 
The TCF4 gene has numerous exons and produces several mRNA transcripts. Currently 
two human transcripts (isoforms TCF4A [ITF2A; SEF2-1A] and the canonical sequence 
TCF4B [ITF2B; SEF2-1B]; accession numbers NM_001083962.1 and NM_003199.2) are 
commonly referred to in the literature, along with a third known isoform SEF2-1D 
(TCF4D). Likewise, two transcripts of human TCF4 are annotated in the NCBI Entrez 
database, but four in Ensembl, 10 in UCSC and 38 in NCBI AceView database (version 
April 2007) (Thierry-Mieg and Thierry-Mieg, 2006). More than 459 mRNA or EST 
sequences are related to human TCF4. Forty one splice variants are recorded at 
Ensembl’s latest version (version 66), many of which are derived from RNA-seq (de novo 
sequencing of transcripts (Ozsolak and Milos, 2011) experiments from the Illumina Body 
Map and ENCODE projects and therefore the splice junctions are likely to be real. 
Increasing availability of RNA-seq data will help to elucidate the full coding potential of 
the gene as well as possible transcriptional biases for different isoforms on specific 
tissues. 
 
TCF4 mRNA transcripts have been experimentally verified in mice (Brzózka et al., 2010), 
rat (Yoon and Chikaraishi, 1994), and humans (Pscherer et al., 1996). Sepp et al. (Sepp 
et al., 2011) used RT-PCR in a detailed bioinformatic and experimental study of TCF4. 
They demonstrated the existence of several 5’ exons that potentially yield 18 different N-
termini in TCF4 proteins, and alternative splicing of several internal exons that may give 
rise to further isoforms. All the isoforms contain transactivation domain AD2 and the 
bHLH domain; however, only the isoforms with the longest N-terminal have the amino-
terminal transactivation domain AD1. AD1 and AD2 are able to activate transcription 
individually and together they act synergistically (Sepp et al., 2011). 
 
Some of these isoforms contain a nuclear localization signal (NLS) and are only found in 
the nucleus, whereas others are also found in the cytoplasm. Isoforms without an NLS 
may rely on binding to bHLH partner proteins, such as NeuroD which contains an NLS, in 
order to enter the nucleus. Sepp et al. (Sepp et al., 2011) also conclude that isoforms 
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lacking NLS can be exported from the nucleus by heterodimerization with nuclear export 
signal (NES) containing partner proteins. In the present study, I also detected a leucine-
rich NES (amino acid position 14), which could also explain its export from the nucleus. 
Supplementary Table VI (Appendix 1) provides identifier mapping for isoforms across 
different databases that can be useful for researchers aiming to use information across 
these databases. 
 
2.6.2 Potential miRNA Regulation 
TCF4 is known to be regulated by at least two differentially expressed microRNAs, miR-
221 and miR-222, which regulate plasmacytoid versus conventional dendritic cell 
development (Kuipers et al., 2010). MicroRNAs are likely to confer tissue-specific fine-
tuning of TCF4 expression, for example in neurons. In order to explore this, I used the 
TargetSCAN (Lewis et al., 2005) database to identify predicted miRNA binding sites in 
the TCF4 UTR conserved regions. There were 45 miRNA predicted binding sites 
conserved across vertebrates. Of them, 37 have been associated with human diseases 
and 30 specifically with CNS disorders (Table 2.2). Interestingly, hsa-mir-106a/b, hsa-mir-
7-1/2/3, hsa-mir-92a-1/2, hsa-mir-92b, and hsa-mir-20a/b have been associated with 
schizophrenia and autism (Abu-Elneel et al., 2008; Perkins et al., 2007; Talebizadeh et 
al., 2008). Furthermore, a genetic variant near hsa- mir-137 has been associated with 
schizophrenia at genome-wide significant level (Ripke et al., 2011). The targeting of hsa-
mir-137 to TCF4 has been confirmed by Kwon et al. (Kwon et al., 2013). hsa-mir-155 has 
been also validated experimentally according to the database mirWalk (Dweep et al., 
2011) (http://www.ma.uni-heidelberg.de/ apps/zmf/mirwalk/mirnatargetpub.html). 
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Table 2.2 Predicted conserved miRNA target sites in TCF4. miRNA potentially regulating 
TCF4 and associated with CNS diseases. 
miRNA Disease Reference 
hsa-mir-106a / hsa-mir-106b    Schizophrenia, Alzheimer Disease, Autistic 
Disorder, Glioma  
(Abu-Elneel et al., 2008; Hebert et al., 2009; 
Lavon et al., 2010; Perkins et al., 2007) 
hsa-mir-7-1 /  hsa-mir-7-2 /  hsa-mir-
7-3    
Schizophrenia, Autistic Disorder  (Abu-Elneel et al., 2008; Perkins et al., 2007) 
hsa-mir-92a-1 /  hsa-mir-92a-2 /   
hsa-mir-92b    
Schizophrenia, Autistic Disorder, 
Medulloblastoma,  Brain Neoplasms 
(Nass et al., 2009; Northcott et al., 2009; 
Perkins et al., 2007; Talebizadeh et al., 2008; 
Uziel et al., 2009) 
hsa-mir-20a  / hsa-mir-20b   Schizophrenia, Alzheimer Disease, 
Medulloblastoma, Glioma, Glioblastoma 
(Ernst et al., 2010; Hebert et al., 2009; Lavon 
et al., 2010; Northcott et al., 2009; Perkins et 
al., 2007; Uziel et al., 2009) 
hsa-mir-93    Autistic Disorder, Glioma (Abu-Elneel et al., 2008; Lavon et al., 2010) 
hsa-mir-129-1 /  hsa-mir-129-2   Autistic Disorder (Abu-Elneel et al., 2008) 
hsa-mir-363    Autistic Disorder (Talebizadeh et al., 2008) 
hsa-mir-193b   Autistic Disorder (Abu-Elneel et al., 2008) 
hsa-mir-17    
 
 
Alzheimer Disease, Medulloblastoma, 
Glioma, Glioblastoma 
(Ernst et al., 2010; Hebert et al., 2009; Lavon 
et al., 2010; Northcott et al., 2009; Uziel et 
al., 2009; Xu et al., 2010) 
hsa-mir-139    Neurodegenerative Diseases (Saba et al., 2008) 
hsa-mir-155   
 
Down Syndrome, Cerebral Hemorrhage, 
Stroke, Glioblastoma 
(Care et al., 2007; Liu et al., 2010; 
Sethupathy et al., 2007) 
hsa-mir-124-1 /   hsa-mir-124-2 /  
hsa-mir-124-3    
Glioblastoma, Medulloblastoma, Stroke, 
Cocaine-Related Disorders  
(Chandrasekar and Dreyer, 2009; Laterza et 
al., 2009; Pierson et al., 2008; Silber et al., 
2008) 
hsa-mir-128-1 / hsa-mir-128-2    Neuroblastoma (Evangelisti et al., 2009) 
hsa-mir-137   Glioblastoma (Silber et al., 2008) 
hsa-mir-141    ACTH-Secreting Pituitary Adenoma (Amaral et al., 2009) 
hsa-mir-145   ACTH-Secreting Pituitary Adenoma, 
Atherosclerosis 
(Amaral et al., 2009; Zhang, 2009) 
hsa-mir-183    Glioma (Lavon et al., 2010) 
hsa-mir-200a   Meningioma (Poethig, 2009) 
hsa-mir-221   Astrocytoma (Conti et al., 2009) 
hsa-mir-367    Glioma (Lavon et al., 2010) 
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2.6.3 SNPs in TCF4 
18,636 SNPs (db130) were found at the locus, which I defined as the gene boundaries 
plus approximately 2 Mb in each direction to cover all proximal haplotype blocks (chr 18: 
49.019.029–52.414.148, human assembly hg18). Of them, 4,417 and 6,762 have been 
genotyped by the HapMap and 1,000 genomes project, respectively, and 2,706 in both. 
Galaxy tools (Blankenberg et al., 2010) were used to intersect these SNPs with a set of 
putative and validated DNA functional elements which found that 12,500 SNPs (67%) are 
within potentially regulatory regions, including multispecies conserved sequences and 
known protein binding sites, and 64 were within exons (Figure 2.3). Among the latter, 29 
were validated non-synonymous SNPs, as listed in the UCSC genome browser 
(Supplementary Table IX; Appendix 1). Williams et al., (Williams et al., 2011b) used data 
from the 1,000 genomes project to identify non-synonymous coding variants in the TCF4 
gene, but did not find any evidence for association and conclude that association 
between schizophrenia and TCF4 is not mediated by a relatively common non-
synonymous variant. They also performed allele-specific expression analysis using 
human post mortem brain samples, but found no evidence for cis-regulated mRNA 




Figure 2.3 Summary of the strategy used to find the 88 potentially regulatory SNPs in LD 
with the SNPs associated with schizophrenia. 
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Eighty-eight out of the 4,417 SNPs genotyped by HapMap were both in high LD (r2 > 0.8) 
with the SNPs associated with schizophrenia, rs4309482 and rs9960767, and within 
potentially regulatory sites (Table 2.3), suggesting that the disease-susceptibility alleles 
may capture variants influencing gene expression. To test this I looked at an eQTL 
dataset at http:// eqtl.uchicago.edu/Home.html (Veyrieras et al., 2008) where I found one 
eQTL mapping to the TCF4 gene region, rs1261085. However, this eQTL showed low LD 
with the three schizophrenia-associated SNPs, for example with rs996076 it had an r2 of 
0.073, and an r2 of 0.003 with rs4309482 and rs12966547. 
 
 
Table 2.3 Putative functional SNPs in LD with schizophrenia associated SNPs 
SNP 1 SNP ID Position r2 Functional element 
rs4309482 rs4309482 50901467 1 Nucleosome occupancy (MEC) 
 rs12966547 50903015 1 phastConsElements28wayPlacMammal, 
phastConsElements28way, Nucleosome occupancy 
(MEC) 
 rs4801131 50903698 1 Nucleosome occupancy (MEC) 
 rs4131791 50898869 1 Nucleosome occupancy (MEC) 
rs9960767 rs9960767 51306000 1 Nucleosome occupancy (MEC), Sunny RBP 
 rs12327270 51319071 1 phastConsElements28wayPlacMammal, 
phastConsElements28way, Nucleosome occupancy 
(MEC), Regulatory Potential 7x, Gis Chip (c-Myc) , 
Sunny RBP  
 rs10401120 51343496 0.867 Nucleosome occupancy (MEC), Sunny RBP 
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2.7 Co-expression and protein–protein interaction networks of 
TCF4 
Network biology information was used to get an insight into the function of TCF4 by using 
higher-level biological information (Geschwind and Konopka, 2009). Gene co-expression 
networks derived from gene-expression analysis of human brains (Oldham et al., 2008) 
revealed 139 genes tightly co-expressed with TCF4. These genes were analyzed by 
gene-set enrichment analysis with MetaCore (GeneGO, Inc.) showing that they are 
characterized by specific biological processes including Alpha-2 adrenergic receptor 
activation of mitogen-activated protein kinase 1 and 3 (MAPK1/3) (P = 1.5 X 10-3), WNT 
signaling pathway (P = 5.9 X 10-3) and cell adhesion/synaptic contact (P = 3.0 X 10-3) 
(Supplementary Table VII; Appendix 1). It is interesting that some of them have been 
previously associated with schizophrenia, such as the WNT signaling pathway (Cotter et 
al., 1998; Freyberg et al., 2010; Miyaoka et al., 1999) and cell adhesion/synaptic contact 
(Eastwood, 2004; Gross et al., 2003; Hayashi-Takagi and Sawa, 2010; O'Dushlaine et al., 
2011; Stephan et al., 2009).  
 
In addition, GeneGO Metacore (GeneGo, Inc.) manually curated information was used to 
identify TCF4 interacting partners, based on physical or regulatory interactions, that are 
also known to be associated with schizophrenia. I identified six proteins, namely TP53, 
NR3C1, AR, CTNNB1, ESR1, and EGFR, known to regulate or interact with TCF4 and 
further seven from among the co-expression partners, that is GSK3b, NRXN1, GABRA1, 
MILL, GRIA3, GNAL, and ADRA2A. I used the manually curated interactions and the co-
expression results to build a network of potential schizophrenia susceptibility genes 
around TCF4 (Figure 2.4). This sheds light on its relationship with other potential 
schizophrenia susceptibility genes. 






Figure 2.4 Network relationships between TCF4, genes that are coexpressed with TCF4 in 
human cortex and genes that are associated with schizophrenia.   
Red is the genes coexpressed with TCF4 and associated with schizophrenia and blue is the genes 
associated with schizophrenia. The arrows show the direction of the interaction and the colour if it is 
activation (red), inhibition (blue), and unspecified (black). 
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2.8 Summary and future directions 
TCF4 is still a poorly characterized gene in terms of function and biology. However, the 
compelling evidence for genetic association of TCF4 with schizophrenia calls for 
additional detailed studies. For example, the current literature only refers to three protein 
isoforms at the most, but there is experimental evidence for many more (Sepp et al., 
2011). Future studies will benefit from a careful dissection of the functional differences 
between TCF4 splice variants, especially since they differ in functional motifs. This 
potential array of different protein products from the TCF4 gene may account for its 
pleiotropic associations with disease. 
 
Although the role of TCF4 during development has not been elucidated, it seems 
plausible, based on its known interactions with Math1, HASH1, and neuroD2, to suggest 
that TCF4 plays an important role during CNS development. Because of its interaction 
with calmodulin and involvement in calcium signaling, TCF4 may also be involved in 
acute functional effects in neurons. The advent of second generation sequencing 
technologies will allow a more thorough study of transcription factor binding site targets of 
TCF4, using methods such as ChIP-seq, as well as isoform abundance at different points 
during development of CNS tissues using RNA-Seq. These analyses will reveal further 
information on the TCF4 biological regulatory network, the role of the protein in brain 
development and function and, in turn, TCF4’s involvement in psychiatric and 
neurodevelopmental disorders. 
 
The role of TCF4 in brain neural function, especially in relation to schizophrenia, also 
needs to be elucidated. For example, preliminary studies are examining the role of TCF4 
polymorphisms on putative endophenotypes of schizophrenia have shown an effect on 
sensory gating, as measured by the P50 suppression of the auditory evoked potential 
(Quednow et al., 2012), and on prepulse inhibition of the acoustic startle response, a 
different measurement of sensorimotor gating (Quednow et al., 2011). These studies may 
provide important information on the relationship between TCF4 risk polymorphisms and 
neuropsychiatric dysfunctions in schizophrenia. 
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Examination for putative functional genetic variants revealed that several common SNPs 
are both within likely functional DNA elements and in LD with SNPs associated to 
schizophrenia. In line with these findings, one of these elements is known to drive gene 
expression in mouse CNS. Additional studies exploring the function of these DNA 
sequences can provide clues as to which transcription factors are regulating TCF4 and in 
turn how TCF4 is being integrated into wider regulatory processes. In addition, TCF4 
transcripts have several potential binding sites for miRNAs whose expression has been 
associated with mental illnesses. Additional validation of these regulatory links is 
warranted and could provide important clues between TCF4 and other genes underlying 
risk of mental disorders. Thus, the information compiled here suggests it may be possible 
to use additional targeted functional studies to start drawing a functional network relating 
TCF4 to other key molecular players in brain development and mental illness. 
Furthermore, I showed that by compiling gene-expression data and protein–protein 
interaction information TCF4 is readily linked to other genes associated with 
schizophrenia. A major challenge will be to understand the mechanisms relating these 
genes and in which context, for example cell type or developmental stage, their 
interactions are important as mediators of risk for schizophrenia. This effort will need to 
be undertaken by a wide community applying a plethora of experimental approaches. 
Nonetheless, this represents the start of a path lead to biological understanding and 
possibly new treatments for schizophrenia and other psychiatric disorders. 
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2.9 Methodology.  
 
2.9.1 Sequence analyses 
The annotated TCF4 gene was searched in Ensembl data base version 56 
(http://www.ensembl.org) and UCSC genome browser (http://genome.ucsc.edu/). 
Ensembl annotates 47 orthologues for human TCF4 (ENSG00000196628) gene, but the 
analysis was restricted to only 14 representative species. The species used were: Human 
(specie Homo sapiens, assembly GRCh37), Chimpanzee (Pan troglodytes, CHIMP2.1), 
Orangutan (Pongo pygmaeus, PPYG2), Macaque (Macaca mulatta, MMUL 1.0), Mouse 
(Mus musculus, NCBI m37), Rat (Rattus norvegicus, RGSC 3.4), Dog (Canis familiaris, 
CanFam 2.0), Horse (Equus caballus, Equ Cab 2), Anole Lizard (Anolis carolinensis, 
AnoCar1.0), Platypus (Ornithorhynchus anatinus, Ornithorhynchus_anatinus-5.0), 
Opossum (Monodelphis domestica, monDom5), Xenopus (Xenopus tropicalis, JGI 4.1), 
Medaka (Oryzias latipes, HdrR) and Fugu (Takifugu rubripes, FUGU 4.0).  
 
All the analyses were performed with the canonical protein, which Ensembl defines as the 
longest deduced transcript for each species. Manual inspection of the predicted 
orthologous revealed a possible error. The predicted orthologous in Dog is 
ENSCAFT00000000229 but this gene only has 3 exons, compared with 21 in human. A 
predicted paralogous of this gene (ENSCAFT00000000232) has 17 exons. Because an 
intron loss event is needed to explain this and the more parsimonious answer is that 
orthologous of the human TCF4 is ENSCAFT00000000232 and that 
ENSCAFT00000000229 may have been generated by a retrotransposition event, which 
could explain the fewer introns of this gene. ENSCAFT00000000232 was retained as the 
orthologous for further analyses. 
 
Sequence identity and similarity was calculated with BLAST (Altschul et al., 1990). DNA 
sequence repeats identified by Repeat Masker were extracted from the UCSC tables 
using the software Galaxy (Blankenberg et al., 2010). Amino-acid alignments were 
performed with MUSCLE (Edgar, 2004) and the visualization was generated with Clustal 
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X (2.0.12) (Larkin et al., 2007). The secondary structure analysis was performed using 
the program ali2d (Biegert et al., 2006) (http://toolkit.tuebingen.mpg.de/ali2d). In order to 
characterize the N- terminal region found in chimpanzee and human I followed the 
protocol described by Emanuelsson et al., (Emanuelsson et al., 2007), which involves the 
use of a suite of bioinformatic software publicly available to predict subcellular location of 
eukaryotic proteins.  
 
2.9.2 TCF4 transcripts  
The alternative transcripts of the human TCF4 gene were obtained from NCBI AceView 
(version April 2007) (Thierry-Mieg and Thierry-Mieg, 2006) 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html), Ensembl (release 
GRCh37) and UCSC (Mar. 2006 (NCBI36/hg18) assembly). Next TCF4 expression was 
examined in different tissues using the microarray data integrated in Geneinvestigator 
(V3, http://www.geninvestigator.ethz.ch/) (Hruz et al., 2008), BioGPS 
(http://biogps.gnf.org/#goto=welcome) (Wu et al., 2009) and the Sestan Lab Human Brain 
Atlas Microarrays data set, which is available at the UCSC Browser.  
 
2.9.3 Analysis of SNPs in the TCF4 gene 
Galaxy (Blankenberg et al., 2010) was used to extract all SNPs annotated in db130 within 
the TCF4 locus (chr. 18: 49019029 – 52414148, assembly hg18) and a bioinformatics 
protocol was applied to evaluate if they were within possible functional sites. SNPs were 
also extracted from HAPMAP (Release #28) and 1000 genomes pilot data 1 (Durbin et 
al., 2010). Functional regions were defined with several UCSC Tables (Supplementary 
Table 8). The software SNAP (Johnson et al., 2008) was used to evaluate the LD 
between SNPs.  
 
2.9.4 Identification of possible regulatory elements 
Multispecies Conserved Sequences (MCS) within the TCF4 locus identified with VISTA 
genome browser (Frazer et al., 2004) and UCSC tracks were examined to investigate the 
possible function of these regions based on the overlap with functional genomic 
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experiments results deposited in the browser. I searched for conserved miRNA predicted 
binding sites on TCF4’s 3’ UTR using TargetScan DB (Lewis et al., 2005). Predicted 
miRNA were examined to determine their association with human diseases using the 
miRNA and Disease database (Lu et al., 2008). 
 
2.9.5 Co-expression and protein-protein interactions networks of TCF4  
Gene co-expression data was taken from a published work for human brain (Oldham et 
al., 2008) to identify TCF4 co-expression partners. These were analysed using gene-set 



























Chapter 3  Effect of TCF4 knockdown on neuronal 
progenitor cells proliferation  
 
3.1 Introduction 
In addition to the literature review presented on Chapter 2, here I provide additional 
information regarding the molecular and cell biology of TCF4 gathered post-publication of 
our literature review (Navarrete et al., 2013). New studies have provided additional 
support to the statistical association between genetic variation at the TCF4 locus and 
schizophrenia (Aberg et al., 2013; Albanna et al., 2014; Irish Schizophrenia Genomics 
and the Wellcome Trust Case Control, 2012; Kwon et al., 2013; Ripke et al., 2013), other 
studies have examined the association between TCF4's expression and schizophrenia 
(Umeda-Yano et al., 2014; Wirgenes et al., 2012), and additional studies have 
investigated the relationship between risk variant at TCF4 locus and cognition (Albanna 
et al., 2014; Zhu et al., 2013). However, there has been very little progress in 
understanding the molecular and cellular mechanisms that might mediate the association 
between TCF4 variation and risk for schizophrenia. To date, only one study has used 
manipulation of TCF4 expression to investigate its effect in human cells of neuronal origin 
(Forrest et al., 2013). Knockdown of TCF4 in human neuroblastoma-derived cells (SH-
SY5Y) induced changes in the expression of genes involved in TGF-b signalling, 
epithelial to mesenchymal transition, neuronal differentiation and apoptosis. However, the 
use of the SH-SY5Y cell line as neuronal cell model has been criticised, among other 
things due to its chromosomal abnormalities which are expected of cancer cell lines (Bray 
et al., 2012).  
 
In an unpublished study conducted by colleagues in Dr Bray’s group the expression of 
TCF4 was manipulated in two karyotypically-normal human neuronal progenitor cell lines 
(CTX0E16 and CTX0E03) using RNAi and the effects on the cellular transcriptome was 
assessed using expression micro-arrays. The gene-expression data for the CTX0E03 cell 
line showed nominally significant (P < 0.05) gene expression differences shared by the 




two TCF4 siRNA conditions in the same direction relative to control at 628 probes while 
for CTX0E16 cell line the same was observed for 197 probes. Interestingly, these 
differentially expressed probes were enriched for genes involved in cell cycling in both 
cell lines. However, weighted gene co-expression network analyses (WGCNA, 
(Langfelder and Horvath, 2008)) showed that the module enriched for cell cycling was 
positively correlated with TCF4 expression in one cell line and negatively correlated in the 
other. This suggests that TCF4 knockdown might have cell-specific effects on cell cycling. 
The implication that knockdown of TCF4 can affect cell proliferation in neuronal 
progenitors prompted the study presented in this Chapter.  
 
TCF4 is a member of the class I basic helix-loop-helix (bHLH) family of proteins and 
previous studies have shown that TCF4 is highly expressed in the brain (de Pontual et 
al., 2009; Sepp et al., 2011). The bHLH family of transcription factors have been shown to 
be essential in determining the cell fate of neuronal progenitor populations and animal 
studies have indicated that it participates in the regulation of proliferation, differentiation 
and migration of distinct neuronal progenitors during neurogenesis (Ben-Arie et al., 1997; 
Bhattacharya and Baker, 2011; Chiaramello et al., 1995; Gohlke et al., 2008; Olson et al., 
2001; Pagliuca et al., 2000; Ross et al., 2003). Outside the CNS, TCF4 appears to be 
involved in multiple biological functions including in the immune system where it plays an 
important role in lymphocyte development (Bergqvist et al., 2000; de Pooter and Kee, 
2010; Engel and Murre, 2001; Murre, 2005; Quong et al., 2002; Zhuang et al., 1996) and 
regulates plasmacytoid dendritic cells (Cisse et al., 2008; Ghosh et al., 2010; Watowich 
and Liu, 2010).  
 
TCF4 expression in the brain is likely to play a key mechanistic role in neurodevelopment 
by interacting with several transcription factors involved in defining neuronal functions. 
These factors include those from the class II bHLH family of transcription regulators like 
Math1 (Flora et al., 2007), HASH1 (Persson et al., 2000), neuroD1 and neuroD2 (Brzózka 
et al., 2010; Ravanpay and Olson, 2008), and the inhibitor factors Id1 and Id2 (Einarson 
and Chao, 1995; Langlands et al., 1997; Parrinello et al., 2001), which are essential to 




determine the fate of cells in the mammalian nervous system and are considered 
essential to specify all the neurons of the mammalians nervous system (Bhattacharya 
and Baker, 2011).  
 
The role of TCF4 during development is supported by findings from human and animal 
studies. In humans, TCF4 deletions leading to haploinsufficiency are a confirmed cause 
of Pitt-Hopkins syndrome, a severe neurodevelopmental disorder (Amiel et al., 2007; 
Whalen et al., 2012). Findings in animal models have confirmed that TCF4 is critical for 
normal brain development. Homozygous Tcf4 knockout mice die soon after birth and 
present with disrupted pontine nucleus development (Flora et al., 2007), while TCF4 
knockdown in zebrafish results in developmental delay or defects in terminal 
differentiation of brain and eyes (Brockschmidt et al., 2011). Transgenic mice 
overexpressing Tcf4 post-natally present with cognitive and sensorimotor impairments 
(Brzózka et al., 2010).  
 
TCF4 is a downstream target of the WNT/TCF pathway where its expression is regulated 
by β-catenin via its TCF binding site in cancer cell lines (Kolligs et al., 2002) (Kollings et al 
2002). The WNT signalling pathway is important in neuronal development (Abu-Khalil et 
al., 2004) and plays an essential role in several cellular processes including regulating 
cell proliferation, differentiation and neurogenesis (Chevallier et al., 2005; Malaterre et al., 
2007; Zechner et al., 2003). TCF4 has been identified as a direct target of the imprinted 
gene Zac1/Plagl1 during early neurogenesis in mouse neural stem cells (Schmidt-
Edelkraut et al., 2014). Zac1 is a zinc finger protein expressed in the brain described as a 
regulator of proliferation, cell cycle arrest and apoptosis (Liu et al., 2011; Pagotto et al., 
1999; Spengler et al., 1997; Valente et al., 2005). Schmidt-Edelkraut et al, (Schmidt-
Edelkraut et al., 2014) also showed that TCF4 regulates the expression of the cycling 
dependent kinase inhibitor gene p57kip2, increasing the number of cells in G1 phase. They 
conclude that cycle arrest in mouse neuronal progenitors controlled by Zac1 occurs 
through the induction of p57kip2 via TCF4. Additionally, TCF4 participates in the induction 
of cell cycle arrest by regulation of p21cip1 gene expression in colorectal cancer cells lines 




(Herbst et al., 2009). p21cip1 is a negative regulator of cell proliferation and a direct target 
of Zac1 (Liu et al., 2011; Spengler et al., 1997).  
 
Overall, the gene expression changes observed by Dr Bray’s group following TCF4 
knockdown in human neural progenitor cells together with previous evidence from human 
and animal model cell biology and biochemical studies lend support to the idea that TCF4 
has a role in cell proliferation. Therefore, I tested whether TCF4 knockdown would lead to 
changes in the proliferation of the CTX0E03 and CTX0E16 neural progenitor cell lines 
and, as predicted by the micro-array results, this effect would differ between them.  
 
 
3.1.1 The aim of the present study 
The aim of the experiments presented in this chapter was to test the hypothesis that 
TCF4 knockdown leads to changes in the proliferation of the CTX0E16 and CTX0E03 
neural progenitor cell lines. In addition, in accordance with the WGCNA data, I tested the 
hypothesis that this effect differs in direction between the cell lines. To this end, I used 
RNAi to knockdown endogenous TCF4 in the two neural progenitor cell lines followed by 
a cell proliferation assay. 
 





3.2.1 Human neural progenitor cell line 
Experiments were carried out in two clones (CTX0E03 and CTX0E16) of a conditionally 
immortalised neural progenitor cell line. This cell line was obtained from ReNeuron Ltd 
(www.reneuron.com) under a Material Transfer Agreement. It was derived from first 
trimester human foetal cortical neuroepithelium (Pollock et al., 2006). The cells have 
been conditionally immortalised by genomic incorporation of the c-mycERTAM transgene, 
which can be conditionally activated by 4-hydroxy-tamoxifen (4-OHT) to stimulate 
proliferation (Littlewood et al., 1995). A detailed description of the CTX0E03 cell line can 
be found in Pollock et al. (Pollock et al., 2006). 
 
Cells were grown in laminin-coated NunclonTM Surface T75 culture flasks (Thermo 
Scientific, MA, USA) in Reduced Modified Media (RMM) at 37 ºC and 5% CO2 in a 
humidified incubator. NunclonTM Surface T75 culture flasks (Thermo Scientific, MA, USA) 
were coated with Engelbreth-Holm-Swarm murine sarcoma basement membrane laminin 
(Sigma Aldrich, Dorset, UK) at 1 µg/cm2. For T75 flask, 75 µL of laminin was dissolved in 
7.5 mL of Dubelcco’s Phosphate Buffered Saline (DPBS) pH 7.4 (Sigma-Aldrich). Flasks 
were incubated for 3 hours at 37 ºC and then rinsed with warm DPBS. 
 
Cells were expanded in 10 mL of Reduced Modified Media (RMM). RMM media was 
prepared by supplementing DMEM: F12 with 15 mM HEPES and sodium bicarbonate but 
without L-glutamine (Sigma-Aldrich, D6421) with the following components: 0.03% 
human serum albumin, 2 mM L-glutamine, human transferrin (100 µg/mL), putrescine 
dihydrochloride (16.2 µg/mL), human insulin (5 µg/mL), human progesterone (60 ng/mL), 
sodium selenite (40 ng/mL), 100 nM 4-OHT (all Sigma-Aldrich), and the growth factors 
bFGF (10 ng/mL) and hEGF (20 ng/mL) (Peprotech, Inc., NJ, USA). Table 3.1 shows in 
detail concentrations and volumes used for each component. 
 
Cells were grown to 70-90% confluence and the media was changed every two days. 
When cells had expanded to the required confluence they were passaged using Accutase 




solution (Invitrogen). 3 mL of accutase was added to the flask and incubated for 5-10 
minutes at 37 ºC. Following this, the cells were resuspended in RMM to inactivate the 
accutase and transferred to a 15 mL Falcon tube. For cell counting, 10 µL of the cell 
suspension was placed on a haemocytometer and counted under a light microscope. To 
pellet the cell, the tube was centrifuged at 900 rpm for 5 minutes at room temperature. 
The pelleted cells were then resuspended at an appropriate density in RMM media. 
 
 
Table 3.1 Components of Reduced Modified Media (RMM). 




Supplier Volume for 
500 mL 
DMEM:F12 - - Sigma: D6421 500 mL 
Discard volume    10.5 mL 
Human serum  
albumin solution 










8.1 mg/mL 16.2 µg/mL Sigma: P5780 1.0 mL 
Human  
recombinant insulin 
10 mg/mL 5 µg/mL Sigma: I9278 0.25 mL 
Progesterone 30 µg/mL 60 ng/mL Sigma: P6149 1.0 mL 
L-glutamine 200 mM 2 mM Sigma:G7513 5.0 mL 
Sodium selenite 20 µg/mL 40 ng/mL Sigma: S9133 1.0 mL 
Human FGF-basic 10 µg/mL 10 ng/mL PeproTech: 
100-18B 
0.5 mL 
Human EGF 100 µg/mL 20 ng/mL PeproTech:  
AF-100-15 
100 µL 
4-OHT 1 mM 100 nM Sigma: H7904 50 µL 




3.2.2 siRNA transfection  
CTX0E16 and CTX0E03 cells used for transfection were expanded in laminin-coated T75 
flask to 90-100% confluence. Twenty-four hours before siRNA transfection cells were 
passaged using Accutase solution (Invitrogen), 1*106 cells were seeded per T75 flask 
that would be used for all siRNA conditions. For proliferation assays 4500 cells were 
cultured per well in a Nunc-Immuno™ MicroWell™ 96 well solid plate. All cells were 
cultured, on laminin, in 10 mL of RMM media without 4-OHT (represented: RMM ++-). 4-
OHT was excluded so that proliferation was not artificially stimulated by c-myc 
overexpression. CTX0E16 and CTX0E3 cells can retain their nestin-positive, neuronal 
progenitor state in the presence of growth factors bFGF and EGF (Dr G. Anderson and 
Dr B. Williams, personal communication). Separate flasks of CTX0E16 and CTX0E03 
cells were transfected with either Stealth siRNA1, Stealth siRNA2, Stealth siRNATM 
negative universal control and positive control BLOCK-iTTM Alexa Fluor® Red Fluorescent 
oligo (all from Invitrogen).  
 
For proliferation assays 10 wells, containing CTX0E16 or CTX0E03 cells, were 
transfected for each siRNA treatment. Transfection of siRNAs was performed using the 
N-TER™ Nanoparticle siRNA Transfection System (Sigma). RNAi was achieved using 
pre-designed Stealth RNAi™ (Invitrogen), which uses next-generation RNAi chemistry to 
prevent off-target effects. Two non-overlapping Stealth RNAi™ siRNA for TCF4 (siRNA1: 
S13863 and siRNA2: S13864) were transfected alongside a Stealth RNAiTM siRNA 
negative universal control (Invitrogen), and a BLOCK-iT™ Alexa Fluor® Red Fluorescent 
Oligo to assess the transfection efficiency. The sequences of the siRNA targeting TCF4 
are shown in Table 3.2. siRNA1 targets exon 18 and siRNA2 targets exon 15 of full 
length TCF4 mRNA sequence (NM001243226.1). 




Table 3.2 Details of siRNAs used for TCF4 knockdown. 
siRNA ID Oligo Sequence TCF4 exon 
siRNA1 S13863 GCUCUGAGAUCAAAUCCGA 18 
siRNA2 S13864 GAAGGACCCUUACACUCUU 15 
 
 
All siRNA and the red fluorescent oligo were combined with N-TERTM transfection reagent 
to a 9 nM final concentration in 12 mL RMM ++-. Details of reagents used per each 
transfected flask are shown in Table 3.3. In separate microcentrifuge tubes siRNAs and 
the N-TER peptide were mixed by vortexing and incubated at room temperature for 30 
minutes, allowing the siRNA and NTER peptide to combine. For each transfection, 166 
µL of the siRNA/N-TER or RedOligo/N-TER mix was added to a falcon tube containing 12 
mL of RMM ++- and mixed by inversion. Media from previously prepared flasks and wells 
was replaced with RMM++- containing siRNA or Red Fluorescent Oligo. 10 mL of the mix 
was added to each flask and 50 µL to each well. 
 
Table 3.3 Component of one siRNA transfection reaction 
Reagent Concentration Final volume added 









2 nM - 2 µM siRNA: 
siRNA1 
siRNA2 
negative control siRNA 
Red Fluorescent Oligo 





Dilution buffer - 93.5 µL 
N-TER - 16 µL 
H2O - 84 µL 
Total - 166 µL 





Twenty-four hours post-transfection, its efficiency was estimated by monitoring 
fluorescence of cells transfected with BLOCK-iTTM Alexa Fluor® Red Fluorescent Oligo 
by fluorescence microscopy.  
 
Media was replaced at 48 hours post-transfection with RMM (++-). At 90 hours post-
transfection cells from each T75 were separately harvested by addition of Accutase. 
Resuspended cells from each treatment were divided into 2 Falcon tubes and centrifuged 
at 900 rpm for 5 minutes. One of the cell pellets was used for RNA extraction to which 
500 µL of Tri-Reagent® Solution (Ambion, Life Technologies, Grand Island, N.Y.) was 
added. The second pellet was used for protein extraction. Both tubes were stored at -80 
°C. 
 
Nunc-Immuno™ MicroWell™ 96 well solid plates containing cells transfected with 
siRNA1, siRNA2 and Stealth siRNATM negative universal control were washed with 100 
µL per well of warm DPBS, and then fixed with 4% paraformaldehyde (PFA) for further 
proliferation assays. A detailed protocol for the proliferation assays is described below in 
this section. 
 
An overview of the transfection time-line is represented in Table 3.4. The whole protocol 
for the 4 treatments (siRNA1, siRNA2, Stealth siRNATM negative universal control and 
BLOCK-iTTM Alexa Fluor® Red Fluorescent oligo) was repeated five times. 





Table 3.4 Time-line protocol for TCF4 knockdown assay. 
Day -1 Cells are seeded on laminin-coated flasks with 10 mL of RMM ++-, or in 
laminin-coated wells of a 96 well solid plate with 50 µL RMM ++- 
Day 0 Transfect: 
• 1 flask with siRNA 1 
• 1 flask with siRNA 2 
• 1 flask with negative control siRNA 
• 1 flask with red oligo 
• 36 wells of a 96 well plate, 12 wells for each siRNA condition (siRNA1, 
siRNA2 and negative control siRNA) 
Day 1 Check fluorescence of cells transfected with red-oligo  
Day 2 Replace media to all flasks and 96 well plate with RMM ++- (10 mL per flask and 50 
µL per well) 
Day 3 - 
Day 4 Collect cells from the different treatments for RNA extraction and protein extraction. 




3.2.3 Total RNA extraction  
Pelleted cells were separately homogenized with 500 µL of Tri-Reagent® Solution 
(Ambion, Life Technologies, Grand Island, N.Y.). After homogenization, samples were 
transferred to a clean microcentrifuge tube. 50 µL of 1-Bromo-3-cloropropane (Sigma-
Aldrich) was added to each sample, vortexed for 2 seconds and incubated at room 
temperature for 10 minutes. The samples were then transferred to a Phase lock gel tubes 
(5Prime) and centrifuged at 12000 rpm for 15 minutes at 4 ºC.  The upper aqueous phase 
was transferred to a clean microcentrifuge tube and 250 µL of isopropanol (Sigma-
Aldrich) were added. The tubes were vortexed for 5-10 seconds, incubated at room 
temperature for 10 minutes and centrifuged at 12000 rpm for 15 minutes at 4 ºC. The 
supernatant was discarded and the pellet was washed with 500 mL of 75% ethanol 
(Sigma-Aldrich) and centrifuged at 7500 rpm for 5 minutes at room temperature. The 




ethanol was removed and the pellet was air dried before being resuspended in 30 µL of 
nuclease-free water (Sigma-Aldrich) and stored at -80 ºC.    
 
3.2.4 DNAse treatment of total RNA samples 
Extracted RNA samples were treated with TURBO DNA-freeTM (Ambion) to remove any 
contaminating genomic DNA. 30 µL of total RNA from each sample was treated with 3.5 
µL of 10x TURBO DNAse Buffer and 2.1 µL of TURBO DNAse (2 U/µL). The samples 
were gently mixed and then incubated at 37 °C for 30 minutes. The samples were then 
incubated at room temperature with 7 µL of DNAse Inactivating Reagent (Ambion) for 2 
minutes, while being mixed occasionally. Finally, the samples were centrifuged at 1000 
rpm for 2 minutes and the supernatant was transferred to a clean 0.6 mL microcentrifuge 
tube and stored at -80 °C. 
 
3.2.5 RNA quantification 
A NanoDropTM 1000 spectrophotometer was used to measure the concentration and 
purity of each RNA sample. 1 µL of each sample was used to quantify the absorbance of 
RNA at 260 nm. The presence of contaminating proteins or phenol was assessed with 
the ratio 280/260 nm, while the ratio 260/230 nm was used to determine the presence of 
other contaminants.  
 
3.2.6 Reverse Transcription (RT) 
RT reactions were performed using SuperScriptTM III reverse transcriptase (Invitrogen) 
and random decamers (Ambion). SuperScriptTM III is an engineered version of M-MLV 
reverse transcriptase that is more efficient for synthesizing cDNA. It has a reduced 
RNase H activity and increase thermal stability. RT reactions were performed for each 
sample using 1 µg total RNA concentration in a final reaction volume of 20 µL. Table 3.5 
shows the volumes and concentration of reagents used. The RT was carried out in two 
steps. First, the RNA was incubated at 65 °C for 5 minutes with the random decamers, 
dNTP mix (10 mM) (Promega) and nuclease-free water (Sigma-Aldrich). Then, the 
samples were placed on ice for 1 minute. On the second step, buffer, DTT, SuperScriptTM 




III RT and nuclease-free water was added. The samples were transferred to a G-storm 
thermal cycler (Somerston Biotechnology Centre, UK) for the following incubation steps: 
25 ºC for 5 minutes, 42 ºC for 1 hour, 50 ºC for 30 minutes, 55 ºC for 30 minutes and a 
final temperature step at 70 ºC for 10 minutes was used to inactivate the enzyme.   
 
Table 3.5 Details of reagents used for each RT reactions. 
Reagent Supplier Concentration Volume 
(µL) 
Random decamers primers Ambion 50 µM 2 
dNTP mix (dATP, dTTP, dCTP, dGTP) Promega 10 mM 1 
Nuclease-free water Sigma - 9 
First-Strand Buffer (250 mM Tris-HCL, 375 mM 
KCL, 15 mM MgCl2) 
Invitrogen 5x 4 
DTT 0.1 M 1 
SuperScript III RT 200 U/µL 1 
RNA template - 1 µg/µL 1 
Total  - - 20 
 
 
The resulting cDNA samples were diluted 1/7, by adding 120 µL of nuclease-free water 
(Sigma-Aldrich) to each 20 µL of cDNA. This concentration is referred to in this thesis as 
the “standard cDNA concentration”. cDNA samples were stored at -20 ºC. 
 
3.2.7 Quantitative PCR (qPCR) 
Quantitative PCR was used to assess TCF4 knockdown. qPCRs were completed on 96-
well plates using an MJ Chromo4TM Real Time PCR Detector (Bio-Rad) and MJ Opticon 
Monitor analytic software (Bio-Rad). Reactions were carried out in a total volume of 20 
µL, containing diluted cDNA, primers at 200 nM and 1x HOT FIREPol® EvaGreen® 
qPCR Mix Plus (Solis BioDyne). Table 3.6 shows the volume and concentration of the 
reagents used. The cycling programme used for qPCR reactions can be found in Table 
3.7.





Table 3.6 Details of reagents used for each qPCR reaction. 
Reagent Supplier Concentration Volume (µL) 
HOT FIREPol ® EvaGreen ® qPCR Mix Plus Solis BioDyne 5x 4 
Forward and reverse primer mix Sigma-Aldrich 
 
2 µM 2 
Nuclease-free water - 6 
cDNA template/nuclease-free water - - 8 
Total  - - 20 
 
 
Table 3.7 Typical qPCR cycling conditions. 
Step Temperature (°C) Time (minutes) Number of Cycles 
Initial denaturation 95 15 1 
Denaturation 95 0.3 44 
Annealing 60 0.3 
Extension 72 0.3 
For the melting profile, the temperature was raised from 60 to 95 and the fluorescence read every 
1°C increase in temperature with a hold time of 10 sec. 
 
 
QPCR primers were designed using the Primer3Plus program available online 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/). Sequences of the 
primers used for qPCR are shown in Table 3.8. 





Table 3.8 Detail of primers sequences used for qPCR analysis. 
Gene Primer Sequence (5’ - 3’) 
TCF4 Forward GAAAGCTGCGTGTCTGAAAA 
Reverse CATCTGTCCCATGTGATTCG 
GAPDH Forward CCTGACCTGCCGTCTAGAAA 
Reverse ATCCTGGTGCTCAGTGTAGCC 
RPL13A Forward CCTGGAGGAGAAGAGGAAAGAGA 
Reverse TTGAGGACCTCTGTGTATTTGTC 




Three technical replicates for qPCR reactions were performed to measure TCF4 and the 
internal control genes RPLI3A, GADPH and HPRT1 for each cDNA sample. QPCRs for 
TCF4 and the internal controls were carried out on the same PCR plate for every 
transfection experiment and each treatment (siRNA1, siRNA2 and Stealth siRNATM 
negative universal control). The level of expression of each gene was measured against 
a relative standard curve created by serial dilution of pooled cDNA taken from each of the 
assayed samples. The following arbitrary values were given to the standard curve: “5000” 
(undiluted), “1000”, “200”, and “40”, according to their relative dilutions. Consequently, a 
relative value was obtained for each of the three replicate reactions for each cDNA 
sample.  
 
3.2.8 Statistical analysis for qPCR  
Description of the data:  
1. Transfection experiments were done in five biological replicates. Each biological 
replicate has three treatments, siRNA1, siRNA2 and Stealth siRNATM negative 
universal control, leading to five biological replicates per treatment. 
2. cDNA was obtained from RNA for the five biological replicates for each treatment. 
This gave 15 cDNA samples in total. 




3. qPCR was used to measure the expression of TCF4 and three internal control 
genes, RPLI3A, GADPH and HPRT1. This was performed in triplicate, leading to 
three technical replicates for each of the 15 cDNA samples. qPCR for TCF4 and 
the internal controls was carried out on the same PCR plate.  
4. For each technical replicate I obtained one normalized value for TCF4 per 
treatment per biological replicate. Normalization was calculated using the 
geometric normalization method (Vandesompele et al., 2002). Thus, from each 
technical replicate I obtained one normalized value for TCF4 for each treatment 
per biological replicate. In total I obtained three technical replicates for 5 
biological replicates each including the three treatments. These normalized 
values were used for statistical analyses.  
 
The objective of the statistical analyses was to identify expression changes on TCF4 
mRNA level between control siRNA and siRNA conditions. To this end I used a linear 
mixed model including treatments as a fixed effect and biological replicates as random 
effects. I used a linear mixed model because it considers the systematic variation 
between biological replicates. Statistical analysis was performed using a linear mixed 
model in R (R Core Team (2013). R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria. URL http://www.R-
project.org/.) Differences of P < 0.05 were considered significant. The exact command 
using R was:  
lmer(log(normalized expression) ~ 1 + treatment +  (1|biological_replicate),data=qpcr.m). 
 
3.2.9 Proliferation assay 
Cell fixing: 
Nunc-Immuno™ MicroWell™ 96 well solid plates containing cells transfected with 
siRNA1, siRNA2 and Stealth siRNATM negative universal control were washed with 100 
µL per well of warm DPBS, and then fixed with 4% PFA for 20 minutes at room 
temperature. This was followed by two washes with DPBS for 5 minutes. Plates were 
stored at 4 °C with 100 µL per well of DPBS. 





Plates were incubated with 2N HCl, 50 µL/well for 25 minutes. Next, HCl was neutralized 
with 100 µL per well of 0.1 M Borate buffer for 10 minutes at room temperature. The wells 
were washed twice with 100 µL DPBS and then incubated with 50 µL/well of blocking 
solution (0.3% triton X-100, 5% normal donkey serum in DPBS) for 1 hour at room 
temperature. Following this, the plates were incubated overnight at with 4 °C with primary 
antibody for anti-Ki67 (Abcam, ab15580) diluted in blocking solution 1:500. The next day 
the primary antibody was removed and the wells were washed twice with DPBS. 
Subsequently, the plates were incubated with 50 µL/well of blocking solution for 30 
minutes at room temperature and the secondary antibody, Alexa Fluor® 555 Donkey 
Anti-Rabbit IgG (Invitrogen, A31542), diluted 1:500 in blocking solution was added. The 
secondary antibody was incubated for 2 h at room temperature covered from light. Next, 
the cells were washed two times with DPBS and then DAPI diluted 1:1000 in DPBS was 
added for 5 min at room temperature. The cells were then washed with DPBS and the 
plates scanned using the CellInsightTM Personal Cell Imager Cytometer (Thermo 
Scientific). 
 
Analysis of cell proliferation using Ki67 in CellInsight  
The CellInsightTM Personal Cell Imager Cytometer (Thermo Scientific) is a high content 
platform designed for quantitative imaging; it allows automated fluorescence analysis and 
quantification of proliferative cells. Cellinsight automatically scans 96 well plates and 
takes images from 15 different fields in each well. On the basis these images the platform 
can quantify total number of cell and total number of proliferative cells per well.  
 
3.2.10 Statistical analysis for cell proliferation 
Description of the data:  
1. Transfection experiments were done in five biological replicates. Each biological 
replicate has three treatments, siRNA1, siRNA2 and Stealth siRNATM negative 
universal control, leading to five biological replicates per treatment. For 
proliferation assays 10 wells of a Nunc-Immuno™ MicroWell™ 96 well solid 




plate, containing CTX0E16 or CTX0E03 cells, were transfected for each siRNA 
treatment, leading to 10 technical replicates for each biological replicates for each 
cell line. 
2. The effect of TCF4 knockdown on the proliferation of CTX0E16 and CTX0E03 
cells was analysed by ki67 inmunostaining. Cell counts for proliferating cells (ki67 
positives) and total number of cells per well for each treatment in the five 
biological replicates (five plates) were obtained from Cellinsight. These values 
were used in the statistical analyses. 
 
The objective of the statistical analyses was to identify the differences in cell proliferation 
between cells treated with control siRNA and TCF4 siRNA conditions. To this end I used 
a Poisson linear mixed model in R (R Core Team (2013). R: A language and environment 
for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL 
http://www.R-project.org/.). This model compares the rate between treatments, taking into 
account the sample size, including cell counts for proliferating cell and total number of 
cells per treatment (siRNA1, siRNA2 and negative control siRNA) in the five biological 
replicates. The analysis considers the systematic variation between plates with a fixed 
effect per treatment and random effect per plate. Differences of P < 0.05 were considered 
significant. 
The exact command using R was:  
glmer(count_proliferating_cells ~  offset(log(count_total_cells)) + Treatment + (1|Plate) 
,data=data.m2 , family='poisson'). 





3.3.1 Transfection efficiency of siRNA. 
To determine transfection efficiency, cells transfected with the BLOCK-iT Alexa Fluor® 
Red Fluorescent Oligo were checked 24 hours post-transfection by fluorescence 
microscopy. Transfection efficiency was very high with >80% of cells presenting red 






Figure 3.1 Assay of transfection efficiency using the N-TER™ Nanoparticle siRNA 
Transfection System from Sigma. 
Transfection efficiency was measured by the uptake of BLOCK-iT Alexa Fluor red Fluorescent 
Oligo into neuronal progenitor cells CTX0E03 (A) and CTX0E16 (B). Fluorescence was checked 24 
hours post-transfection. Images were taken using the inverted microscope Olympus Ix70 using 
AxioVision 4.8 Imaging software (Zeiss). Scale bar 100 nm. 





3.3.2 Knockdown of TCF4 mRNA in CTX0E16 and CTX0E03 cells. 
Confirmation of TCF4 mRNA knockdown, relative to the negative control siRNA, was 
assessed by quantitative qPCR. The qPCR values for TCF4 mRNA expression level were 
normalized against the geometric average of three internal control genes (RPLI3A, 
GADPH and HPRT1). Table 3.9 and Table 3.10 show the normalized data for CTX0E16 
and CTX0E03 cell lines, used in the statistical analyses.  
 
 
Table 3.9 Normalized TCF4 expression values obtained in CTX0E16 cell line. These values 
were used in statistical analysis applying a linear mixed model. 
Treatment Normalized values for TCF4 Biological 
replicate qPCR 1 qPCR 2 qPCR 3 
siRNA1 0.8892 0.8812 0.7748 1 
siRNA1 1.0809 0.9022 1.3119 2 
siRNA1 0.6614 0.4276 0.5016 3 
siRNA1 0.2254 0.1397 0.3057 4 
siRNA1 0.2545 0.0826 0.3571 5 
siRNA2  0.8365 0.7772 1 
siRNA2 0.7370 0.6437 0.7138 2 
siRNA2 0.7008 0.4941 0.4140 3 
siRNA2 0.2094 0.1693 0.3433 4 
siRNA2 0.3859 0.3864 1.2033 5 
control 0.8080 0.9786 0.7820 1 
control 1.2124 1.0225 0.9007 2 
control 0.5042 0.3978 0.3929 3 
control 0.7143 0.7145 0.6797 4 
control 0.3202 0.4193 0.6579 5 
 





Table 3.10 Normalized TCF4 expression values obtained for CTX0E03 cell line. These values 
were used in statistical analysis applying a linear mixed model. 
Treatment Normalized values for TCF4 Biological replicate 
qPCR 1 qPCR 2 qPCR 3 
siRNA1 0.8031 0.6791 0.6266 1 
siRNA1 1.0834 0.9797 1.2306 2 
siRNA1 0.6731 0.4935 0.6576 3 
siRNA1 0.1597 0.1219 0.0949 4 
siRNA1 0.3400 0.2880 0.3295 5 
siRNA2 0.8907 0.8487 0.9828 1 
siRNA2 1.0506 1.0723 0.8381 2 
siRNA2 0.5474 0.5629 0.5394 3 
siRNA2 0.1881 0.1755 0.2088 4 
siRNA2 0.2385 0.2526 0.3655 5 
control 0.6591 0.5180 0.8369 1 
control 1.2239 1.5834 1.5326 2 
control 0.5677 0.5152 0.7036 3 
control 1.2455 0.3860 0.6460 4 
control 0.2575 0.2206 0.2576 5 
 
 
Statistical analyses were performed applying a linear mixed model in order to identify 
expression changes in TCF4 mRNA level between control siRNA and TCF4 siRNA 
conditions. The results obtained from the statistical analysis, for CTX0E16 and CTX0E03 
cell lines, are show in Table 3.11 and Table 3.12. 
!
 
Table 3.11 Statistical results for TCF4 expression in the CTX0E16 cell line. 
Treatment Estimate SE Pr(>|t|) Mean 
expression 
mean-1SE mean+1SE Fold 
change (%) 
control -0.4265 0.2310  0.6528 0.5181 0.8224 100 
siRNA1 -0.7827 0.2310 0.0347 * 0.4572 0.3629 0.5760 70.0333 
siRNA2 -0.6564 0.2332  0.1731 0.5187 0.4108 0.6550 79.4613 





Table 3.12 Statistical results for TCF4 expression in the CTX0E03 cell line. 
 
 
TCF4 expression was represented relative to the negative control for both cell lines in 
Figure 3.2.  The Figure 3.2 show reduced TCF4 expression on CTX0E16 cell by 30% and 
21% respectively relative to negative control siRNA, being only significant (P = 0.0347) 
for siRNA1. Similarly, a significant reduction of 28% in TCF4 expression was observed in 
CTX0E03 cells transfected with siRNA1 (P = 0.0261). siRNA2 reduced TCF4 expression 





Treatment Estimate SE Pr(>|t|) Mean 
expression 
mean-1SE mean+1SE Fold 
change (%) 
Control -0.4759 0.3024  0.6213 0.4592 0.8407 100 
siRNA1 -0.8037 0.3024 0.0261 * 0.4477 0.3308 0.6057 72.0507 
siRNA2 -0.7295 0.3024  0.0812 0.4822 0.3563 0.6524 77.6002 








Figure 3.2 Expression of TCF4 mRNA after RNAi transfection 
QPCR result showing TCF4 mRNA expression 90 hours post-transfection with two independent 
TCF4 siRNAs (siRNA1 and siRNA2). Data are normalized against the geometric average of 3 
housekeeper genes and plotted relative to the negative control siRNA. TCF4 mRNA was reduced 
by 30 % and 21% in association with siRNA1 (P = 0.0347) and siRNA 2 (P = 0.1731) respectively 
for CTX0E16 cells (A). A reduction of TCF4 mRNA expression of 28% and 22.4% in association 
with siRNA1 (P = 0.0261) and siRNA 2 (P = 0.0812) respectively was observed on CTX0E03 (B). 
Error bars represent SEM derived from five separate transfection experiments. Asterisks shows 
where the expression of TCF4 is significantly different from control (P < 0.05). 





3.3.3 Effect of TCF4 knockdown on cell proliferation. 
The effect of TCF4 knockdown on the proliferation of CTX0E16/02 and CTX0E03 cells 
was analysed by ki67 inmunostaining. Background staining for ki67 was removed by 





Figure 3.3 Examination of ki67 inmunostaining.  
90 hours after transfection cell proliferation was evaluated by ki67 inmunostaining assay. For all 
conditions a negative control, which was only stained for secondary antibody and DAPI, was used 
to eliminate background (false positive staining for ki67). Positive ki67 cells were quantified using 
Cell Insight. Images were taken using Cell Insight (Thermo). Scale bar 50 μm.  




Cell counts for proliferating cells (ki67 positives) and total number of cells per well for 
each treatment in the five biological replicates (five plates) were used in the statistical 
analyses. Because the number of cells observed per well in each treatment and in the 
five biological replicates was variable, I decided to analyse my data using a mixed-model 
to account for this systematic variation. In addition, I used a Poisson linear mixed-model 
in order to account explicitly for the total number of cells in the well when comparing the 
fraction of proliferating cells. This helps avoid potentially misleading results due to very 
different number of cells across treatments or biological replicates. For instance, simply 
using the fraction of proliferating cells but ignoring the total number of cells would deem a 
ratio of 50% equal from a well with 100 or 10000 total cells, when in the second case 
there is much more certainty that the ratio is 50%. The analysis considers treatments as 
fixed effects and aims to account for the systematic variation between by modelling 
biological replicates as random effects. Below, I will describe in detail the process used to 
summarise and filter the data in order to perform statistical analyses as well as checks I 
did to understand the statistical results and their robustness. 
 
Data analysis for CTX0E16 
1. Firstly, I explored the variability in total number of cells per biological replicate 
and well (Figure 3.4, top). Plate 4 had very few cells for both siRNA and plate 5 
had more cells than any other plate for all the three treatments. I also examined 
the fraction of proliferative cells (Figure 3.4, bottom); plate 4 showed the greatest 
variability in the raw proliferation ratio. 





Figure 3.4 Total number of cells for each treatment per plate (top) and fraction of 
proliferative cells for each treatment per plate (bottom), for CTX0E16 cell line. 





2. Then I examined the relationship between total number of cells and number of 
proliferating cells (Figure 3.5). This confirmed previous observations for plate 4 
and showed that some wells have a very low number of proliferating cells, which 
coincide with wells with low cell counts. It also showed that plate 5 has more 





Figure 3.5 Relationship between total number of cells and proliferating cells for each 




3. Based on observations from point 2, I decided to remove from the analysis wells 
with less than 100 cells and to remove plate 4 due to the low cell counts 













Figure 3.6 Total number of cells for each treatment per plate (top) and fraction of 
proliferative cells (bottom). These data excluded plate 4 and wells with less than 100 cells. 
Data obtained on CTX0E16 cell line. 
!
!
4. In order to take into account the difference in the total number of proliferating 
cells in different wells I used a Poisson model, which explicitly models this. As 
explained before, using the ratio of proliferating/total number of cells would ignore 
differences in total number of cells and regards as equal a case with ratio of 50% 
from counts 10/20 or 1000/2000 in spite that the second case has a much more 
certainty that the ratio is 50%. In order to account for the systematic variation 
across wells and biological replicates I used a generalized linear mixed model. 
a) First I analysed the data removing plate 4 and wells with less than 100 
proliferating cells. The statistical results are show in Table 3.13: 
 





Table 3.13 Statistical results for proliferating CTX0E16 cells with plate 4 removed and 
removed wells with less than 100 proliferating cells. 
!
!
! b) Finally, I analysed the data removing plate 4 and wells with less than 100 
proliferating cells, and removing plate 5 to test if the significance of 
treatment ‘siRNA2’ is driven by this plate with unusual high levels of cell 
count and proliferation: This is the final data to be used for discussion 
(Table 3.14).#
 
Table 3.14 Final data showing the effect of TCF4 knockdown on CTX0E16 cell proliferation. 
Statistical results were obtained by removing plate 4 and 5 as well as wells with less than 
100 proliferating cells. 
 
 
Treatment Estimate SE Pr(>|z|) Mean 
proliferation 
mean-1SE mean+1SE Fold 
change (%) 
Control -0.2714 0.0597  0.7623 0.7181 0.8092 100 
siRNA1 -0.2384 0.0598 2.96E-11*** 0.7879 0.7422 0.8364 103.3582 
siRNA2 -0.2527 0.0597 3.88E-05*** 0.7767 0.7317 0.8245 101.8937 
Treatment Estimate SE Pr(>|z|) Mean 
proliferation 
mean-1SE mean+1SE Fold 
change (%) 
Control -0.2207 0.0631 ! 0.802 0.7529 0.8542 100 
siRNA1 -0.1788 0.0632 4.53E-09*** 0.8363 0.785 0.8908 104.2801 
siRNA2 -0.2272 0.0631 0.2942 0.7968 0.748 0.8487 99.3561 





Data analysis for CTX0E03 
I repeated the same process used on the CTX0E16 cell line: 
1. First I examined the variability in total number of cells per biological replicate and 
wells (Figure 3.7, top), plate 1 and 5 showed a low number of cells in all the wells 
and treatments. Then I looked at the fraction of proliferative cells (Figure 3.7, 
bottom), and observed a general variability in the fraction of proliferative cell 
across biological replicates. It could be misleading not to account for total number 




Figure 3.7 Total number of cells for each treatments per plate (top) and fraction of 










2. Then I examined the relationship between total number of cells and number of 
proliferating cells (Figure 3.8). A consistent linear relationship between the 
number of proliferating cells and the total number of cells was observed. This is 
expected if the cells proliferate at a constant rate across biological replicates. 
However, there were some wells with very low number of proliferating cells. This 




Figure 3.8 Relationship between total number of cells and proliferating cells for each 
treatment per plate, observed on CTX0E03 cell line. 
!
!
3. Based on observations from point 2, I decided to remove the wells with less than 
100 total cells, since they seemed to behave differently from the rest. This 
removed completely plates 1 and 5 and some wells from the remaining plates. 
This lead to the following dataset: Figure 3.9. 
 








Figure 3.9 Total number of cells for each treatment per plate (top) and fraction of 
proliferative cells (bottom). These data excluded plates 1 and 5. Data obtained on the 
CTX0E03 cell line. 
 
!
4. In order to account for the systematic variation across wells and the two 
remaining biological replicates I used a generalized Poisson linear mixed model. 
a) First I analysed the filtered data, removing wells with less than 100 




Table 3.15 Statistical result for proliferating CTX0E03 cells, with wells with less than 100 
proliferating cells removed. 
Treatment Estimate SE Pr(>|z|) Mean 
proliferation 
mean-1SE mean+1SE Fold 
change (%) 
Control -0.4933 0.0563  0.6106 0.5772 0.6460 100 
siRNA1 -0.6940 0.0567 3.25E-23*** 0.4996 0.47219 0.5287 81.8202 
siRNA2 -0.5263 0.0565 0.0964 0.5908 0.5583 0.6251 96.7527 
!





b) Finally, in order to compare I re-analysed the data without filtering, the 
statistical results are show in Table 3.16: 
!
!
Table 3.16 Statistical result for proliferating CTX0E03 cells, without filtering. 
!
!
The comparison of both statistical results suggests that both results are consistent. 
Without filtering the data siRNA2 would be declared significant (P < 0.05). Given that this 
result is only seen with the data I considered not reliable was included, I did not consider 
the results obtained by analysing all the data robust. For the CTX0E03 cell line, the final 
data used for discussion was therefore the filtered data for >100 cells.  
 
Summary of proliferation results for CTX0E16 and CTX0E03 cell line: 
The fraction CTX0E16 proliferative cells increased when TCF4 was knocked down with 
siRNA1 and siRNA2, relative to the negative control siRNA condition. Table 3.14 shows 
an increase in cell proliferation occurring in association with siRNA1 and siRNA2, 
although this was only significant for siRNA1 (P = 4.53x10-9, fold change 104.3%). In 
contrast, when CTX0E03 were transfected with TCF4 siRNAs a decrease in cell 
proliferation was observed in association with siRNA1 and siRNA2, which was again only 
significant for siRNA1 (P = 3.25x10-23, fold change 81.8%), Table 3.15.  #
 
Treatment Estimate SE Pr(>|z|) mean 
proliferation 
mean-1SE mean+1SE Fold 
change (%) 
Control -0.9388 0.3980  0.3911 0.2627 0.5823 100 
siRNA1 -1.2065 0.3981 2.03E-42*** 0.2992 0.2010 0.4456 76.5127 
siRNA2 -1.0020 0.3980 0.0011** 0.3671 0.2466 0.5466 93.8703 






The main aim of the experiments described in this Chapter was to assess the effect of 
downregulating endogenous TCF4 on the proliferation of two karyotypically normal neural 
progenitor cell lines derived from human foetal brain, CTX0E16 and CTX0E03, and 
determine if the direction of the effect differs between the cell lines. To this end I used 
RNAi followed by cell proliferation assays. 
 
TCF4 knockdown altered the proliferation of both cell lines, with one cell line showing 
decreased proliferation and the other showing increased proliferation. Interestingly, the 
effect on proliferation and the direction of the effect is consistent with the gene expression 
data obtained by Dr Nick Bray’s group. Both lines of evidence suggest a cell-specific 
effect of TCF4 knockdown. I have two possible explanations for these results. The first 
one is that the two cell lines are expressing different TCF4 transcripts that are being 
knocked down. A previous study showed that TCF4 gene has numerous exons and 
produces several transcripts resulting in a differential subcellular distribution and 
transactivational capacity of TCF4 isoforms (Sepp et al., 2011). However, RT-PCR data 
obtained by James Docker, a former MSc student in Dr Bray’s Lab, found no differences 
in the TCF4 transcripts being expressed by both cell lines (Figure 3.10). 
 
Figure 3.10 Expression of alterative TCF4 transcript in CTX0E16 and CTX0E03 neuronal 
progenitor cell lines. RT-PCR analysis of TCF4 transcripts with different 5' exons. 
 




A second possible explanation is that both cell lines are expressing different interactors of 
TCF4 and this may cause the opposing effects. As previously described, TCF4 can act as 
a transcriptional activator or repressor depending on the heterodimers formed with other 
bHLH proteins (Murre, 2005; Sweatt, 2013), and TCF4 subcellular localization is also 
dependant on its interactors (Sepp et al., 2011). Furthermore, heterodimers with tissue 
specific bHLH proteins are essential in regulating the function of bHLH proteins and 
determining which specific DNA sites will be recognized (Goldfarb et al., 1996). 
Consistently, the micro-array data obtained by Dr Nick Bray show that both cell lines 
expressed a distinctive group of bHLH genes (assessed in the control cells). 44 bHLH 
genes are commonly expressed in both cell lines of the total of 58. 3 and 5 bHLH genes 
are unique for CTX0E03 and CTX0E16 respectively. Unique bHLH genes for CTX0E03 
cell line are, BHLHB3, HES2 and SOHLH2; and for CTX0E16 cell line, ARNT, ATOH8, 
MYCN, OLIG2 and SREBF2. Additionally, 10 out of the 37 bHLH genes expressed in 
both cell lines show significant differences in expression between them (Bonferroni 
corrected P < 0.05, for 45 probes tested). Of these, ID1 is an interesting candidate to 
explain the opposite behavior of the two cell lines. Parrinello et al (Parrinello et al., 2001) 
provides evidence suggesting that the effect of ID1 in mammary epithelial cell 
proliferation occurs through its interaction with TCF4. They observed a reduction of ID1 
stimulated proliferation when TCF4 was overexpressed; suggesting that higher 
expression of ID1 is associated with higher proliferation. Interestingly, in the present 
study the CTX0E16 cell line showed higher proliferation than CTX0E03 in the control 
condition and this correlated with ID1 expression. ID1 expression is on average 16% 
higher for CTX0E16 compared with CTX0E03 (P = 0.0001, Bonferroni corrected P = 
0.0045, for 45 probes tested). This suggests that interaction between TCF4 and ID1 
might account for the differences in proliferation observed between both cell lines. 
However, more studies are necessary to confirm this observation and the mechanism for 
these effects. 
 
In addition, preceding studies revealed that TCF4 regulates the expression of two genes 
involved in cell cycling and proliferation, namely p57kip2 and p21cip1 (Herbst et al., 2009; 




Schmidt-Edelkraut et al., 2014). These studies were conducted in mouse neuronal 
progenitors and colorectal cancer cells lines for p57kip2 and p21cip1, respectively. As ID1, 
p57kip2 and p21cip1 are candidates to explain the mechanism by which TCF4 effects cell 
proliferation, it would be interesting to investigate the expression of these in the two cell 
lines. 
 
Several studies have focused on the role of cell proliferation in the pathogenesis of 
schizophrenia. Reif et al (Reif et al., 2006) report reduced ki67 staining in post-mortem 
brain from patients with schizophrenia, but not depression, compared with that from 
controls. Additionally, Wang et al, (Wang et al., 2010) demonstrated altered cellular 
proliferation and growth pathways in fibroblast obtained from schizophrenia patients and 
recent studies in olfactory neurosphere-derived cells from schizophrenia patients showed 
an association between altered cell cycle and schizophrenia (Fan et al., 2012). Patients 
with schizophrenia showed increased cell proliferation associated with altered dynamics 
of expression of cyclin proteins. Furthermore, there is evidence showing changes in cell 
proliferation mediated by drugs used to treat schizophrenia, such as valproic acid, 
olanzapine and others (Dodurga et al., 2014; Kimoto et al., 2011; Kurihara et al., 2014; 
Niu et al., 2010; Schwarz et al., 2008).  
 
Here, knockdown of TCF4 in two neuronal progenitor cell lines provides evidence for its 
involvement in the regulation of cell proliferation. These physiological data strongly 
complement the gene expression data previously obtained by Dr Bray's Lab and accord 
well with the known biology of TCF4 and multiple lines of evidence associating altered 
cell proliferation with schizophrenia pathogenesis. Altogether, these findings suggest that 
allelic variation on the TFC4 loci might affect proliferation of neural cells and in this way 
contributes to the pathogenesis of schizophrenia. The differential effect on the two cell 
lines highlights how cellular consequences of altered gene function can depend on cell 
type, potentially, among other factors, due to interacting genes showing cell type 
differential expression. ID1, p57kip2 and p21cip1 constitute potential candidates to further 
elucidate this cell type specific effect.  




Limitations of the study: 
The present study is the first one to provide experimental evidence for the biological 
effect of TCF4 knockdown in neural progenitor cell lines derived from human foetal brain. 
However, in order to understand the cell specific trasncriptional effect of TCF4 
knockdown follow up studies in mature neuronal cells will be needed. 
Additionally, the present study fail to show the relevance of the risk variant effect for 
schizophrenia. So far studies have been unsuccessful in finding association between the 
risk variants and TCF4 expression in adult brain. This may reflect outcomes for other 
schizophrenia risk SNP exerting its effect only in foetal brain such in ZNF804a (Hill and 























Chapter 4. Allelic expression of VRK2 in the human brain 
 
4.1 Introduction 
VRK2 is a member of the vaccinia-related kinase (VRK) family of serine/threonine 
kinases and is located at chromosome 2p16.1. VRK2 gene is widely expressed in human 
tissues, especially those that are highly proliferative (Nezu et al., 1997). Two splice 
variants generate isoforms A and B of 508 and 397 amino acids, respectively (Figure 
4.1). The specific subcellular location of these isoforms is dependant of cell type (Blanco 
et al., 2006). 
 
The single nucleotide polymorphism (SNP) rs2312147 is located at chromosome 2p15.1 
within the first intron of the long splicing isoform of VRK2 and about 50kb upstream of the 
short isoform. The C-allele of this variant has been associated with increased risk to 
schizophrenia in multiple GWAS. Stefansson et al. (Stefansson et al., 2009) initially 
reported the association at rs2312147 with a p-value not reaching genome-wide 
significance (odd ratio OR = 1.09, P = 3.2x10-7) but a follow up study provided robust 
statistical evidence of association with rs2312147[C] (odd ratio OR = 1.10, P = 5.4x10-10) 
(Steinberg et al., 2011). This association has gained additional support in a recent meta-
analysis in Asian populations (Li et al., 2012) and is supported by replication studies (Irish 
Schizophrenia Genomics and the Wellcome Trust Case Control, 2012; Li et al., 2012). 
 
 






















Figure 4.1 Genome browser view of VRK2. 
Information displayed from top to bottom is: scale, chromosome position, chromosome band, VRK2 
gene models provided by UCSC, Schizophrenia associated SNP, Histone binding determined by 
Chip-Seq (ENCODE project), promoter activity (ENCODE project), transcription activity (ENCODE 
project), DNase I hypersensitivity (ENCODE project), transcription factor binding sites determined 
by Chip-seq (ENCODE project), multiple species conservation and comparisons, linkage 
disequilibrium in HapMap CEU samples. 





Rs2312147 has been associated with brain structure variations in healthy subjects, 
including total brain and white matter volume, with individuals carrying the risk C-allele 
tending to have smaller volumes (Li et al., 2012). However, as with most loci associated 
by GWAS, the molecular mechanisms mediating the statistical association at rs2312147 
have not been clearly elucidated. Given its location in noncoding sequence close to the 
first exon it is plausible that this genetic variant (or another in LD with it) affects the 
regulation of the expression of the gene.  
Differences in gene expression are an important determinant of human phenotypic 
variability including susceptibility to complex diseases (Bray et al., 2003; Dermitzakis, 
2008). For example, it has been shown that schizophrenia susceptibility alleles are en 
masse enriched for alleles that affect gene expression in brain (Richards et al., 2012). A 
gene’s expression is regulated by both trans and cis-acting influences. Trans-acting 
regulation operates on both chromosomal genes copies through a remote source (e.g., 
transcription factors), generally affecting expression of each allele to the same extent. 
Cis-acting influences reside in the same DNA molecule as the regulated gene (Figure 
4.2) and are allele-specific. Importantly, both regulatory mechanisms are affected by 
genetic variation and epigenetic marks (Bell et al., 2011; Dimas et al., 2008; Dixon et al., 
2007b; Stranger et al., 2007). 
 
 








a  Cis (local)
b  Trans (distal)
T
Figure 2 | Effect of cis- and trans-acting DNA variants on expression levels of genes. 
Polymorphic forms of regulators that act in cis (a) or in trans (b) to the target genes 
(also called local and distal regulators, respectively) result in variation in expression 
levels of the target genes. Cis-acting variants are found close to the target genes  
and trans-acting variants are located far from the target genes, often on another 
chromosome. Different allelic forms of the cis- and trans-acting variants have 
different influence on gene expression. In this example, individuals with the G 
variant of the cis regulator have a higher expression level  of the target gene than 
individuals with the C variant of the regulator. Similarly, individuals with the A 
variant of the trans regulator have a higher expression level of the target gene than 
those with the T variant of the regulator. 
RNA-Seq
Sequence analysis of RNA (for 
example, after conversion into 
cDNA); the results can be used 
for various analyses, including 
study of gene expression, 
identification of coding SNPs 
and determination of 
allele-specific gene expression.
Some insights are offered by fine association mapping 
(BOX 1), which can identify more precisely where the reg-
ulatory variants are relative to the target genes. For exam-
ple, in our analysis of 133 gene expression phenotypes, 
association mapping results showed that the regulatory 
sites are found in approximately the same proportion 
at the 5? (27%) and 3? (34%) ends of the genes, and within 
the target genes (25%)7. For 14% of the phenotypes, link-
age disequilibrium was so strong that we were not able to 
narrow the region of cis association. The variants in the 
5? ends of genes may affect RNA polymerase II and tran-
scription factor binding7,45,46, those in the 3? ends may 
affect stability of the transcripts47,48, and variants in genes 
can also affect binding of transcription factors27.
Trans-acting variants. Trans-acting variants are more 
difficult to identify because, unlike cis variants, they can 
be anywhere in the genome relative to the target gene, 
and genetic mapping results suggest that their effects 
on gene expression are smaller than the effects of cis-
acting variants. This is probably because genes are usu-
ally influenced by several trans-acting regulators and, 
therefore, the effect of each trans-acting regulator on 
expression of its target gene is small, whereas there is 
usually one or only a few cis-acting regulators. However, 
to understand gene regulation, it is crucial to identify 
trans-acting regulators. 
Although trans-acting regulatory regions have been 
identified through linkage analysis6,26,27 and associa-
tion studies32, only a few trans-acting determinants of 
baseline gene expression have been identified. In 
linkage analysis, the candidate regulatory regions are 
often megabases in size and include several candidate 
regulators. FIGURE 4 illustrates how trans-acting regula-
tory regions can be found by linkage analysis: for the 
expression level of PDCD10 (programmed cell death 
10, located on chromosome 3), two significant link-
age peaks were found — one on chromosome 4 and 
another on chromosome 19. The peaks on both chro-
mosomes are several megabases in size. These regions 
contain the polymorphic trans-acting regulators that 
influence expression of PDCD10; fine mapping of the 
regions is needed to identify the regulatory variants. 
Despite the challenge of identifying trans-acting reg-
ulators, some examples of polymorphic trans-acting 
regulators of gene expression are beginning to emerge. 
Examples of genes in which regulatory variants exert 
a trans-acting effect include the epoxide hydrolase 1 
gene (EPHX1), which regulates expression of ORMDL3 
(REF. 31), and BCL11A (encoding a zinc finger pro-
tein), which influences γ-globin gene expression49. 
EPHX1 was identified in a genome-wide association 
analysis of gene expression, and regulatory variants in 
BCL11A were identified in a search for regulators that 
influence individual variation in fetal haemoglobin 
level. 
Even though only a few trans-acting regulators of 
gene expression have been identified, and many trans-
acting regulatory regions are large, analyses of these 
regions in the human genome are leading to a better 
understanding of gene regulation. These analyses sug-
gest that trans-acting regulators are not enriched for 
known regulators of gene expression such as transcrip-
tion factors or signalling molecules; instead, the poly-
morphic trans-acting regulators belong to diverse groups 
of genes, from cell surface receptor genes to structural 
genes. Similar findings were reported by Kruglyak and 
colleagues in their analysis of gene expression vari-
ation in yeast50. Despite the relative lack of progress 
in identifying trans-acting regulators of baseline gene 
expression, we discuss in a later section how poly-
morphic trans-acting regulators have been identified 
in studies of cells exposed to external stimuli. 
Regulatory landscapes among different cell types. 
Unlike studies in model organisms such as yeast and 
Caenorhabditis elegans, studies of human gene expres-
sion cannot be carried out on whole organisms; instead, 
they are mostly restricted to specific cell types. As men-
tioned above, GOGE studies in humans have been car-
ried out in various cell types, including lymphocytes, 
immortalized B cells, brain cells and liver cells. Even 
though some gene expression patterns are cell type 
specific, a large fraction of GOGE findings seem to be 
shared across different types of cells. For example, a 
comparison of results from a study of immortalized 
B cells with those from primary lymphocytes showed 
that seven of eight cis-linked phenotypes were shared 
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Figure 4.2 Cis and trans regulatory variations. a) A cis-regulatory variant gives more mRNA 
from the gene copy carrying the G allele than th  C allel . b) Trans regulatory variant can have 
different affinity for a target gene leading to different levels of RNA transcription (taken from 
Cheung and Spielman, (Cheung and Spielman, 2009)). 
 
 
Rs2312147 could regulate VRK2’s transcription and therefore affect its mRNA levels in 
cis. This can be determined using an eQTL (expre sion qu ntitative trait loci) approach, 
where measurements of total gene expression are correlated with genotype in order to 
estimate the functional contribution of regulatory variant  (Nica and Dermitzakis, 2008). 
However, in a previous study, Li et al (Li et al., 2012) did not found an association of 
rs2312147 with gene expression in blood samples.  
 
It is important to consider that measures f total expression are complicated and fail to 
distinguish between cis-acting and trans-acting influences (Stamatoyannopoulos, 2004). 
The eQTL approach is prone to all types of confounds reducing the power to detect cis 
effects of SNPs, particularly in post-mortem brain. Some of these confounding factors 
are: differences in tissue and mRNA quality, cellular composition of samples, 
environmental exposure such as drugs or pre-agonal state and trans-effects of other 
gene loci. Furthermore, a recent study (Almlof et al., 2012) showed that eQTL 




approaches required up to 8 times more samples than allelic expression measures to 
detect the effects of the same cis-regulatory variants.  This study was performed using 
lymphoblast where the tissue variables are largely controlled. 
 
Analysis of allelic expression appears as an alternative and powerful method to indirectly 
detect influences of specific haplotypes on a gene’s expression (Yan et al., 2002). It has 
been successfully used to detect differences in allelic expression of other schizophrenia 
susceptibility genes in adult and foetal brain (Buonocore et al., 2010; Hill and Bray, 2012), 
supporting its ability to generate new insight into the fundamental biology of 
neuropsychiatric phenotypes. 
 
Assays of allelic expression make use of a SNP localised in an exonic region of the gene 
to quantify and discriminate RNA molecules transcribed from each chromosome in 
heterozygous subjects (Figure 4.3). This method focuses on allelic variation within a 
subject so each allele serves as an internal control while controlling for potential trans-
acting influences, like tissue preparation, RNA quality or environmental influences 
between others (Bray et al., 2003). A significant departure from the expected 1:1 allele 
ratio in any assayed sample denotes the presence of cis-acting regulatory variation (Bray 
et al., 2003; Yan et al., 2002).  
 
Interestingly, previous studies have revealed that the effects of cis-regulatory variations 
can differ between tissues, cell types and even developmental stages (Buonocore et al., 
2010; Cowles et al., 2002; Dimas et al., 2009; Hill and Bray, 2012; Zhang et al., 2009), 
making analyses of allelic expression an attractive tool to determine when and where a 
risk variant affects the expression of a gene. 






Figure 4.3 Principles of relative allelic expression. 
In the absence of cis-acting regulatory variation, each copy of a gene (both alleles) will be equally 
expressed. Conversely, if the subject is heterozygous for a cis-acting variant affecting the 
expression of the gene, the mRNA from each copy is expressed differentially (Reproduced from 
http://www.icarda.org/generationcp/cp-1-allele.htm). 
 
In this study, the effect of the schizophrenia associated polymorphism rs2312147 on 
VRK2’s allelic expression imbalance was tested by comparing homozygotes and 
heterozygotes for this SNP. If rs2312147 was associated with altered gene expression a 
greater relative difference in the expression of each gene copy would be observed in 
heterozygous individuals compared with homozygotes (Bray and O'Donovan, 2006). 
 
4.1.1 The aim of the present study 
The aim of experiments presented on this chapter was to test two hypotheses: a) that 
VRK2’s expression is subject to variable cis-regulatory influences in the human brain, and 
b) that rs2312147 is associated with altered cis-regulation of VRK2 in the human brain. 
To this end I performed allelic expression assays on dorsolateral prefrontal cortex 
(DLPFC) in adult human brain and two stages of foetal brain development. 
 





4.2.1 Brain Samples 
Adult brain samples 
Post-mortem adult human brain tissue was obtained from the Medical Research Council 
London Neurodegenerative Diseases Brain Bank. Genomic DNA had previously been 
extracted from 96 of these subjects by Dr N. Bray and was made available for this study. 
All subjects were free from a psychiatric or neurological diagnosis at the time of death. 
The allelic expression assay was performed using RNA derived from the dorsolateral 
prefrontal cortex (DLPFC) of 35 of these subjects who were identified by genotyping (see 
section 4.2.9) as heterozygous for the expressed SNP rs1051061. RNA was already 
available from 24 of these subjects within Dr Bray’s lab. Tissue from the DLPFC of the 
remaining 11 heterozygous subjects was requested from the brain bank and RNA 
extracted (see section 4.2.2). Demographics for the 35 adult subjects assayed for VRK2 
allelic expression are shown in Table 4.1. 
 
Foetal brain samples 
Human foetal brain tissue from terminations of pregnancy was provided by the Human 
Developmental Biology Resource, Institute of Child Health, University College London. 
Genomic DNA from 40 first trimester and 110 second trimester foetal brain samples had 
previously been extracted by Dr N. Bray and Dr M. Hill was made available for this study. 
The allelic expression assay was performed using RNA derived from the whole brain of 
10 first trimester foetuses and 38 second trimester foetuses that were identified by 
genotyping (see section 4.2.9) as heterozygous for the expressed SNP rs1051061. RNA 
was already available from all samples within Dr Bray’s lab.  Demographics of the 10 first 
trimester and 38 second trimester samples assayed for VRK2 allelic expression are 
shown in Table 4.1. 
 
Ethical approval for this study was obtained from the Joint South London and Maudsley 
and the Institute of Psychiatry National Health Service Research Ethics Committee 
PNM/12/13-102. 





Table 4.1 Demographics of subjects assayed for VRK2 allelic expression in the present 
study. 




Age at Death  Post mortem delay 
(h) 
M F Mean Range Mean Range 
Adult Brain 
DLPFC 









































N= the total number of subjects used in the study. Sex: F=female, M= male. Numbers in 
parenthesis represent the standard deviation.  
 
 
4.2.2 RNA  extraction and cDNA synthesis 
Total RNA was extracted from frozen brain samples using the Tri-Reagent® Solution 
(Ambion, Life Technologies, Grand Island, N.Y.). Each human brain sample was stored at 
-80 °C in Lysing Matrix D tubes (MP Biomedicals). ~100 mg per sample was 
homogenized with 1 mL of Tri-Reagent® Solution using FastPrep® -24 Instrument (MP 
Biomedical) for 45 seconds at speed setting of 5. After homogenization, samples were 
transferred to a clean microcentrifuge tube. Total RNA was extracted following the 
protocol described in section 3.2.3 (Chapter 3). RNA concentration and purity was 
quantified using the NanoDropTM 1000 spectrophotometer.  
 
DNAse treatment of total RNA samples was performed with TURBO DNA-freeTM 
(Ambion) (as described in section 3.2.4, Chapter 3). Two RT reactions were performed 
for each sample. cDNA was synthesized from 1 µg total RNA from each sample using 
SuperScriptTM III reverse transcriptase (Invitrogen) and random decamers (Ambion) in 
final reaction volume of 20 µL (a detailed protocol can be found in section 3.2.6, Chapter 




3). The resulting cDNA samples were diluted 1/7, by adding 120 µL of nuclease-free 
water (Sigma-Aldrich) to each 20 µL of cDNA, before assaying allelic expression. This 
concentration is referred to in this thesis as the “standard cDNA concentration”. cDNA 
samples were stored at -20 °C 
 
4.2.3 Primer design 
PCR primers used to amplify the region containing the SNPs of interest (Table 4.2) were 
designed using the Primer3Plus program available online 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/). Input DNA sequences 
were retrieved from the Chip Bioinformatics Tool website (http://snpper.chip.org/), the 
UCSC genome browser (http://genome.ucsc.edu/) and from the ENSEMBL genome 
browser (http://www.ensembl.org/index.html).  
 
 
Table 4.2 Details of primers used for genotyping and in the allelic expression assay. 












4.2.4 Polymerase Chain Reaction (PCR) protocol 
PCR reactions were performed in a total reaction volume of 12 µL, containing 6 µL of 
genomic DNA (8 ng/µL), cDNA or nuclease-free water (Sigma). Nuclease-free water was 
used in as negative control PCR reaction to check for contaminating templates. 
FIREPol® DNA Polymerase 5X mix (SolisBioDyne) was used to carry out the PCR 
reactions.  FIREPol® is a highly processive, thermostable DNA polymerase, with an 




enhanced stability at room temperature. It has 5’→3’ polymerization-dependent 
exonuclease replacement activity but lacks 3’→ 5’ exonuclease activity. Table 4.3 shows 
details of volumes and concentrations of the reagents used per PCR reaction. 
 
 
Table 4.3 Reagents used in each PCR reaction. 
Reagent  Supplier Concentration Volume 
(µL) 
FIREPol®  DNA Polymerase mix (0.4 M Tris-HCl, 0.1 
M (NH4)2SO4, 0.1% w/v Tween-20, 12.5 mM MgCl2 
2.5, 2 mM dNTPs of each – 200 µM dATP, 200 µM 







10 µM 0.4 
Reverse primer 10 µM 0.4 
Nuclease-free water - 2.8 
DNA template/nuclease-free water - 6 
Total  - - 12 
 
 
PCR reactions were performed in 96-well plates in a G-Storm thermal cycler (Somerton 
Biotechnology Centre, UK), with 35 cycles and annealing temperatures between of 50 °C 
and 60 °C according to the primers used. 
 
Annealing temperature for each set of primers was optimized by using a thermal cycler 
block with a gradient of annealing temperatures between 50 °C and 60 °C. PCR 
amplification was checked by agarose gel electrophoresis and UV visualization. The 
optimal annealing temperature was defined by the strongest band, which has the right 
size without non-specific amplification. Table 4.4 shows a typical thermal cycling 
program. 





Table 4.4 Typical PCR cycling conditions. 
Step Temperature (°C) Time (minutes) Number of Cycles 
Initial denaturation 95 5 1 
Denaturation 95 0.4 35 
Annealing 50 0.30 
Extension 75 0.4 
Final extension 74 10 1 




4.2.5 Agarose gel electrophoresis 
Agarose gels were made at 3% (w/v) agarose (Invitrogen) in 1 X TAE buffer (40 mM Tris-
acetic acid, 10 mM EDTA pH 8.0). The agarose was dissolved in 1 X TAE buffer by 
heating in a microwave. The solution was cooled down before adding ethidium bromide 
(EtBr) to a final concentration of 0.5 µg/mL.  
 
DNA samples were prepared for electrophoresis by mixing 4 µL of each PCR product 
with 4 µL of Orange G gel loading buffer before loading into the pre-made wells in the 
agarose gel. 1 µL of a 100 base pair (bp) DNA ladder (Solis BioDye), containing 12 DNA 
fragments in a range of 100 – 3000bp, was run alongside the samples. 
 
The gel was placed into an electrophoresis tank and submerged with 1 X TAE and it was 
run at 120 V for approximately 30 minutes.  
 
EtBr staining of the acid nucleic was visualized using the UV transilluminator system 
BioSpectrum® Imaging System (UVP, USA) and pictures of the gels were taken using 
the software Vision Works LS (UVP, USA). 






Genomic DNA samples were genotyping for the VRK2 expressed ‘tag’ SNP rs1051061 
and the schizophrenia risk SNP rs2312147. Genotyping was carried out by a single base 
primer extension using the SNaPshot Multiplex Kit (Applied Biosystems). The SNaPshot 
protocol comprises PCR, post-PCR clean up, SNaPshot primer extension, and capillary 
gel electrophoresis. A detailed description of each of these steps is found in the next 
section. SNP genotype data was analysed with GeneMarker software v1.91 
(SoftGenetics). 
 
4.2.7 Allelic expression assays 
Assays of relative allelic expression makes use of a SNP localised in an exonic region of 
the gene to quantify and discriminate RNA molecules transcribed from each chromosome 
in heterozygous subjects. The exonic SNP rs1051061 was used to assay VRK2. This 
SNP was in moderate linkage disequilibrium with the schizophrenia risk SNP rs2312147 
(combined sample D’ = 0.82; r2 = 0.20). Because the LD was not complete (i.e. r2 < 1), the 
effect of the risk SNP rs2312147 genotype on VRK2 allelic expression could be tested by 
further separating our assayed rs1051061 heterozygotes into two groups, those that were 
homozygous and those that were heterozygous for the schizophrenia risk SNP 
rs2312147.  
 
First, individuals heterozygous for the exonic SNP rs1051061 were identified by 
genotyping genomic DNA from the 96 adult brain samples and 150 foetal brain samples 
(first and second trimester).  cDNA from the brain RNA of heterozygous subjects was 
then assayed for VRK2 allelic expression, alongside the corresponding heterozygous 
genomic DNA samples and negative controls. The assay was carried out by a single 
base primer extension using the SNaPshot Multiplex Kit (Applied Biosystems). SNaPshot 
protocol comprises PCR, post-PCR clean up, SNaPshot primer extension, and capillary 
gel electrophoresis. Figure 4.4 summarise the SnaPshot protocol.  





Amplification of cDNA and genomic DNA 
 
 
Figure 4.4 Protocol to measure differential allelic expression.  
(Taken from ABI PRISM® SNaPshot™ Multiplex Kit Protocol 4323357B, Applied Biosystems) 
 
A detailed explanation of each step can be found below:  
 
PCR and post-PCR cleanup 
Sequence containing the exonic SNP rs1051061 was PCR-amplified twice from two RT 
reactions products from each brain sample, two heterozygous genomic DNA samples 
and two negative controls. PCR primers were based on a single exon sequence, 
designed to produce the same amplicon from both genomic DNA and cDNA (Table 4.2). 




PCR was carried out in a total reaction volume of 12 µL, containing 6 µL of genomic DNA 
(8 ng/µL), cDNA or nuclease-free water (Sigma). The PCR protocol is described in detail 
in section 3.2.8.  To confirm amplification and no contamination, 4 µL of each amplified 
sample was electrophoresed on an agarose gel and EtBr staining of the acid nucleic was 
visualized by UV transillumination. PCR reactions were then incubated with 1 µL (1U) of 
rAPid Alkaline Phosphatase (Roche), 0.2 µL (2U) Exo-I (New England Biolab) and 1.8 µL 
of sterile water (Sigma-Aldrich) for 45 minutes at 37 °C and then for 15 minutes at     85 
°C prior to primer extension reactions. 
 
SNaPshot primer extension 
Primer extension reactions were performed in a total volume of 10 µL, containing 2 µL 
treated PCR product, 1,25 µL SNaPshot Multiplex Kit (Applied Biosystems), 5.75 µL 
nuclease free water (Sigma) and 1 pM extension primer (sequence on Table 4.2). Primer 
extension thermal cycling conditions are described on Table 4.5. The reaction was 
carried out in a 96-well plate in a G-storm thermal cycler.  
 
Table 4.5 Thermal cycling protocol for SNaPshot primer extension. 
Step Temperature (°C) Time (minutes) Number of Cycles 
Initial denaturation 95 2 1 
Denaturation 95 0.5 30 
Annealing 43 0.5 
Extension 60 0.5 
 





Capillary electrophoresis of SNaPshot products 
Capillary electrophoresis was used to separate DNA fragment fluorescently labelled by 
SNaPshot primer extension. Following primer extension, aliquots of 2 µL of SNaPshot 
reaction was combined with 8 µL of Hi-Di formamide (Applied Biosystems) and 
electrophoresed on an ABI PRISM® 3130xl Genetic Analyzer (Applied Biosystems) on a 
36 cm capillary array with POP-7 ™ Polymer (Applied Biosystems), controlled by data 
collection software 3.0 (Applied Biosystems).  
 
Peaks heights of allelic specific extended primers were determined using GeneMarker 
software (SoftGenetics). The allele ratio of the two peaks heights was calculated for each 
reaction by dividing the peak height of the minor allele by the peak height of the major 
allele. This ratio was used as an indicator of the relative expression of the two alleles in 
each individual sample.  
 
It could be assumed that genomic DNA should reflect a perfect 1:1 ratio of the two alleles 
(Bray et al., 2003). Consequently, for each plate, the average ratio of all genomic DNA 
was used to correct the ratios obtained from all cDNA and genomic DNA samples for any 
inequalities in allelic representation specific to each assay. This technique was repeated 
four times for each sample, giving a total of four corrected ratios for cDNA and genomic 
DNA per sample.  
 
4.2.8 Statistical analysis 
The effect of genotype at schizophrenia risk SNP rs2312147 on VRK2 allelic expression 
was tested by comparing corrected cDNA allele ratios from rs2312147 heterozygotes with 
those from rs2312147 homozygotes. Additionally, to test any potential cis-effects 
associated with the expressed SNP rs1051061 itself, all corrected cDNA allele ratios 
were compared against all corrected genomic DNA allele ratios. All statistical 
comparisons were made by t tests using SPSS 20 for Mac (SPSS, Inc.). All t tests were 




two tailed and where differences in variance were detected between comparison groups 
(Levene’s test, p<0.05), a t test that assumes unequal variance was used.  
 
 
4.2.9 Linkage disequilibrium and Haplotype analysis  
Linkage disequilibrium (LD) between the schizophrenia risk SNP rs2312147 and the 
expressed SNP rs1051061 was assessed using Haploview 4.2 (Barrett et al., 2005). LD 
was calculated separately for the 96 post-mortem adult subjects and for the 40 first-
trimester and 110 second-trimester foetal samples that were initially genotyped. 
Demographics of the individuals used for the LD analysis are shown in Table 4.6 
 
 
Table 4.6 Demographics of individuals used to assess linkage disequilibrium between 
rs2312147 and rs1051061. 
Brain sample N Sex Age at Death  Post mortem delay 
(h) 
M F Mean Range Mean Range 
Adult Brain 
DLPFC 




34.6 (18.1) 5 - 85 
Foetal Brain 













15.4        (2.6)  
weeks 

















* N= the total number of subject used in the study. Sex: F=female, M= male. Numbers in 











4.2.10 Bioinformatic analysis  
All the genetic variants within the VRK2 locus (chr. 2: 58.134.786 – 58.387.055, assembly 
hg19) were retrieved from 1000 genomes (Genomes Project et al., 2012) using tabix (Li, 
2011). LD values between those variants and the expressed SNP rs1051061 and risk 
SNP rs2312147 were obtained using PLINK (http://pngu.mgh.harvard.edu/purcell/plink/) 
and the software SNAP (Johnson et al., 2008).  
 
The variant effect predictor tool from ENSEMBL genome browser 
(http://www.ensembl.org/index.html) was used to extract the functional consequences of 
the variants in the VRK2 region. 
 
The software CONDEL (http://bg.upf.edu/condel/home) (Gonzalez-Perez and Lopez-
Bigas, 2011) was used to evaluate the deleteriousness of non-synonymous variants in 
the VRK2 region. 





4.3.1 Linkage disequilibrium 
Linkage disequilibrium analyses were carried out between the expressed SNP 
rs1051061, used for the allelic expression analysis, and schizophrenia risk SNP 
rs2312147. LD analysis results for adult and foetal samples are shown in Figure 4.5 and 
4.6.  
 
The estimated frequency of the 4 haplotypes in the adult brain sample and the combined 
sample (adult brain and foetal brain sample) are shown in Table 4.7. Frequencies for the 
combined sample were obtained because Haploview did not generate the haplotype 
frequencies for the foetal sample alone (first and second trimester of gestation).  
 
Haploview results indicated that the risk C-allele of rs2312147 was usually in phase with 
the G-allele of the expressed SNP rs1051061, and the non-risk T-allele of rs2312147 
usually in phase with the A-allele of expressed SNP rs1051061, when a subject was 
heterozygous at both loci.  
 
Table 4.7 Estimated frequency for all haplotypes for adult brain and combined sample. 
 rs1051061 rs2312147 Frequency 





G C 0.420 0.349 
A T 0.331 0.315 
A C 0.234 0.315 
G T 0.015 0.022 












Figure 4.6 LD analysis of SZ risk SNP rs2312147 and the expressed SNP rs1051061 in Foetal 
brain samples. 





4.3.2 Effect of schizophrenia risk SNP rs2312147 on VRK2 allelic expression in 
adult brain 
Allelic expression of VRK2 at the expressed SNP rs1051061 in the dorsolateral prefrontal 
cortex is illustrated in Figure 4.7. The effect of the schizophrenia associated 
polymorphism rs2312147 on the VRK2 allelic expression imbalance was tested by 
comparing homozygotes and heterozygotes for rs2312147. The average corrected cDNA 
allele ratio for individuals who were heterozygous for rs2312147 was 0.73 (range: 0.44– 
1.12) compared with an average ratio of 0.69 (range: 0.04 –1.11) for rs2312147 
homozygotes. Allele ratios did not significantly differ between rs2312147 homozygous 
and heterozygous in adult DLPFC (P = 0.63). Conversely, significant differences were 
detected between cDNA and genomic DNA allele ratios in both rs2312147 homozygotes 
and heterozygotes (P = 1.32*10-7, respectively). This suggests the presence of regulatory 
variants other than rs2312147 operating in this brain region, which are in strong LD with 
the expressed SNP rs1051061 and responsible for the allelic expression imbalance of 
VRK2.  
 





Figure 4.7 VRK2 Allelic Expression in Adult Human DLPFC 
Individual data points represent the average G/A allele ratio at the expressed single-nucleotide 
polymorphism (SNP) rs1051061 from four assays of genomic DNA (gDNA) or cDNA from each 
heterozygous subject. All gDNA ratios, cDNA ratios and cDNA ratios divided into rs2312147 
heterozygotes and homozygotes are presented. The mean allele ratio is represented by a 
horizontal bar. The 1:1 ratio derived from the average cDNA ratio is indicated by a dotted line. 
There is no significant difference in cDNA allele ratios between homozygotes (N= 11) and 
heterozygotes (N=21) for the schizophrenia risk SNP rs2312147. cDNA allele ratios for 
heterozygotes and homozygotes for rs1051061 are significantly lower than gDNA allele ratios (P = 
7.78*10-7 and P = 0.002, respectively) 
 
 
4.3.3 Effect of schizophrenia risk SNP rs2312147 on VRK2 allelic expression in 
foetal brain 
Since schizophrenia has been widely described as a neurodevelopmental disorder and 
due to the apparent lack of effect of rs2312147 in adult brain I decided to test the effect of 
rs2312147 on VRK2 allelic expression in the human foetal brain. Whole brain samples 
from foetuses from first and second trimester of gestation were used to analyse allelic 
expression imbalance of VRK2 at the expressed SNP rs1051061 (Figure 4.8).  




In first trimester foetal brain samples, allele ratios between rs2312147 heterozygous and 
homozygous did significantly differ (P = 0.015) with an average corrected cDNA allele 
ratio for individuals who were homozygous for rs2312147 of 0.81 (range: 0.67– 0.90) 
compared with an average ratio of 1.13 (range: 0.95 –1.42) for rs2312147 heterozygotes, 
suggesting a cis effect of the risk SNP from this time point of development.  
 
Allele ratios in cDNA from rs2312147 homozygotes were significantly different from allele 
ratios in gDNA (P = 0.008).  Allele ratios in cDNA from rs2312147 heterozygotes did not 
significantly differ from gDNA allele ratios (P = 0.180). 
 
In common with first trimester brain tissue significant differences were observed 
according to rs2312147 genotype (P = 0.037) in second trimester brain tissue, averaging 
0.92 (range: 0.65 – 1.25) in rs2312147 heterozygotes and 0.71 (range: 0.27– 0.91) in 
homozygotes. Allele ratios in cDNA from both rs2312147 homozygotes and 
heterozygotes were significantly different from allele ratios in gDNA (P = 0.009 and P = 









Figure 4.8 VRK2 Allelic Expression in Foetal Human Brain 
Individual data points represent the average G/A allele ratio at the expressed single-nucleotide 
polymorphism (SNP) rs1051061 from four assays of genomic DNA (gDNA) or cDNA from each 
heterozygous subject. All gDNA ratios, cDNA ratios and cDNA ratios divided into rs2312147 
heterozygotes and homozygotes are presented. The mean allele ratio is represented by a 
horizontal bar. The 1:1 ratio derived from the average cDNA ratio is indicated by a dotted line. In 
the first trimester foetal brain, there is a significant difference in cDNA allele ratios between 
homozygotes (N= 5) and heterozygotes (N=5) for the schizophrenia risk SNP rs2312147. Allele 
ratios in cDNA from rs2312147 homozygotes were significantly different from allele ratios in gDNA 
(P = 0.008).  Allele ratios in cDNA from rs2312147 heterozygotes did not significantly differ from 
gDNA allele ratios (P = 0.180) In the second trimester foetal brain, there are again significant 
differences in cDNA allele ratios between homozygotes (N= 8) and heterozygotes (N=25) for the 
schizophrenia risk SNP rs2312147 (P = 0.002). cDNA allele ratios for heterozygotes and 
homozygotes for rs1051061 are significantly lower than gDNA allele ratios (P = 0.045 and p= 
0.009) 





4.3.4  Bioinformatics analysis to explain allelic expression imbalance of VRK2.  
The data described above indicate a cis-regulatory effect associated with genotype at 
schizophrenia SNP rs2312147 in foetal brain. However, as cDNA allele ratios in 
homozygotes were significantly different from gDNA allele ratios, it appears that there are 
additional cis-regulatory variants, active in all assayed tissues, operating on VRK2. As 
allele ratios in cDNA were generally reduced relative to those in gDNA, the regulatory 
variant is likely to be in strong LD with the expressed SNP (rs1051061) used to assay 
VRK2 allelic expression.  I therefore used the software SNAP (Johnson et al., 2008) and 
the variant effect predictor tool from ENSEMBL genome browser 
(http://www.ensembl.org/index.html) to identify SNPs at the VRK2 locus that are in strong 
LD (r2 > 0.8) with rs1051061 and have regulatory potential (Table 4.8).   
 
 
Table 4.8 Variants in VRK2 locus in high LD with expressed SNP rs1051061 and their 
predicted functional consequences. 
 SNP ID r2 D'  Consequence 
rs1051061 1 1 missense_variant, 
3_prime_UTR_variant,NMD_transcript_variant,downstream_gene_variant 
rs1016771 1 1 intron_variant,NMD_transcript_variant, regulatory_region_variant 
rs13011711 1 1 intron_variant,NMD_transcript_variant, regulatory_region_variant 
rs3771213 0.961 1 intron_variant,NMD_transcript_variant 
rs12999901 0.922 1 intron_variant,NMD_transcript_variant 
rs13033536 0.922 1 intron_variant,nc_transcript_variant 
rs35248619 0.922 0.96 intron_variant,NMD_transcript_variant 
rs57390191 0.922 0.96 intron_variant,NMD_transcript_variant 
rs62140014 0.922 0.96 intron_variant,NMD_transcript_variant 









Additional bioinformatic analysis indicated that the expressed SNP rs1051061 encodes 
an amino acid change (Isoleucine to valine, aminoacid 167) in the VRK2 protein, within 
the Serine/Threonine kinase domain. Condel predicts that this change is likely to have a 
functional effect on protein function. The analyses showed that the expressed SNP 
rs1051061 is a missense variant. I used the software Condel to find out it deleteriousness 
score, the results are in the table below: 
 
Table 4.9 Condel scores for rs1051061. 











G  VRK2 167 I/V 0.04 0.947 0.74 deleterious 
 
Condel score ranges from 0 to 1, with 0.0 = neutral and 1.0 = deleterious; SIFT: Ranges from 0 to 
1, being <= 0.05 predicted to be damaging and > 0.05 tolerated; PPH2: Ranges from 0 to 2, being 
<= 0.05 neutral and > 0.05 probably damaging. 
 






The main aim of the experiments described in this Chapter was to assess allele-specific 
expression of VRK2 and determine if a SNP associated with schizophrenia (rs2312147, 
(Steinberg et al., 2011)) is also associated with altered cis-regulation of VRK2. VRK2 
allelic expression was assessed in adult DLPFC and whole brain from two stages of 
foetal development. 
 
The general distortion in cDNA allele ratios at expressed SNP rs1051061 suggests the 
presence of cis-acting influences affecting VRK2 expression in the adult and foetal brain. 
However, as homozygotes for risk SNP rs2312147 show distortion in cDNA allele ratios, 
it would appear that rs2312147 cannot account for this apparent cis-effect. An interesting 
possible explanation, albeit speculative without further evidence and assuming that the 
findings are not due to differences in reverse transcription efficacy between the two 
alleles, is that the observed allelic imbalance is due to either the expressed SNP itself or 
to one in high LD with it. The expressed SNP is non-synonymous and according to 
ENCODE data localizes within a nonsense mediated decay (NMD) site. It is therefore 
possible that G-allele appears as less expressed due to NMD. Additionally, the expressed 
SNP is in high LD with several SNPs that are in potentially regulatory regions, like 
rs13011711 (r2 = 1) localized in the middle of DNAse hypersensitivity site and 
transcription binding site, according to ENCODE data (Table 4.8).  Further analyses will 
be necessary to rule out or establish the role of these variants.  
 
The effect of rs2312147 on VRK2 allelic expression was initially tested in the DLPFC of 
the adult brain. This region was chosen because a large number of RNA samples from 
this brain region were already available within Dr Bray’s lab and it has been strongly 
implicated in schizophrenia pathophysiology (Berman et al., 1988). There was no 
significant effect of genotype at rs2312147 on VRK2 allelic expression in adult DLPFC. 
However, it is also important to consider that effects of cis-regulatory variation can differ 
across brain regions (Buonocore et al., 2010), and potentially across cell types. Hence, 




effects of rs2312147 on VRK2 allelic expression in other adult brain regions cannot be 
excluded. 
 
Genotype at rs2312147 had a significant effect on VRK2 allelic expression in foetal brain 
samples from both the 1st and 2nd trimester of gestation. However, in both 1st and 2nd 
trimester tissue, heterozygosity for rs2312147 was associated with less allelic expression 
imbalance of VRK2, with the risk (C) allele increasing the expression of the allele of the 
expressed SNP that is otherwise under-expressed. A possible explanation for how this 
could influence schizophrenia risk would be that the cis-effects of rs2312147 alter the 
functional impact of the deleterious amino acid encoded by the expressed SNP 
rs1051061. Lappalainen et al.  (Lappalainen et al., 2011) present data to suggest strong 
selection pressure against deleterious amino acids occurring on high expression 
haplotypes. They further report an enrichment of putative epistatic effects between 
deleterious coding variants and eQTL associated with common diseases by GWAS. 
 
The association between genotype at a schizophrenia risk variant and VRK2 allelic 
expression in foetal brain suggests a molecular risk mechanism for schizophrenia 
operating during early brain development. Schizophrenia is widely hypothesized to be a 
neurodevelopmental disorder (Harrison, 1997; Weinberger, 1995), but direct molecular 
evidence for this is lacking. Genome-wide significant risk variation for schizophrenia has 
recently been reported to affect ZNF804A expression specifically in the foetal brain (Hill 
and Bray, 2012). However, whereas that study found that the effects on ZNF804A 
expression were specific to 2nd trimester tissue, the effects on VRK2 appear to start even 
earlier, during the 1st trimester of foetal development.  This study also provides evidence 
for genetic mediated risk for schizophrenia operating long before the evident appearance 














The VRK2 gene is located at chromosome 2p16.1, encodes a member of the vaccine-
related kinase family (VRK) serine/threonine kinases. Alternative splicing generates two 
known isoforms, A and B, of 508 and 397 amino acids in length, respectively. VRK2A has 
been shown to localise to the cytoplasmic side of the endoplasmic reticulum and 
mitochondrial membrane by virtue of a hydrophobic tail in the C-terminal region (Blanco 
et al., 2006). VRK2B is shorter and is localised to the cytosol as well as the nucleus and 
outside the nucleolus (Blanco et al., 2006). Subcellular localization of VRK2 A and B is 
dependant on cell type (Blanco et al., 2006).  
 
Genetic variation at the VRK2 locus has been associated with schizophrenia and the 
SNP rs2312147 was identified as the strongest statistical signal (Irish Schizophrenia 
Genomics and the Wellcome Trust Case Control, 2012; Steinberg et al., 2011). However, 
the mechanism behind this association is unknown. To date there is only one study from 
Li et al., (Li et al., 2012) reporting an up-regulation of VRK2 mRNA expression in 
schizophrenic patients, but they did not find a significant association between the risk 
SNP rs2312147 and VRK2 mRNA expression.  
 
VRK2 has been associated to epilepsy (Consortium et al., 2012) and a microdeletion 
syndrome involving chromosome 2p15-p16.1 (Chabchoub et al., 2008; de Leeuw et al., 
2008; Felix et al., 2010; Liang et al., 2009; Rajcan-Separovic et al., 2007). To date, most 
reported functional studies on VRK2 are concerned with its involvement in cancer, as it 
has been linked to breast cancer via its regulation of ErbB2-MAPK signalling (Blanco et 
al., 2006; Fernandez et al., 2010). Given the evidence for an effect of schizophrenia risk 
variant rs2312147 on VRK2 expression in foetal brain reported in chapter 4, it is 




important to characterise the functional role(s) of VRK2 in the developing human brain. 
However, there are no published data on this to date.   
 
The VRK family of serine/threonine kinases are upstream of several transcription factors 
and form part of multiple signalling pathways. In non-neural tissues they are known to be 
involved in several cellular processes such as proliferation, apoptosis and response to 
stress (Blanco et al., 2006; Blanco et al., 2007; Monsalve et al., 2013). VRK2 expression 
has been detected in many tissues (Lukk et al., 2010; Nezu et al., 1997), and several 
different human brain regions (Allen Brain Atlas, (Hawrylycz et al., 2012)). RNA 
sequencing projects suggest the long but not the short isoform may be present in brain 
tissue (Illumina Human Bodymap 2.0 Data displayed at www.ensembl.org). This dataset 
represents a first approximation and additional surveys will help clarify the relevance of 
different isoforms for brain function. In brain tissue, VRK2 has a marked developmental 
expression pattern with high expression in the first weeks of embryonic development and 
then decreasing expression (no data available from 24 to 40 weeks). VRK2 later shows 
increasing expression during childhood and a more stable pattern from 10 years onwards 
(data available up to 80 years) (Figure 5.1). A more detailed inspection suggests that this 
pattern is consistent for different brain regions with the exception of the cerebellum, 
where it does not show much variation in expression throughout life (Figure 5.2).  
 
Interestingly, Tebbenkamp et al., (Tebbenkamp et al., 2014) summarised the 
developmental brain expression pattern of the human brain and found that genes 
associated with broad biological functions follow distinct expression patterns. During 
embryonic development VRK2 follows a pattern associated with genes involved in cell 
proliferation and after birth of those associated with myelination, dendrite development 
and (less so), synaptic development. It does not; however, seem to adhere to the 
expression pattern of genes associated with progenitors and immature neurons (Figure 
5.3). VRK2 shows high expression under conditions of cell proliferation, such as early 
brain development (Figure 5.2), and in highly proliferative tissues such as testis, thymus 
and foetal brain (Nezu et al., 1997).  







Figure 5.1 Expression of VRK2 in prefrontal cortex samples ranging from 14 post-
conception weeks to 80 years of age. Data was generated by the National Institute of Mental 
Health / Lieber Institute for Brain Development, using spotted microarray and accessed via their 
publicly available database at http://braincloud.jhmi.edu, (Colantuoni et al., 2011). 



































































































































































































































































































Figure 5.2 Expression of VRK2 in 6 human brain regions ranging from 6 post-conception 
weeks to 82 years of age. Data were generated by the Department of Neurobiology, Yale 
University School of Medicine, using Affymetrix GeneChip Human Exon 1.0 ST Arrays and 
accessed via their publicly available database at http://hbatlas.org. NCX= neocortex; HIP= 
hippocampus; AMY= amygdala; STR= atriatum; MD= mediodorsal nucleous of the thalamus; CBC= 
cerebellar cortex (Johnson et al., 2009; Kang et al., 2011). 







Figure 5.3 Expression trajectories of genes involved in neurodevelopmental processes 
ranging from early brain development until adulthood (taken from Tebbenkamp et al., 
(Tebbenkamp et al., 2014)) 
 
 




VRK2A and B isoforms are able to undergo autophosphorylation on their Thr residues 
(Nichols and Traktman, 2004) and both of them are able to phosphorylate p53 at Thr-18 
modulating its stability (Blanco et al., 2006), and c-Jun (Sevilla et al., 2004). Other known 
substrates are the transcription factor nuclear factor of activated T-cell (NFAT1), involved 
in cell invasion (Vazquez-Cedeira and Lazo, 2012), the barrier to autointegration factor 
(BAF), which plays an important role as a regulator of nuclear architecture during the 
phases of the cell cycle (Nichols et al., 2006) and coilin (COIL), a nuclear protein involved 
in neurological conditions (Sanz-Garcia et al., 2011). 
 
Protein-protein interaction studies have shown that VRK2 proteins are regulated by their 
interaction with Ran GTPase (Sanz-Garcia et al., 2008). Additionally, these studies have 
shown that the VRK2A isoform; anchored to the endoplasmic reticulum, interacts directly 
with scaffold proteins that regulate cellular signalling pathways. It has been shown to 
interact with JIP1, a scaffold protein that assembles mitogen-associated protein (MAP) 
kinase signalling complexes (Blanco et al., 2008), and this interaction can modulate the 
magnitude of the stress response to hypoxia and to interleukin-β (Blanco et al., 2007; 
Blanco et al., 2008). VRK2 also interacts with the kinase suppressor of RAS1 (KSR1) 
scaffold protein, reducing the signal mediated by MAPK in response to ErbB2 in breast 
cancer. Additionally, VRK2 interacts with MEK, a kinase suppressor of Ras 1, resulting in 
ERK signalling pathway inhibition (Fernandez et al., 2010; Fernandez et al., 2012). VRK2 
also appears to regulate apoptosis by its interaction with BHRF (Epstein-Barr virus) and 
with Bcl-xL (Li et al., 2006; Monsalve et al., 2013). Furthermore, VRK2 interacts with the 
eukaryotic chaperonin TCP-1 ring complex (TRiC) leading to its ubiquitination through 
activation of COP1 E3 ligase activity. In turn this has been shown to lead to poly-Q-
aggregation and cytotoxicity involved in neurodegenerative disorders such as 
Huntington’s disease (Kim et al., 2014).  
 
Overall, based on its expression pattern, functional studies and the literature associated 
with its interactions, VRK2 is likely involved in the regulation of multiple cellular signalling 
pathways controlling cell proliferation, apoptosis and response to stress. Its expression in 




brain development (especially early on) and its involvement in pathways linked to 
neurological disorders support an important function in the CNS. However, no studies of 
VRK2 function in brain have been reported to date. 
 
 
5.1.1 The aim of the present study 
The aim of the experiments presented in this chapter was to explore the molecular and 
cellular consequences of VRK2 manipulation in cells derived from human foetal brain. 
To this end I used a combination of siRNA, genome-wide expression profiling, pathway 
analysis and automated assays of cell proliferation. 
 







5.2.1 Human neuronal progenitor cell line 
Experiments were carried out in the conditionally immortalised neuronal progenitor cell 
line CTX0E16. The cell line CTX0E16 was obtained from ReNeuron Ltd 
(www.reneuron.com) under a Material Transfer Agreement. It was derived from first 
trimester human foetal cortical neuroepithelium (Pollock et al., 2006). The cells have 
been conditionally immortalised by genomic incorporation of the c-mycERTAM transgene, 
which can be conditionally activated by 4-hydroxy-tamoxifen (4-OHT) to stimulate 
proliferation (Littlewood et al., 1995).  
 
A detailed description of cell culture protocol followed in the present study has been 
described in Chapter 3 section 3.2.1. 
 
5.2.2 Transfection of siRNA  and DNA vectors with a nucleofection system 
Transfection of siRNAs and DNA vectors was performed by NucleofectionTM technology 
from Amaxa® (now Lonza, Gaithersburg, MD), using the Cell Line Nucleofector® Kit V 
(VACA-1003) and the Nucleofector™ Device from Amaxa® (now Lonza, Gaithersburg, 
MD). NucleofectionTM technology is an electroporation method developed by Lonza to 
efficiently delivery siRNAs and plasmids into cells (Gresch et al., 2004). 
 
RNAi was achieved using pre-designed Stealth RNAi™ (Invitrogen), which uses next-
generation RNAi chemistry to prevent off-target effects. Two non-overlapping Stealth 
RNAi™ siRNA for VRK2 (siRNA1: HSS111310 and siRNA2: HSS111311) were 
transfected into separate flasks of seeded cells alongside a Stealth RNAiTM siRNA 
negative universal control (Invitrogen), and a BLOCK-iT™ Alexa Fluor® Red Fluorescent 
Oligo to assess the transfection efficiency. 
 




The sequences of the siRNA targeting VRK2 are shown in Table 5.1. Both siRNAs target 
sequence present in exon 5 and therefore target all VRK2 transcripts.  
 
Table 5.1 Details of siRNAs used for VRK2 knockdown. 
siRNA ID Oligo Sequence VRK2 exon 
siRNA1 HSS111310 GGAUAGAACGCAAACAACUUGAUUA 5 
siRNA2 HSS111311 UGGAUCUGGUCUGACUGAAUUCAAG 5 
 
 
Overexpression of VRK2 was attempted using the mammal expression vector pCMV-
SPORT6-VRK2 (pVRK2) (Thermo Scientific, MHS6278-202801669). To monitor 
transfection efficiency the pmaxGFP® Vector (Lonza) was transfected alongside pVRK2. 
A map for each vectors is shown in Figures 5.4 and 5.5. 
 
 
Figure 5.4 Map of pmaxGFP vector. 
Positive control vector pmaxGFP® encodes the green fluorescent protein (GFP) from copepod 
Pontellina p.  Cells expressing maxGFP® can be examined by fluorescence microscopy to check 
transfection efficiency. (Image taken from www.Lonza.com) 








Figure 5.5 Map of overexpression vector for VRK2, pCMV-SPORT6. 
The pCMV-SPORT-VRK2 construct contained the full cDNA sequence of VRK2 clone BC027854. 




CTX0E16 cells used for transfection were expanded in laminin-coated T75 flask to 80% 
confluence, as the nucleofection protocol requires cells in their logarithmic growth phase. 
24 hours before transfection the RMM media was replaced with 10 mL of RMM media 
without 4-OHT (represented as RMM ++-). 4-OHT was excluded so that proliferation was 
not artificially stimulated by c-myc overexpression. CTX0E16 cells are able to retain their 
nestin-positive, neuronal progenitor state in the presence of growth factors bFGF and 
EGF (Dr G. Anderson and Dr B. Williams, personal communication). Separate flasks of 
CTX0E16 cells were transfected with either Stealth siRNA1, Stealth siRNA2, Stealth 
siRNATM negative universal control, positive control BLOCK-iTTM Alexa Fluor® Red 
Fluorescent oligo, pVRK2 vector (Thermo Scientific) or the pmaxGFP® Vector (Lonza).  




                                                                                                                                                                                                                                                                                                                                                                                                                    
A detailed Nucleofection procedure is described below: 
Cells were harvested by addition of Accutase (Invitrogen) and centrifugation at 900 rpm 
for 5 minutes at room temperature. The pelleted cells were washed once with DPBS, to 
eliminate any trace of media that could interfere with transfection, and centrifuged again 
at 900 rpm for 5 minutes. The final cell pellet was resuspended in 100 mL of 
nucleofection® sample, containing siRNA or DNA vector and transferred to an Amaxa™ 
certified 100 µL aluminum electrode cuvette. Details of reagents used per each 
transfected flask are shown in Table 5.2. 
 
Each sample was processed separately to avoid storing the cells for more than 15 
minutes in Nucleofector® solution. 
 
The cuvette was inserted into the Nucleofector™ Device and the program T-030 was 
selected for nucleofection. The cuvette was then rinsed with 500 µL of pre-warmed RMM 
(++-) media (using the provided pipette) and the suspension was transferred to a laminin-
coated flask with 9.5 mL of warmed media and incubated in humidified 37 °C/5% CO2 
incubator until analysis. 
 
Table 5.2 Contents of one Nucleofection® Sample. 
Reagent Concentration Final volume added 
CTX0E16 cells 5*106 cells - 
1 - 5 µg pVRK2 (in max. 5 µL)  
or 2 µg pmaxGFP®  
or 2 nM-2 µM siRNA 
2 µg/ µL 





Nucleofector® solution containing: 
18 µL stabilizer supplement and  
82 µL Nucleofector™ Solution 
 100 µL 




For proliferation assays, 50 µL of suspended cells was taken from the transfected flask 
and transferred to a well in a Nunc-Immuno™ MicroWell™ 96 well solid plate. This was 
repeated for each treatment with a total of 10 wells per treatment.  
 
In order to estimate transfection efficiency, cells transfected with the BLOCK-iTTM Alexa 
Fluor® Red Fluorescent oligo and the pmaxGFP® Vector were checked 24 hours post-
transfection by fluorescence microscopy.  
 
Media was replaced at 48 hours post-transfection with RMM (++-). At 120 hours post-
transfection cells from each T75 were separately harvested by addition of Accutase. 
Resuspended cells from each treatment were divided into 2 Falcon tubes and centrifuged 
at 900 rpm for 5 minutes. One of the cell pellets was used for RNA extraction to which 
500 µL of Tri-Reagent® Solution (Ambion, Life Technologies, Grand Island, N.Y.) was 
added. The second pellet was used for protein extraction. Both tubes were stored at -
80°C. An overview of the transfection time-line is represented in Table 5.3. 
 
Cells in proliferation plates were fixed with 4% Paraformaldehyde (PFA). A detailed 
protocol for the proliferation assays is described in detail below this section.  
 
The whole protocol for the six treatments (siRNA1, siRNA2, Stealth siRNATM negative 
universal control, BLOCK-iTTM Alexa Fluor® Red Fluorescent oligo, pVRK2 and the 
pmaxGFP® Vector) was repeated four times to give four biological replicates for each 
condition. 





Table 5.3 Time-line protocol for VRK2 knockdown and overexpression assays. 
Day 0 Replace RMM media for 10 mL of RMM ++- 
Day 1 Transfect: 
• 1 flask with siRNA 1 
• 1 flask with siRNA 2 
• 1 flask with negative control 
• 1 flask with red oligo 
• 1 flask with pVRK2 
• 1 flask with pmaxGFP® 
Transfer 50 uL suspension cell from each flask (each treatment) to 10 wells of a 96 
well plate. 
 
Day 2 Check florescent cell in flask transfected with red-oligo and pmaxGFP®  
Day 3 Replace media to all flasks and 96 well plate with RMM ++- (10 mL per flask and 50 
µl per well) 
Day 4 - 




5.2.3 RNA  extraction and cDNA synthesis 
Pelleted cells were separately homogenized in 500 µL of Tri-Reagent® Solution (Ambion, 
Life Technologies, Grand Island, N.Y.). Total RNA was extracted following the protocol 
described in section 3.2.3 (Chapter 3). RNA concentration and purity was quantified using 
the NanoDropTM 1000 spectrophotometer. RNA integrity was measured using the Agilent 
2100 Bioanalyzer (Agilent Technologies, CA, USA) following manufacturer protocol. All 
samples had an RNA integrity number (RIN) >9.4. 
 
DNAse treatment of total RNA samples was performed with TURBO DNA-freeTM 
(Ambion) (as described in section 3.2.4, Chapter 3). cDNA was synthesized from 1 µg 
total RNA from each sample using SuperScriptTM III reverse transcriptase (Invitrogen) and 




random decamers (Ambion) in final reaction volume of 20 µL (a detailed protocol can be 
found in section 3.2.6, Chapter 3). The resulting cDNA samples were diluted to the 
“standard cDNA concentration” (1/7), by adding 120 µL of nuclease-free water (Sigma-
Aldrich) to each 20 µL of cDNA. 
 
5.2.4 Quantitative PCR (qPCR) 
Quantitative PCR was used to assess VRK2 knockdown and overexpression. qPCRs 
were completed on 96-well plates using an MJ Chromo4TM Real Time PCR Detector (Bio-
Rad) and MJ Opticon Monitor analytic software (Bio-Rad). Reactions were carried out in 
a total volume of 20 µL, containing diluted cDNA, primers at 200 nM and 1x HOT 
FIREPol® EvaGreen® qPCR Mix Plus (Solis BioDyne). Table 5.4 shows the volume and 
concentration of the reagents used. The cycling programme used for qPCR reactions can 
be found in Table 5.5. 
 
Table 5.4 Details of reagents used for each qPCR reaction. 
Reagent Supplier Concentration Volume (µL) 
HOT FIREPol ® EvaGreen ® qPCR Mix Plus Solis BioDyne 5x 4 
Forward and reverse primer mix Sigma-Aldrich 
 
2 µM 2 
Nuclease-free water - 6 
cDNA template/nuclease-free water - - 8 
Total  - - 20 
 
 
Table 5.5 Typical qPCR cycling conditions. 
Step Temperature (°C) Time (minutes) Number of Cycles 
Initial denaturation 95 15 1 
Denaturation 95 0.3 44 
Annealing 60 0.30 
Extension 72 0.3 
For the melting profile, the temperature was raised from 60 to 95 and the fluorescence read every 
1°C increase in temperature with a hold time of 10 sec. 





QPCR primers were design using the Primer3Plus program available online 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/). Sequences of the 
primers used for qPCR are shown in Table 5.6. 
 
Table 5.6 Detail of primers sequences used for qPCR analysis. 
Gene Primer Sequence (5’ - 3’) 
VRK2 Forward AGCAAGTCAACAAGGCACAC 
Reverse CCAATCAGTTTCTCCTCTTTC 
GAPDH Forward CCTGACCTGCCGTCTAGAAA 
Reverse ATCCTGGTGCTCAGTGTAGCC 
RPL13A Forward CCTGGAGGAGAAGAGGAAAGAGA 
Reverse TTGAGGACCTCTGTGTATTTGTC 




Four technical replicate qPCR reactions were performed to measure VRK2 and the 
internal control genes RPLI3A, GADPH and CFDP1 for each cDNA sample. QPCRs for 
VRK2 and the internal controls were carried out on the same PCR plate for every 
transfection experiment and each treatment (siRNA1, siRNA2, Stealth siRNATM negative 
universal control, pVRK2 and the pmaxGFP® Vector). The level of expression of each 
gene was measured against a relative standard curve created by serial dilution of pooled 
cDNA taken from each of the assayed samples. The following arbitrary values were given 
to standard curve: “5000” (undiluted), “1000”, “200”, and “40”, according to their relative 
dilutions. Consequently, a relative value was obtained for each of the four replicate 








5.2.5 Statistical analysis for qPCR  
Description of the data:  
1. Transfection experiments were done in four biological replicates. Each biological 
replicate has five treatments, siRNA1, siRNA2, Stealth siRNATM negative 
universal control, pVRK2 and the pmaxGFP® Vector, leading to four biological 
replicates per treatment. 
2. cDNA was obtained from RNA for the four biological replicates for each 
treatment. This gave 20 cDNA samples in total. 
3. qPCR was used to measure the expression of VRK2 and three internal control 
genes, RPLI3A, GADPH and CFDP1. This was performed four times, leading to 
four technical replicates for each of the 20 cDNA samples. qPCR for VRK2 and 
the internal controls was carried out on the same PCR plate.  
4. For each technical replicate I obtained one normalized value for VRK2 per 
treatment per biological replicate. Normalization was calculated using the 
geometric normalization method (Vandesompele et al., 2002). Thus, from each 
technical replicate I obtained one normalized value for VRK2 for each treatment 
per biological replicate. In total I obtained four technical replicates for four 
biological replicates each including the five treatments. These normalized values 
were used for statistical analyses.  
 
The objective of the statistical analyses was to identify expression changes on VRK2 
mRNA level between control siRNA and VRK2 siRNA conditions and pmaxGFP and 
pVRK2 conditions. To this end I used a linear mixed model including treatments as a 
fixed effect and biological replicates as random effects. I used a linear mixed model 
because it considers the systematic variation between biological replicates. Statistical 
analysis was performed using a linear mixed model in R (R Core Team (2013). R: A 
language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. URL http://www.R-project.org/.) Differences of P < 0.05 were 
considered significant. The exact command using R was:  
lmer(log(normalized expression) ~ 1 + treatment +  (1|biological_replicate),data=qpcr.m). 





5.2.6 Total protein extraction and quantification for VRK2 knockdown. 
Total protein was extracted from cells transfected with siRNA1, siRNA2 and Stealth 
siRNATM negative universal control. Cells were lysed with the Pierce IP Lysis Buffer 
(25mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40 and 5% glycerol) (Thermo 
Scientific) containing a protein inhibitor cocktail (Thermo Scientific). 300 µL of lysing 
buffer was added to each sample separately and the mixture was transferred to a pre-
chilled microcentrifuge tube and agitated in a rotary mixer for 30 minutes at 4 °C. The 
lysates were then clarified by centrifugation at 10.000 rpm for 10 minutes at 4 °C. The 
supernatant was then transferred to a clean pre-chilled microcentrifuge tube and store at 
-80 °C. 
 
Quantification of total protein was achieved by using the Novagen® BCA Protein Assay 
Kit (Merck Millipore, 71285), following the micro-scale assay according to the 
manufacturer’s instructions. 
 
5.2.7 SDS-PAGE and inmunobloting  
5 µg of total protein from each sample was separated on a 8% SDS/polyacrylamide gel 
and transferred to a polyvinylidene difluoride (PVDF) membrane in western transfer buffer 
(10% methanol, 25mM Tris-HCl, 190 mM glycine, pH 8.5) at 100 Volts for 1 hour at 4 °C. 
The membrane was then incubated in blocking buffer (3% (w/v) BSA in Tris-buffered 
saline with Tween-20 (TBST buffer: 50 mM Tris, 150 mM NaCl, 0.05% Tween-20, pH 
7.5)) for 1 hour at room temperature. The membrane was then incubated overnight at 4°C 
with the primary antibody anti-VRK2 (Sigma-Aldrich, WH0007444M1) diluted 1:500 in 
blocking buffer. The blot was then washed three times with TBST buffer for 20 minutes 
and subsequently incubated for 1 hour at room temperature with the horseradish 
peroxidase-conjugated secondary antibody, goat anti-mouse (Pierce) diluted 1:20000. 
Finally, the membrane was washed three times with TBST buffer for 20 minutes and 
proteins were detected by using the SuperSignal™ West Pico Chemiluminescent 
Substrate (Thermo Scientific), according to the manufacturer’s instructions.  




Afterwards, the membrane was stripped with the Fluorescent WB striping buffer (Thermo 
Scientific) and incubated with primary antibodies for housekeeper proteins applied in 
blocking buffer at the following dilution: anti-GAPDH (AbD Serotec) 1:2000, anti-β-actin 
(Thermo Scientific) 1:2000 and anti-α-Tubulin (Genetex) 1:5000, for 1 hour at room 
temperature. The membrane was then washed three times with TBST buffer for 20 
minutes and then incubated for 1 hour at room temperature with the horseradish 
peroxidase-conjugated secondary antibody, goat anti-mouse (Pierce) diluted 1:10000. 
Finally, the membrane was washed three times with TBST buffer for 20 minutes and 
proteins were detected by using the SuperSignal™ West Pico Chemiluminescent 
Substrate (Thermo Scientific), according to the manufacturer’s instructions.  
Protein levels were quantified by measuring density of the band in ImageJ (Schneider et 
al., 2012). 
 
5.2.8 Proliferation assay 
Proliferation assay was performed following the protocol described in section 3.2.3 
(Chapter 3). 
 
5.2.9 Statistical analysis for cell proliferation 
Data analysis 
1. Transfection experiments were done in four biological replicates. Each biological 
replicate has three treatments, siRNA1, siRNA2 and Stealth siRNATM negative 
universal control, leading to four biological replicates per treatment. For 
proliferation assays 10 wells of a Nunc-Immuno™ MicroWell™ 96 well solid 
plate, containing CTX0E16 cells, were transfected for each siRNA treatment, 
leading to 10 technical replicates for each biological replicates for each cell line. 
2. The effect of VRK2 knockdown on the proliferation of CTX0E16 cells was 
analysed by ki67 inmunostaining. Cell counts for proliferating cells (ki67 
positives) and total number of cells per well for each treatment in the four 
biological replicates (four plates) were obtained from Cellinsight. These values 
were used in the statistical analyses. 





The objective of the statistical analyses was to identify the differences in cell proliferation 
between cells treated with control siRNA and VRK2 siRNA conditions. To this end I used 
a Poisson linear mixed model in R (R Core Team (2013). R: A language and environment 
for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL 
http://www.R-project.org/.). This model compares the rate between treatments, taking into 
account the sample size, including cell counts for proliferating cell and total number of 
cells per treatment (siRNA1, siRNA2 and negative control siRNA) in the four biological 
replicates. The analysis considers the systematic variation between plates with a fixed 
effect per treatment and random effect per plate. Differences of P < 0.05 were considered 
significant. 
The exact command using R was:  
glmer(count_proliferating_cells ~  offset(log(count_total_cells)) + Treatment + (1|Plate) 
,data=data.m2 , family='poisson'). 
 
 
5.2.10 Genome-wide gene expression profiling 
After confirming significant VRK2 knockdown, by qPCR, in both VRK2 siRNA conditions 
(siRNA1 and siRNA2) compared against the control condition (Stealth siRNATM negative 
universal control), the 12 RNA samples obtained from cells transfected with siRNAs (4 for 
siRNA1, 4 for siRNA2 and 4 for the negative control) were sent to the SGDP MRC centre, 
Institute of Psychiatry, King’s College London, for microarray analysis. Genome-wide 
gene expression profiling was performed using the HumanHT-12 v4 Expression 
BeadChip (Illumina).  
 
Microarray data was analysed using Bioconductor in R. First the lumidat Bioconductor 
package (M.J. Cowley, M. Pinese, D. Eby, M.R. Reich, A.V. Biankin, J. Wu, 2011. 
IlluminaIDatReader: A program for reading raw Illumina Gene Expression data 
(manuscript in prepration)) (https://github.com/drmjc/lumidat) was used to pre-process 
Illumina gene expression idat files, the format in which the data was received from the 




SGDP centre. Then the lumi Bioconductor package (Du et al., 2008) was used to perform 
quality control, variance stabilization, normalization and gene annotation analysis.   
 
5.2.11 Identification of differentially expressed genes and bioinformatic analyses. 
Genes differentially expressed as a result of VRK2 knockdown were identified using the 
limma Bioconductor package (Smyth, 2004). 
 
To limit false results arising from low expression genes, probes that were not detected in 
at least all four samples of one of the comparison conditions with a detection P value > 
0.95 were excluded. Microarray probes showing differences in expression between each 
VRK2 siRNA and the negative siRNA condition were identified based on moderated t-test 
using limma on normalized microarray data. To identify genes differentially expressed I 
set a multiple-testing correction threshold of FDR < 0.05 and to select genes for 
additional analyses a nominally significant threshold of P < 0.05. 
 
Additionally, a further selection of significant gene expression changes associated with 
the two VRK2 siRNA conditions that occurred a nominally significant P < 0.05 and in the 
same direction (i.e. up- or down-regulation) relative to the negative control siRNA 
condition was performed. This was done to refine the data set to those changes reflecting 
VRK2 knockdown rather than off-target effects of individual VRK2 siRNA. The 
overlapping gene set resulting from this selection was subjected to Gene Ontology 
analysis (GO) through the DAVID Bioinformatics Resource 6.7 (Huang da et al., 2009), 
using all gene probes that had a detection P value > 0.95 in at least all four samples of 
one of the comparison conditions as the background comparison. 
 
 






5.3.1 Transfection efficiency of siRNA and DNA vectors. 
To determine transfection efficiency, cells transfected with the BLOCK-iTTM Alexa Fluor® 
Red Fluorescent oligo or the pmaxGFP® Vector were checked 24 hours post-transfection 
by fluorescence microscopy. Transfection efficiency was very high with >80% of cells 
presenting red or green fluorescence 24 hours post-transfection (Figure 5.6) 
 
 
Figure 5.6 Assay of transfection efficiency using the NucleofectionTM technology from 
Lonza 
Transfection efficiency was measured by the uptake of BLOCK-iT Alexa Fluor red Fluorescent 
Oligo (A) or pmaxGFP® Vector (B) into neuronal progenitor cells CTX0E16. Fluorescence was 
checked 24 hours post-transfection. Images were taken using the inverted microscope Olympus 














5.3.2 Knockdown of VRK2 mRNA in CTX0E16 cells. 
Confirmation of VRK2 mRNA knockdown, relative to the negative control siRNA, was 
assessed by quantitative qPCR. The qPCR values for VRK2 mRNA expression level 
were normalized against the geometric average of three internal control genes (RPLI3A, 
GADPH and CFDP1). Table 5.7 show the normalized data for CTX0E16 cell line, used in 
the statistical analysis. 
 
 
Table 5.7 Normalized VRK2 expression values after RNAi transfection, obtained in CTX0E16 









qPCR1 qPCR2 qPCR3 qPCR4 
siRNA1 0.4158 0.3706 0.3249 0.3688 1 
siRNA1 1.1820 0.8482 0.7298 0.8805 2 
siRNA1 0.9056 0.6906 0.6694 0.6026 3 
siRNA1 0.5647 0.3781 0.2782 0.2900 4 
siRNA2 1.6384 0.4008 0.2349 0.3621 1 
siRNA2 0.4757 0.4344 0.4628 0.5074 2 
siRNA2 0.4583 0.4281 0.4541 0.5112 3 
siRNA2 0.6768 0.4889 0.4176 0.5729 4 
control 2.0984 0.6679 0.6572 0.5794 1 
control 0.2573 0.8983 0.8844 1.2668 2 
control 1.4906 1.0181 1.0341 1.0036 3 
control 1.2838 0.9038 0.6599 0.6045 4 
 
 
Statistical analyses were performed applying a linear mixed model in order to identify 
expression changes in VRK2 mRNA level between control siRNA and VRK2 siRNA 
conditions. The results obtained from the statistical analysis are show in Table 5.8.  
 








VRK2 expression was represented relative to the negative control, Figure 5.7 show that 
siRNA1 and siRNA2 reduced VRK2 expression by 38% and 44% respectively relative to 
control siRNA1, being both significant (P = 0.0040 and P = 0.0006, respectively). 
 
 
Figure 5.7 Expression of VRK2 mRNA after RNAi transfection 
QPCR results showing VRK2 mRNA expression 120 hours post-transfection with two independent 
VRK2 siRNAs (siRNA1 and siRNA2). Data are normalized against the geometric average of 3 
housekeeper genes and plotted relative to the negative control siRNA. VRK2 mRNA was reduced 
by 38 % and 44% in association with siRNA1 (P = 0.004) and siRNA 2 (P = 0.0006) respectively. 
Error bars represent SEM derived from four separate transfection experiments. Asterisks show 
where the expression of VRK2 is significantly different from control. Asterisks show where the 
expression of VRK2 is significantly different from control (P < 0.05). 
Treatment Estimate SE Pr(>|t|) Mean 
expression 
mean-1SE mean+1SE Fold 
change (%) 
Control -0.1434 0.1162  0.8664 0.7714 0.9732 100 
siRNA1 -0.6169 0.1162 0.0040** 0.5396 0.4805 0.6061 62.2819 
siRNA2 -0.721 0.1162 0.0006 *** 0.4863 0.4330 0.5462 56.1244 




5.3.3 Overexpression of VRK2 mRNA in CTX0E16 cells. 
Confirmation of VRK2 mRNA overexpression, relative to the negative control pmaxGFP 
was assessed by quantitative qPCR. The qPCR values for VRK2 mRNA expression level 
were normalized against the geometric average of three internal control genes (RPLI3A, 
GADPH and CFDP1). Table 5.9 show the normalized data for CTX0E16 cell line, used in 
the statistical analysis. 
 
Table 5.9 Normalized VRK2 expression values after overexpression, obtained in CTX0E16 
cell line. These values were used in statistical analysis applying a linear mixed model. 
 
 
Statistical analyses were performed applying a linear mixed model in order to identify 
expression changes in VRK2 mRNA level between control pmaxGFP and pVRK2 
conditions. The results obtained from the statistical analysis are show in Table 5.10. 
 
Table 5.10 Statistical result for VRK2 expression after overexpression, in the CTX0E16 cell 
line. 




qPCR1 qPCR2 qPCR3 qPCR4 
pVRK21 1.064911298 0.759224598 0.485146328 1.07645406 1 
pVRK22 1.074722625 2.156801469 1.843783161 1.110078615 2 
pVRK23 1.330978842 0.650571805 0.591582528 0.739045715 3 
pVRK24 1.001125166 0.64745185 0.697898028 0.664713035 4 
pGFP1 1.597601312 0.818814737 0.79111003 1.039437635 1 
pGFP2 0.777440249 0.757331832 0.79898748 1.047042158 2 
pGFP3 0.702510167 0.900261514 0.861260649 1.088427272 3 
pGFP4 0.420753151 0.553121785 0.592258908 0.742052644 4 
Treatment Estimate SE Pr(>|t|) Mean 
expression 
mean-1SE mean+1SE Fold 
change (%) 
pGFP -0.2149 0.1256  0.8066 0.7115 0.9146 100 
pVRK2 -0.0924 0.1256 0.288 0.9117 0.8041 1.0337 113.0297 
 




VRK2 expression was represented relative to the negative control. Transfection of 
CTX0E16 with pVRK2 produced an increase in the relative expression of VRK2 mRNA of 
13%. However, this overexpression of VRK2 mRNA was not significant relative to the 
control pmaxGFP  (P = 0.288) (Figure 5.8) 
 
 
Figure 5.8 expression of VRK2 mRNA after overexpression with pVRK2 
QPCR results showing VRK2 mRNA expression 120 hours post-transfection with pVRK2 and the 
negative control pmaxGFP. Data are normalized against the geometric average of 3 housekeeper 
genes and plotted relative to the negative control. A 13 % increase in VRK2 mRNA expression was 
observed in association with pVRK2, but this was not significant (P = 0.288). Error bars represent 
SEM derived from four separate transfection experiments. 
 
 
5.3.4 Effect of VRK2 knockdown on VRK2 protein in CTX0E16 cells. 
Reduced levels of VRK2 protein associated with the siRNA conditions were verified by 
inmunobloting (Figure 5.9). VRK2 protein levels were normalized against the geometric 
average of three internal control proteins (α-tubulin, β-actin and, GADPH) and were 
represented relative to the negative control. 
Knockdown of VRK2 with siRNA1 and siRNA2 resulted in a reduction of 46 % and 48 % 
in VRK2 protein levels respectively. 










         
    
Figure 5.9 Expression of VRK2 protein after RNAi transfection 
(A) Immunoblots for proteins lysates obtained from cells transfected with siRNA1, siRNA2 and 
Stealth siRNATM negative universal control show that both siRNA1 and siRNA2 reduced VRK2 
levels. The image was analyzed by densitometry using ImageJ. (B) VRK2 levels were normalized 
against the geometric average of 3 housekeeper proteins (α-tubulin, β-actin and, GADPH) and 
plotted relative to the negative control siRNA. VRK2 protein was reduced by 46 % and 48% in 
association with siRNA1 (P = 0.005) and siRNA2 (P = 0.05) respectively. Error bars represent SEM 
derived from four separate transfection experiments. Asterisks show where the expression of VRK2 
is significantly different from control. 





5.3.5 Proliferation of CTX0E16 cells. 
The effect of VRK2 knockdown on the proliferation of CTX0E16 was analysed by ki67 
inmunostaining. Background staining for ki67 was removed by quantifying positive ki67 





              
Figure 5.10 Examination of ki67 inmunostaining. 
120 hours after transfection cell proliferation was evaluated by ki67 inmunostaining assay. For all 
conditions a negative control, which was only stained for secondary antibody and DAPI, was used 
to eliminate background (false positive staining for ki67). Positive ki67 cells were quantified using 
Cell Insight. Images were taken using Cell Insight (Thermo). Scale bar 50 μm.  





Cell counts for proliferating cells (ki67 positives) and total number of cells per well for 
each treatment in three biological replicates (3 plates) were used in the statistical 
analyses. I could not use the four biological replicates because one of them had very low 
cell count. This is a disadvantage of the NucleofectionTM technology. 
 
Because the number of cells observed per well in each treatment and in the three 
biological replicates was variable, I decided to analyse my data using a mixed-model to 
account for this systematic variation. In addition, I used a Poisson linear mixed-model in 
order to account explicitly for the total number of cells in the well when comparing the 
fraction of proliferating cells. This helps avoid potentially misleading results due to very 
different number of cells across treatments or biological replicates. For instance, simply 
using the fraction of proliferating cells but ignoring the total number of cells would deem a 
ratio of 50% equal from a well with 100 or 10000 total cells, when in the second case 
there is much more certainty that the ratio is 50%. The analysis considers treatments as 
fixed effects and aims to account for the systematic variation between by modelling 
biological replicates as random effects. Below, I will describe in detail the process used to 
summarise and filter the data in order to perform statistical analyses as well as checks I 
did to understand the statistical results and their robustness. 
 
Data analysis  
1. Firstly, I explored the variability in total number of cells per biological replicate 
and well (Figure 5.11, top). The three plates had low cell counts in all the 
treatments, with only plate 1 having higher number of cells in the control 
condition. I also examined the fraction of proliferative cells (Figure 5.11, bottom); 
plate 1 showed the greatest variability in the raw proliferation ratio. 






Figure 5.11 Total number of cells for each treatment per plate (top) and fraction of 
proliferative cells for each treatment per plate (bottom), for CTX0E16 cell line. 
 
 
2. Then I examined the relationship between total number of cells and number of 
proliferating cells (Figure 5.12). This confirmed previous observations for plate 1 
in the control condition and showed that in general wells have a very low number 
of proliferating cells, which coincide with the observe low cell counts. It also 
showed that plate 3 control condition has the lowest number of cell than any 
other plate or condition (all wells are on the bottom left corner). 








Figure 5.12 Relationship between total number of cells and proliferating cells for each 
treatment per plate, observed on CTX0E16 cell line 
 
 
3. Based on observations from point 2, I decided to remove from the analysis wells 
with less than 100 cells and to remove plate 3 due to the low cell counts 
observed in the control siRNA treatment. This leads to the following dataset: 
Figure 5.13. 






Figure 5.13 Total number of cells for each treatment per plate (top) and fraction of 
proliferative cells (bottom). These data excluded plate 3 and wells with less than 100 cells. 
Data obtained on CTX0E16 cell line. 
 
4. In order to take into account the difference in the total number of proliferating 
cells in different wells I used a Poisson model, which explicitly models this. As 
explained before, using the ratio of proliferating/total number of cells would ignore 
differences in total number of cells and regards as equal a case with ratio of 50% 
from counts 10/20 or 1000/2000 in spite that the second case has a much more 
certainty that the ratio is 50%. In order to account for the systematic variation 
across wells and biological replicates I used a generalized linear mixed model. 
 
a) First I analysed the data removing plate 3 and wells with less than 100 
proliferating cells. The statistical results are show in Table 5.11.





Table 5.11 Statistical results for proliferating CTX0E16 cells with plate 3 removed and 
removed wells with less than 100 proliferating cells. 
 
Treatment Estimate SE Pr(>|z|) Mean 
proliferation 
mean-1SE mean+1SE Fold 
change (%) 
Control -0.0508 0.0646  0.9504 0.8910 1.0138 100 
siRNA1 -0.1470 0.0677 0.0005 *** 0.8633 0.8068 0.9238 90.8346 
siRNA2 -0.2380 0.0701 1.67e-09 *** 0.7882 0.7349 0.8454 82.9353 
 
 
b) Finally, in order to compare I re-analysed the data without filtering, the 
statistical results are show in Table 5.12. 
 
Table 5.12 Statistical result for proliferating CTX0E03 cells, without filtering. 
Treatment Estimate SE Pr(>|z|) Mean 
proliferation 
mean-1SE mean+1SE Fold 
change (%) 
Control -0.0102 0.059  0.9899 0.9331 1.0500 100 
siRNA1 -0.1708 0.0603 8.53e-13 *** 0.8430 0.7937 0.8954 85.1633 
siRNA2 -0.2862 0.0601 < 2e-16 *** 0.7511 0.7073 0.7976 75.8813 
 
 
The comparison of both statistical results suggests that both results are consistent (see 
mean estimates and their standard errors). However, because cell counts in the control 
condition of plate 3 were very low I decided to used the filtered data for >100 cells for 
discussion. 
 
Summary of proliferation results for CTX0E16 cell line: 
Proliferative cells were reduced when VRK2 was knocked down with siRNA1 and 
siRNA2, relative to the negative control siRNA condition. Table 5.11 show that a 9.2% 
reduction in cell proliferation occurs with siRNA1 and 17% with siRNA2 treatment. These 
two results are statistically significant, P =0.0005 and P < 1.67 X 10-9, respectively. 





5.3.6 Microarray analysis of VRK2 knockdown 
A total of 23657 probes were detected with detection P > 0.95 in at least all four cellular 
RNA samples derived from one of the comparison conditions (siRNA1, siRNA2 or 
negative control siRNA). These probes correspond to transcripts for 16047 unique 
Refseq genes, of which 16001 mapped to DAVID IDs.  
 
We did not find evidence of differential expression for any probe at FDR < 0.05. However, 
using a nominal significance threshold (P < 0.05) gene expression differed between 
siRNA1 and the negative control siRNA condition at 760 probes, and expression at 1104 
probes differed (P < 0.05) between siRNA2 and the negative control siRNA condition. 
Gene expression differing between both VRK2 siRNA conditions and occurring in the 
same direction (i.e. up- or down-regulation) relative to the negative control siRNA 
condition was observed at 186 probes. By chance alone we expected 14.7 probes to 
overlap in direction of effect at P < 0.05, this comes from each probe having 5% chance 
of being on the list with a P < 0,05 and 50% chance to have either direction of effects 
and, therefore, the probability of finding the same probe on the list for both siRNA is 
0.05*0.05*0.5*0.5 = 0.000625. Thus, the overlap of the two lists is ~12 (or 186/14.7) 
higher than expected by chance.! Of these, 73 were up-regulated and 114 were down-
regulated, in association with the two VRK2 siRNA conditions. These probes are listed in 
Table 5.13. !





Table 5.13 Genes showing differential expression (P < 0.05), in the same direction relative to 
the negative control siRNA condition, in association with both siRNA VRK2 conditions 
(siRNA1 and siRNA2).  
Gene Symbol pvalue_siRNA1 pvalue_siRNA2 coefficient_siRNA1 coefficient_siRNA2 
Up-regulated genes         
TDGF1 0.000562502 0.015993001 0.108894738 0.065746831 
PARVB 0.001085866 0.000112496 0.162622884 0.213724397 
AI445550 0.001365606 0.006555432 0.103773374 0.082286977 
RMDN1 0.002942841 0.02696716 0.182234814 0.123614249 
PRPSAP2 0.003034752 0.011569297 0.190162548 0.15304456 
C10orf32 0.004484996 0.024736302 0.188158312 0.138540757 
DCUN1D3 0.004689574 0.011744062 0.142917893 0.122535533 
RGNEF 0.004716534 0.020442091 0.10258376 0.079187238 
TMEM14C 0.005739044 0.037346351 0.193072885 0.134851175 
TRAPPC4 0.005756726 0.003204869 0.165322168 0.180963296 
GPS1 0.006612141 0.036460833 0.178045339 0.127965522 
HSFY1, HSFY2 0.006954177 0.003455626 0.097242572 0.108547943 
LILRA4 0.007198439 0.049813285 0.094235205 0.063649731 
ANKRD20A4 0.007823151 0.019291368 0.137449636 0.116525004 
HIST1H4C 0.008874388 0.000404771 0.378797227 0.58700414 
SPATA24 0.009959676 0.032172959 0.108666208 0.086161711 
CAP1 0.010002136 0.00211621 0.225879075 0.288082019 
LOC100129233 0.01000256 0.044690056 0.109945417 0.080729547 
TIMM10 0.012271652 0.0042838 0.178035058 0.212272145 
SATB1 0.012632987 0.018565852 0.112724042 0.10475354 
URM1 0.01308214 0.003544943 0.109511733 0.135975118 
AP4B1 0.013347071 0.025500317 0.135568207 0.1192396 
TDG 0.013693775 0.002797473 0.398735803 0.517123665 
TRIM69 0.014198396 0.003630487 0.145446017 0.182707559 
FKBP14 0.016731267 0.03542051 0.286738231 0.244726163 
NEK8 0.017199312 0.008360029 0.132044749 0.150564639 




NME2 0.018237065 0.004598015 0.089223862 0.113429059 
BOLA2B 0.018299326 0.004733067 0.111064749 0.140653541 
LOC647323 0.018490338 0.038378472 0.080960241 0.069153874 
CCL7 0.019271486 0.025282282 0.07465258 0.070594249 
PPP1R14B 0.020599754 0.035806463 0.158521788 0.140634181 
CHCHD1 0.022042898 0.000227044 0.08754136 0.172347624 
SIVA1 0.023637116 0.013237825 0.196719159 0.220441449 
WWOX 0.023696438 0.002296837 0.13387213 0.199020034 
DERL2 0.024235447 0.005219824 0.144014721 0.190172688 
LEMD3 0.024401448 0.006189997 0.128359244 0.165162351 
MRPL19 0.024778145 0.001833697 0.154065338 0.238648202 
IKZF3 0.025947828 0.027317072 0.104234656 0.10308801 
GTPBP8 0.02631045 0.000347372 0.133452197 0.259325751 
RABL6 0.027108816 0.014815161 0.086454005 0.097664599 
CSH2 0.027950342 0.016341573 0.069668424 0.077756175 
POLR3F 0.028428399 0.005522711 0.120188702 0.162766285 
LOC613206 0.028560332 0.014744227 0.069946322 0.07999019 
SLC35B1 0.029334987 0.00285043 0.137433148 0.207326404 
PRO0611 0.029599822 0.033734001 0.070026468 0.068000092 
KIAA2013 0.036807127 0.011417571 0.097642864 0.123965404 
PVRL3 0.036909957 0.02612173 0.276359121 0.298584447 
HAL 0.037667718 0.015011244 0.07090034 0.086043894 
PLEKHG7 0.03774026 0.018117348 0.107179341 0.125485816 
MYL12B 0.039583775 0.044708841 0.143617241 0.139430759 
IGHG1 0.040730468 0.013665639 0.06263689 0.078821485 
ITGAE 0.042050026 0.018237144 0.182154977 0.218571311 
SNORA27 0.043540208 0.01935361 0.101172768 0.120999481 
TMEM189-UBE2V1 0.043556741 0.048302016 0.089758284 0.087474135 
TPSAB1 0.043738886 0.046670055 0.06964183 0.068529908 
ATM 0.043874994 0.04220882 0.07046269 0.071133044 
TDP1 0.044387372 0.021259967 0.227938905 0.268755905 
AGO2 0.044749699 0.032835495 0.226977968 0.244239789 




SERPINB2 0.045236381 0.03572296 0.06186777 0.065473266 
ZMAT3 0.045804711 0.004634571 0.128419265 0.199814865 
COX11 0.046143623 0.018862172 0.063641551 0.077612275 
C7orf55 0.046602439 0.005850509 0.200221528 0.301542355 
TBX20 0.046848155 0.01969235 0.060775189 0.073761108 
RS1 0.047575471 0.048841409 0.094497173 0.093871283 
FAM106A 0.048036891 0.04634262 0.070360139 0.070998151 
Down-regulated genes         
RNFT2 0.000780343 0.012574238 -0.157913896 -0.103945399 
DCLK1 0.001001211 0.005699693 -0.290390107 -0.226038296 
CYP2D6 0.001517561 0.040931764 -0.115474136 -0.064860085 
IPCEF1 0.001527876 0.002251911 -0.161005181 -0.152539063 
DOCK1 0.001724728 0.034381134 -0.132513671 -0.078921298 
POLR1A 0.001836911 0.025089912 -0.120452769 -0.077574601 
ST6GAL1 0.001954262 0.001435882 -0.229899837 -0.239869289 
DGCR2 0.002354671 0.000425136 -0.160599681 -0.201083166 
EPHA6 0.002604968 0.02128854 -0.102870335 -0.072036574 
ATP1A1 0.002786111 0.004968869 -0.250349693 -0.229354253 
AHNAK 0.002978134 0.003731833 -0.272209645 -0.263201163 
EIF4B 0.003763348 0.001579511 -0.265284115 -0.300554233 
PSG1 0.004060261 0.045760397 -0.112373629 -0.070778042 
CYP39A1 0.004679973 0.017896486 -0.123924834 -0.098112284 
TAOK2 0.004852621 0.003176935 -0.126441692 -0.134875116 
AMZ2 0.006440712 0.002123481 -0.130856495 -0.154824546 
ZFYVE26 0.00702917 0.007859664 -0.14551965 -0.142827269 
ANKHD1-EIF4EBP3 0.007168478 0.012702969 -0.110277432 -0.099799163 
AP3B1 0.008060022 0.038853745 -0.125190085 -0.091616673 
TRIM13 0.008353012 0.013372396 -0.144087343 -0.132535292 
DLL1 0.008800629 0.02985976 -0.128384098 -0.101306428 
RERE 0.009283315 0.016415567 -0.19955757 -0.179811888 
JMY 0.009485717 0.010700525 -0.211169714 -0.206739052 
NHSL2 0.009601524 0.025984737 -0.091800687 -0.07579751 




ZNF490 0.009702641 0.014468097 -0.165404619 -0.153848089 
DYNLRB1 0.010160281 0.048396421 -0.206905124 -0.149334814 
ZNF681 0.01022604 0.037503261 -0.105201316 -0.080895573 
BM665736 0.01057738 0.005113351 -0.111751292 -0.126193002 
LOC388692 0.011108609 0.002645896 -0.085119065 -0.107119267 
RAB4A 0.011173148 0.004092901 -0.100201517 -0.118288295 
ADH6 0.011474485 0.031267651 -0.102582795 -0.083948896 
HOXA3 0.011553113 0.002247779 -0.088183234 -0.114408212 
ZC3H11A 0.012118129 0.014695571 -0.154044295 -0.148637023 
OSBPL2 0.012143725 0.010014164 -0.126358733 -0.130791698 
ARHGEF4 0.012757679 0.00785094 -0.09856025 -0.107347009 
GRIA1 0.013099727 0.045148706 -0.134247586 -0.10321889 
DCTN1-AS1 0.013166385 0.049273455 -0.079656835 -0.059970598 
OCRL 0.013167671 0.00438068 -0.138898402 -0.16718732 
LOC100130480 0.013859029 0.0276356 -0.088939846 -0.077426848 
ERCC6 0.014151489 0.005476056 -0.084841301 -0.099933671 
APLF 0.015114441 0.00450578 -0.0942608 -0.115919875 
TIMP3 0.015465339 0.031911647 -0.219456655 -0.188937054 
RBL2 0.016244972 0.008717631 -0.12660388 -0.141753419 
CDO1 0.01629827 0.047115425 -0.213282384 -0.169074942 
DDX17 0.016638874 0.010175059 -0.178768864 -0.195754012 
FMN1 0.017533046 0.034411144 -0.10310382 -0.089397159 
EIF4B 0.017659595 0.000741158 -0.237100001 -0.386668222 
TMED10 0.01769431 0.000579471 -0.221133802 -0.372132724 
SH2D3C 0.018252657 0.011836221 -0.087792259 -0.095279385 
NACAP1 0.018253896 0.026628278 -0.251248055 -0.232452602 
SNORD59B 0.018382975 0.009357225 -0.08692449 -0.098491053 
C1orf140 0.018437787 0.010483364 -0.085699431 -0.09524226 
DVL3 0.018940265 0.032105339 -0.163158107 -0.145924608 
EEF1G 0.01938727 0.011195302 -0.197917378 -0.219576873 
MPG 0.019621542 0.017963816 -0.089208065 -0.09078551 
HABP2 0.020351517 0.028854455 -0.100713797 -0.093579324 




SNRPN 0.02061835 0.038170653 -0.148733828 -0.130013084 
DPAGT1 0.021210168 0.049096484 -0.091890116 -0.075953408 
TBC1D 0.021291713 0.00174244 -0.086742374 -0.131122775 
PIGZ 0.021749144 0.00633156 -0.096135796 -0.120332482 
TIGD1 0.022364502 0.002801791 -0.084567944 -0.120709416 
OS9 0.022567551 0.011879717 -0.120496646 -0.136410244 
FBXL8 0.022584228 0.033642304 -0.074872957 -0.068665526 
TBL1XR1 0.023009772 0.010678283 -0.199998378 -0.231716767 
ST3GAL1 0.02307969 0.030755188 -0.129256673 -0.121510513 
PARP6 0.024004143 0.003697381 -0.084727252 -0.117777708 
MBTPS1 0.024166971 0.046242439 -0.126390126 -0.108964303 
MEGF8 0.025170328 0.011589213 -0.09100047 -0.105874544 
TET3 0.026521608 0.011541223 -0.076797052 -0.090420603 
PLEKHH1 0.02695187 0.02311532 -0.10937158 -0.112987466 
GOLGA8B 0.027812793 0.017063978 -0.101281992 -0.111976159 
CYP2U1 0.028019221 0.001306604 -0.101065132 -0.168350316 
BF510292 0.028497946 0.006570487 -0.072408921 -0.095392021 
PLBD2 0.029199887 0.025414546 -0.138316206 -0.142533869 
PSG7 0.029593212 0.002992824 -0.066118783 -0.099225083 
CDY1B 0.030745826 0.022470672 -0.103416915 -0.110613634 
RFX2 0.030801713 0.042607595 -0.116428156 -0.107947124 
SLC28A1 0.03114922 0.008392923 -0.087043761 -0.112260069 
LPHN1 0.031361714 0.026934556 -0.177923603 -0.183977194 
APLP2 0.031416411 0.022244413 -0.163533916 -0.17612763 
LOC644172 0.03238532 0.029601484 -0.094192005 -0.096102509 
LGI3 0.032400521 0.016442237 -0.075763651 -0.087272443 
ZNF106 0.032445073 0.028857252 -0.238568249 -0.244877393 
BTN3A3 0.032681786 0.040390835 -0.116110502 -0.110515759 
SDHAP1 0.033250454 0.035993594 -0.128867577 -0.126538966 
GSAP 0.03357984 0.038698394 -0.102397626 -0.099073192 
PAIP1 0.035548359 0.036436877 -0.075008563 -0.074579264 
COL4A5 0.035641767 0.011027767 -0.242370469 -0.307320414 




HAGH 0.036644743 0.024250158 -0.100710863 -0.11035424 
TNFRSF19 0.037432769 0.048173187 -0.084300764 -0.079273494 
ZNF623 0.037565632 0.041901728 -0.082424359 -0.080301 
ZNF23 0.038268478 0.001656927 -0.106328404 -0.184058816 
IRF2BP2 0.038436279 0.004937119 -0.126021494 -0.186057426 
DNAH9 0.038846618 0.027933749 -0.066911643 -0.072118061 
SLC26A3 0.040315742 0.007521603 -0.078384291 -0.109323331 
CACNB2 0.041250155 0.011322676 -0.105734357 -0.138131497 
PCBP2 0.041376541 0.042823288 -0.144939574 -0.143734178 
KRT8P41 0.041412628 0.042083529 -0.077966545 -0.077663402 
RBBP8NL 0.042499429 0.011468001 -0.065808294 -0.086398206 
EFHD1 0.044697831 0.00492456 -0.139686986 -0.213988896 
TMEM164 0.045902708 0.019178661 -0.098079302 -0.119058607 
PDGFD 0.046284602 0.03473703 -0.177677981 -0.190335857 
ZNF580 0.047555963 0.047334681 -0.085923715 -0.08602469 
WNK2 0.047887172 0.011865333 -0.112249787 -0.150867267 
ACADSB 0.048560625 0.027199283 -0.104304442 -0.119436325 
TRIM33 0.048679622 0.037289537 -0.138696578 -0.148016893 
SNX30 0.049283684 0.00360763 -0.108899394 -0.179349825 
EGFEM1P 0.049904746 0.04777355 -0.141701862 -0.143281808 
 
Note: Coefficient indicates differential expression value. 
 
 
Differentially expressed genes were tested for enrichment in particular GO terms using 
the bioinformatic online database DAVID. The most significant terms for differentially 
expressed genes compared with the background list were observed on the cellular 
component process of ‘microsome’ and ‘vesicular fraction’ (GOTERM_CC_FAT) and in 
the subcategories relating to ‘intracellular part’, ‘intracellular’ and ‘vesicular fraction’ 
(Bonferroni corrected P < 0.05). The 10 differentially expressed genes belonging to this 
GOTERM_CC_FAT process are RAB4A, TMED10, CYP2D6, ATP1A1, CYP2U1, 
DGCR2, SLC35B1, DPAGT1 and CYP39A1. Additional GO terms in this category relating 




to ‘cell fraction’, ‘organelle membrane’ and ‘vesicles’ were also significantly enriched 
among differentially expressed genes, although, they did not survive Bonferroni 
correction for all terms in the category. 
 
Compared with the background list, genes annotated as belonging to the biological 
process (GOTERM_BP) of ‘cellular response to stress’, ‘stress activated protein kinase 
and ‘JNK cascade’ were statistically overrepresented in this category (P < 0.05 
uncorrected). A significant enrichment was observed for the molecular function term 
(GOTERM_MF) of ‘nucleic acid binding’ and ‘DNA binding’. However, for both GO 
categories the significance did not survive conservative Bonferroni corrections for all 
terms in each category. All significant GO terms for differentially expressed genes are 
shown in Table 5.14. There was no significant enrichment for differentially expressed 
genes in any KEGG pathway. 
 
When up-regulated genes and down-regulated genes were analyzed separately 
additional GO terms were significantly overrepresented for each set of genes. The most 
significant GO terms for up-regulated genes were ‘intracellular part’ in the cellular 
component category (Bonferroni corrected P < 0.0128). Likewise, genes annotated as 
belonging to the biological process term (GOTERM_BP) of ‘regulation of cell death’, 
‘negative regulation of biological process’ and ‘cellular response to stimulus’ among 
others were statistically overrepresented in this set of genes. Additionally, a significant 
enrichment of genes belonging to the terms ‘nucleus’ and ‘intracellular membrane-
bounded organelle’ from the categories GOTERM_CC_4 and GOTERM_CC_5 
respectively, as well as from the category GOTERM_MF of ‘double-stranded DNA 
binding’ was observed in up-regulated genes (P < 0.05 uncorrected).  
 
When down-regulated genes were analysed separately a significant enrichment was 
observed for ‘endoplasmic reticulum membrane’, ‘microsome’, ‘endomembrane system’, 
and ‘cytoplasmic membrane-bounded vesicle’ in the cellular component category 
(GOTERM_CC) together with ‘electron carrier activity’ and ‘oxidoreductase activity’ in the 




molecular function category (GOTERM_MF) (P < 0.05 uncorrected). Figure 5.14 
represent the GO terms enriched in down-regulated, up-regulated and the overlapping 
set of differentially expressed genes compared with the background list. 




Table 5.14 GO functional enrichment analysis of differentially expressed genes after VRK2 
knockdown in two independent siRNA conditions  
Category Term Count PValue Bonferroni 
GOTERM_CC_4 GO:0044424~intracellular part 101 0.0004 0.0053 
GOTERM_CC_2 GO:0005622~intracellular 104 0.0003 0.0104 
GOTERM_CC_FAT GO:0005792~microsome 10 0.0001 0.0114 
GOTERM_CC_FAT GO:0042598~vesicular fraction 10 0.0001 0.0127 
GOTERM_CC_3 GO:0005622~intracellular 104 0.0001 0.0153 
GOTERM_CC_5 GO:0042598~vesicular fraction 10 0.0001 0.0155 
GOTERM_CC_2 GO:0044424~intracellular part 101 0.0006 0.0195 
GOTERM_CC_3 GO:0044424~intracellular part 101 0.0003 0.0312 
GOTERM_CC_2 GO:0000267~cell fraction 19 0.0024 0.0800 
GOTERM_CC_3 GO:0000267~cell fraction 19 0.0022 0.2042 
GOTERM_CC_FAT GO:0000267~cell fraction 19 0.0012 0.2165 
GOTERM_CC_FAT GO:0005624~membrane fraction 16 0.0012 0.2170 
GOTERM_CC_4 GO:0005624~membrane fraction 16 0.0017 0.2314 
GOTERM_CC_1 GO:0043226~organelle 82 0.0242 0.2364 
GOTERM_CC_3 GO:0005626~insoluble fraction 16 0.0028 0.2576 
GOTERM_CC_5 GO:0005624~membrane fraction 16 0.0020 0.2900 
GOTERM_CC_FAT GO:0005626~insoluble fraction 16 0.0017 0.2969 
GOTERM_CC_1 GO:0044422~organelle part 44 0.0322 0.3021 
GOTERM_CC_4 GO:0005626~insoluble fraction 16 0.0025 0.3130 
GOTERM_CC_2 GO:0043227~membrane-bounded organelle 76 0.0215 0.5320 
GOTERM_CC_2 GO:0012505~endomembrane system 13 0.0235 0.5653 
GOTERM_MF_2 GO:0003676~nucleic acid binding 36 0.0276 0.6343 
GOTERM_CC_3 GO:0044431~Golgi apparatus part 8 0.0109 0.6842 
PANTHER_BP BP00036: DNA repair 6 0.0104 0.7163 
GOTERM_CC_4 GO:0043231~intracellular membrane-bounded organelle 76 0.0089 0.7435 
GOTERM_CC_2 GO:0043229~intracellular organelle 82 0.0389 0.75087 
GOTERM_CC_2 GO:0044446~intracellular organelle part 44 0.0396 0.7572 
GOTERM_CC_2 GO:0031090~organelle membrane 15 0.0406 0.7656 
GOTERM_CC_2 GO:0031982~vesicle 11 0.0407 0.7669 
GOTERM_CC_2 GO:0044422~organelle part 44 0.0426 0.7823 
GOTERM_CC_4 GO:0044431~Golgi apparatus part 8 0.0102 0.7892 
GOTERM_CC_3 GO:0043231~intracellular membrane-bounded organelle 76 0.0161 0.8186 
GOTERM_CC_FAT GO:0044431~Golgi apparatus part 8 0.0085 0.8324 
GOTERM_CC_5 GO:0044431~Golgi apparatus part 8 0.0111 0.8475 
GOTERM_CC_3 GO:0044432~endoplasmic reticulum part 8 0.0218 0.9011 
GOTERM_CC_3 GO:0012505~endomembrane system 13 0.0222 0.9057 
GOTERM_CC_4 GO:0043229~intracellular organelle 82 0.0161 0.9151 
GOTERM_CC_5 GO:0043231~intracellular membrane-bounded organelle 76 0.0147 0.9186 
GOTERM_CC_4 GO:0044432~endoplasmic reticulum part 8 0.0204 0.9566 
GOTERM_CC_3 GO:0043229~intracellular organelle 82 0.0300 0.9590 




GOTERM_CC_FAT GO:0012505~endomembrane system 13 0.0155 0.9626 
GOTERM_CC_3 GO:0031410~cytoplasmic vesicle 11 0.0311 0.9636 
GOTERM_CC_FAT GO:0044432~endoplasmic reticulum part 8 0.0172 0.9737 
GOTERM_CC_3 GO:0044446~intracellular organelle part 44 0.0348 0.9757 
GOTERM_CC_5 GO:0044432~endoplasmic reticulum part 8 0.0221 0.9770 
PANTHER_BP BP00061: Protein biosynthesis 8 0.0313 0.9780 
GOTERM_CC_3 GO:0031300~intrinsic to organelle membrane 5 0.0369 0.9807 
GOTERM_CC_3 GO:0031090~organelle membrane 15 0.0383 0.9835 
GOTERM_CC_4 GO:0044446~intracellular organelle part 44 0.0271 0.9846 
GOTERM_CC_4 GO:0031410~cytoplasmic vesicle 11 0.0287 0.9880 
GOTERM_CC_5 GO:0043229~intracellular organelle 82 0.0273 0.9906 
GOTERM_CC_FAT GO:0031410~cytoplasmic vesicle 11 0.0230 0.9925 
GOTERM_CC_4 GO:0044444~cytoplasmic part 49 0.0327 0.9936 
GOTERM_CC_4 GO:0031090~organelle membrane 15 0.0347 0.9953 
PANTHER_MF MF00124:Oxygenase 4 0.0439 0.9954 
PANTHER_MF MF00071: Translation factor 4 0.0439 0.9954 
GOTERM_CC_5 GO:0031410~cytoplasmic vesicle 11 0.0315 0.9955 
GOTERM_CC_4 GO:0031300~intrinsic to organelle membrane 5 0.0354 0.9959 
GOTERM_CC_FAT GO:0031090~organelle membrane 15 0.0263 0.9963 
GOTERM_CC_4 GO:0005795~Golgi stack 3 0.0365 0.9965 
GOTERM_CC_5 GO:0044446~intracellular organelle part 44 0.0351 0.9976 
PANTHER_BP BP00202:Other developmental process 4 0.0489 0.9976 
GOTERM_CC_FAT GO:0031982~vesicle 11 0.0291 0.9980 
GOTERM_BP_4 GO:0031098~stress-activated protein kinase signalling 
pathway 
4 0.0135 0.9982 
GOTERM_BP_5 GO:0007254~JNK cascade 4 0.0126 0.9984 
GOTERM_CC_5 GO:0031300~intrinsic to organelle membrane 5 0.0373 0.9984 
GOTERM_CC_5 GO:0005795~Golgi stack 3 0.0376 0.9985 
GOTERM_CC_FAT GO:0031300~intrinsic to organelle membrane 5 0.0319 0.9989 
GOTERM_BP_5 GO:0031098~stress-activated protein kinase signalling 
pathway 
4 0.0136 0.9990 
GOTERM_CC_FAT GO:0005795~Golgi stack 3 0.0343 0.9993 
GOTERM_CC_5 GO:0044444~cytoplasmic part 49 0.0431 0.9994 
GOTERM_BP_3 GO:0033554~cellular response to stress 11 0.0266 0.9997 
GOTERM_MF_ALL GO:0003676~nucleic acid binding 36 0.0266 0.9999 
GOTERM_BP_FAT GO:0007254~JNK cascade 4 0.0129 1 
GOTERM_BP_FAT GO:0031098~stress-activated protein kinase signalling 
pathway 
4 0.0139 1 
GOTERM_BP_FAT GO:0000165~MAPKKK cascade 6 0.0217 1 
GOTERM_BP_FAT GO:0033554~cellular response to stress 11 0.0305 1 
GOTERM_BP_FAT GO:0006284~base-excision repair 3 0.0367 1 
GOTERM_CC_3 GO:0044444~cytoplasmic part 49 0.0429 1 
GOTERM_MF_ALL GO:0003677~DNA binding 27 0.0385 1 
 























Figure 5.14 GO terms enriched in down-regulated, up-regulated and the overlapping set of differentially 
expressed genes compared with the background list.  GO terms marked (*) survived Bonferroni corrections. 






The aim of the experiments presented in this chapter was to assess the effect of 
manipulating endogenous VRK2 on the cellular transcriptome and cell proliferation of the 
CTX0E16 neuronal progenitor cell line. To this end I used a combination of siRNA, 
genome-wide expression profiling and assays of cell proliferation associated with VRK2 
knockdown.  
 
Proliferation assays showed that reduced expression of VRK2 decreased cell proliferation 
of the CTX0E16 cell line, and this was consistent with two different siRNAs and across 
biological replicates. This represents, to the best of my knowledge, the first direct link 
between VRK2 and a neural cell phenotype with potential direct relevance to 
schizophrenia. VRK2 has been linked to MAPK signalling which is a known modulator of 
cell proliferation (Zhang and Liu, 2002). VRK2 has been shown to interact directly with 
members of the MAPK signalling pathway such as JIP1 or KRS1 and to modulate the 
response mediated by this pathway (Blanco et al., 2008; Fernandez et al., 2010; 
Fernandez et al., 2012). Another possible explanation is that VRK2 was been shown to 
be able to phosphorylate molecules such as p53 and c-Jun which are known to have a 
role in cell cycling and proliferation (Blanco et al., 2006; Schreiber et al., 1999; Sevilla et 
al., 2004; Vleugel et al., 2006). Although these biochemical experiments were conducted 
in cell lines of cancer origin, my results suggest a similar role in brain cells. Additional 
studies will be needed to clarify the relevance of these known interactions in brain cells 
and to uncover the pathways linking VRK2 to neural progenitor cell proliferation.  
 
The effect of VRK2 knockdown mirrors that of TCF4. TCF4 knockdown was found to 
change expression of genes belonging to cell signalling and proliferation pathways and I 
showed in Chapter 3 that knocking down TCF4 also affects cell proliferation (Chapter 3). 
For my study of VRK2 I performed micro-array analyses in parallel to the cell 
differentiation assays, providing me with the opportunity to test if the physiological effect 




on cell proliferation observed after VRK2 knockdown is also supported by the microarray 
results.  
 
The microarray analysis showed 186 genes to be differentially expressed in association 
with both of the siRNAs at P < 0.05 and with the same direction of change.  Only ~15 
would be expected by chance alone. However, I failed to find significant evidence for any 
gene expression change at FDR < 0.05 suggesting that these changes are small in 
magnitude and that this study lacks statistical power.  
 
Interestingly, among the most genes with P < 0.05 and with same direction of change in 
both siRNA were CACNB2 and C10orf32, two genes at loci that have been implicated in 
schizophrenia by GWAS (Ripke et al., 2013). 
 
Genes belonging to the GO terms ‘intracellular’, ‘microsome’ and ‘vesicular fraction’ were 
enriched (Bonferroni corrected P < 0.05) among those showing altered expression. These 
terms are relatively general GO terms referring to genes encoding proteins found 
associated with cellular and vesicular membranes. It is not straightforward to link these 
cellular processes and compartments with VRK2 function. However, a possible 
explanation is that this result is driven by the knockdown of the VRK2A isoform, which is 
anchored to the endoplasmic reticulum membranes by a C-terminal hydrophobic region 
(Blanco et al., 2006). There is evidence that VRK2A interact with scaffold proteins, which 
play an important role in intracellular signalling compartmentalization (Good et al., 2011). 
VRK2 can form complexes with scaffold and other proteins that modulate the response to 
stimulus mediated by MAPK signalling (Blanco et al., 2007; Blanco et al., 2008; 
Fernandez et al., 2012). 
 
In addition, I looked if any of the GO categories with a nominal significance (P < 0.05) are 
associated with biological processes known to regulate cell proliferation. Four such 
categories, ‘MAPKKK cascade’ (P = 0.0217, Bonferroni = 1), ‘JNK cascade’ (P = 0.0129, 
Bonferroni = 1),  ‘stress-activated protein kinase signalling pathway’ (P = 0.0139, 




Bonferroni = 1), and ‘cellular response to stress’ (P = 0.0305, Bonferroni = 1) were 
overrepresented among the genes with altered expression after VRK2 knockdown, 
although these categories did not survive correction for multiple testing. Several studies 
have described the direct interaction between VRK2 and scaffold proteins such as JIP1 
and KRS1. These together with other proteins form complexes that modulate the 
magnitude of the signal transmission by MAPK signalling pathways in response to 
hypoxia, cytokines and growth factors (Blanco et al., 2007; Blanco et al., 2008; 
Fernandez et al., 2010; Fernandez et al., 2012). Additionally, intracellular levels of VRK2 
conditioned the direction towards a signalling pathway and the magnitude of the response 
mediated for it (Blanco et al., 2007). MAPK pathways play a pivotal role in signal 
transduction in neurons and alteration of these signalling pathways are associated with 
the pathology of schizophrenia (Funk et al., 2012; Kyosseva et al., 1999). Therefore, the 
data presented here although tentative might reflect signal from a potential mechanism 
for VRK2’s role in schizophrenia.  
 
The present work is the first study to show a direct effect of VRK2 on proliferation in 
neural cells. Interestingly, several studies have associated cell proliferation in the 
pathogenesis of schizophrenia (Fan et al., 2012; Reif et al., 2006; Wang et al., 2010) and 
there are some drugs used to treat this disease that have an effect in cell proliferation, 
such as valproic acid, olanzapine and others (Dodurga et al., 2014; Kimoto et al., 2011; 
Kurihara et al., 2014; Niu et al., 2010; Schwarz et al., 2008). This opens the possibility 
that VRK2 and its associated signaling pathways may mediate or be interesting targets 
for drugs to treat schizophrenia. Future studies could explore this possibility and help 
understand the mechanism on effect on cell proliferation and how it can be used to 
develop new therapies. 
 
The present study provides novel data showing a functional effect of VRK2 knockdown 
on the transcriptional programme associated with this kinase, providing a first insight into 
VRK2’s regulated genes and its biological function in the human brain. Contrasting with 
the clear effect seen on cell proliferation and the findings with TCF4, this effect is not 




reflected in pathway analysis where there were no enriched GO terms after Bonferroni 
correction with direct links to cell proliferation. I hypothesise that this may be due to the 
fact that VRK2 is a kinase and its effect on transcription would therefore be indirect, and 
mediated by down-stream transcription factors. Indeed, VRK2 can phosphorylate 
transcription factor like p53 (Blanco et al., 2006) and therefore its knock down is expected 
to have effects on gene-expression mediated by this and other transcription factors. The 
effect on different transcription factors could cancel each other out and provide more 
room for regulatory feedback loops that could correct the deregulation induced by lower 
levels of VRK2. In addition, because a mixture of multiple downstream transcription 
factors can change expression of different signalling pathways, some of which may 
overlap, the genes showing changed expression may not fit as clearly on a few GO 
terms. More importantly, in spite of the observed effect on the transcriptome, VRK2 
knockdown may have more profound effects independent of transcription, for example on 
phosphorylation, activation and modulation of signalling pathways without need of de 
novo transcription.  
 
It is important to note that the analyses conducted in this study were performed at a 
single time point, thus providing only a snapshot of the transcriptional consequences of 
VRK2 knockdown in the CTX0E16 cells. It is therefore likely that some changes in gene 
expression arising from VRK2 knockdown went undetected. 
 
It may be possible to increase the power to detect the effect of VRK2 knockdown on the 
cell transcriptome by inducing lower levels of VRK2 (more knockdown) or to perform 
more biological replicates. However, the clear effect on cell proliferation suggest that 
even small changes in transcription are enough to affect cell physiology or that other 
mechanisms are mediating VRK2’s effect, e.g., regulation of signalling pathways by 
phosphorilation of its targets. Therefore, I suggest that future analyses should ideally 
combine cell phenotype assays (e.g., proliferation) with direct transcriptome as well as 
measurements of VRK2 kinase function, for instance using phosphoproteomics. This may 
provide additional insights and complement those findings described in this study.  




Chapter 6  General Discussion 
 
The main aim of this thesis was to characterise the molecular and cellular mechanisms 
by which genetic variation in TCF4 and VRK2 confers susceptibility to schizophrenia 
(Schizophrenia Psychiatric Genome-Wide Association Study, 2011; Stefansson et al., 
2009). At the outset of this thesis there was very little known about the biological 
functions of these genes in the human brain. The findings presented in this thesis provide 
convincing evidence that TCF4 and VRK2 are involved in the regulation of cell 
proliferation of neuronal progenitor cells in vitro, indicating this as a possible mechanism 
underlying how these genes influence the pathology of schizophrenia. In addition, I found 
evidence for a cis-regulatory effect of a schizophrenia risk variant on VRK2 expression, 
operating during foetal brain development.  
 
As a brief summary, the specific aims of this thesis were: 
A. In silico characterisation of TCF4 through extensive bioinformatics analyses and 
data mining.  
B. Test whether VRK2 expression in the neonatal and adult human brain is 
influenced by the schizophrenia risk allele (rs2312147 allele G, (Steinberg et al., 
2011)) and other common cis-regulatory variation.  
C. Test whether manipulation of the endogenous expression of TCF4 or VRK2 has 
an effect on cell proliferation and to assess the effect on cell transcriptome of 
VRK2 knockdown.  
 
The bioinformatics analyses and literature review presented in Chapter 2 compiled 
information pointing to several potentially interesting roles of TCF4 in brain. In particular I 
found converging evidence of its relationship with other transcription factors known to 
regulate cell fate decision and neuronal differentiation. This information was important to 
interpret the effect on cell proliferation observed upon knockdown of TCF4 mRNA 
presented in Chapter 3. These experiments were prompted by interesting findings from a 
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micro-array study of Dr. Bray’s group where TCF4 knockdown affected the expression of 
genes involved in cell cycling. However, this micro-array data lacked any functional 
evidence to prove that the expression differences really translated into cell physiology 
changes. My data show that knockdown of endogenous TCF4 altered the proliferation of 
two human neural progenitor cell lines, CTX0E16 and CTX0E03. TCF4 knockdown 
increased proliferation of CTX0E16 and decreased proliferation of CTX0E03. This is 
consistent with gene expression data obtained by Dr Nick Bray’s group where genes 
involved in cell cycling changed expression in both cell lines but were positively 
correlated with TCF4 expression in CTX0E16 cells and negatively correlated in CTX0E03 
cells. The data I presented here provide evidence for a functional role of TCF4 in the 
regulation of cell proliferation and, interestingly, suggests that this effect may be 
heterogeneous across cell types. 
 
Regarding VRK2, the data presented in chapter 4 shows the presence of active cis-
regulatory variation affecting VRK2 expression in dorsolateral prefrontal cortex (DLPFC) 
in adult human brain and two stages of foetal brain development. More interestingly, my 
data show an effect of genotype at rs2312147 on VRK2 allelic expression in foetal 
samples from first and second trimester of gestation but not in adult DLPFC. This is the 
first study to provide evidence that VRK2 is subject to variable cis influences on its 
expression. Similarly to TCF4, I found that knockdown of VRK2 has an effect on cell 
proliferation (presented in Chapter 5). This provides the first direct link between VRK2 
and a neural cell phenotype with potential relevance to schizophrenia reported to date. 
The micro-array profiling performed in parallel to the proliferation assay showed an effect 
of VRK2 knockdown on the transcriptional programme of the cell, providing firsts insights 
into VRK2’s downstream genes.  
 
The effect of TCF4 and VRK2 knockdown on the proliferation of neural progenitor cells 
together with evidence for an effect of schizophrenia risk variant rs2312147 on VRK2 
expression in foetal brain provides support for the hypothesis that schizophrenia is, at 
least partially, a neurodevelopmental disorder, i.e., a molecular risk mechanism for 
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schizophrenia operating during brain development and before disease onset.  (Harrison, 
1997; Lewis and Levitt, 2002; Murray and Lewis, 1987; Weinberger, 1987). Interestingly, 
TCF4 and VRK2 are both highly expressed during foetal development, suggesting a role 
for these genes during early brain development (Figure 5.2, Chapter 5, section 5.1). 
Interestingly, recent integrative studies on two different but genetically related psychiatric 
disorders, schizophrenia and autism, have identified gene-networks harbouring genes 
associated with each disorder and have shown that these networks are more active 
during foetal brain development (Tebbenkamp et al., 2014). Thus, there is increasing 
evidence that schizophrenia risk variants may have a functional effect during brain 
development, supporting the neurodevelopmental hypothesis of the disorder. It is 
important to note that the different hypothesis, i.e., neurodevelopmental, 
neuropathological and neurochemical, for the aetiology of schizophrenia are not mutually 
exclusive. Identifying a developmental period where these genetic variants may be more 
relevant is important because it could enable more accurate models of the disorder as 
well as a better understanding of pathogenesis. However, we will ultimately need to 
understand the consequences of these early effects together with the role of the genetic 
variants in adult brain function to develop new effective therapies for adults with 
schizophrenia. Understanding the link between TCF4 and VRK2 and schizophrenia in the 
context of the other aetiological hypotheses remains an open challenge. 
 
It has been previously shown that genes associated with schizophrenia are enriched 
within particular pathways (for example see (O'Dushlaine et al., 2011)). Based on this I 
hypothesize that the mechanism mediating the effect on cell proliferation of TCF4 and 
VRK2 is through a common pathway. TCF4 is a downstream target of the WNT/TCF 
pathway and its expression has been shown to be regulated by β-catenin via its TCF 
binding site in cancer cell lines (Kolligs et al., 2002). Meanwhile, VRK2 has been shown 
to interact directly with members of the MAPK signalling pathway such as JIP1 or KRS1 
and to modulate the response mediated by this pathway (Blanco et al., 2007; Blanco et 
al., 2008; Fernandez et al., 2010; Fernandez et al., 2012). Both pathways WNT/TCF and 
MAPK are important modulators of cell proliferation but I found that is not possible to 
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provide further evidence for a common pathway. However, there is evidence showing 
these two pathways can mutually regulate each other and act synergistically to regulate 
cellular processes in a cell dependent manner (Bikkavilli and Malbon, 2009; Cervenka et 
al., 2011; Guardavaccaro and Clevers, 2012; Jin et al., 2011). Therefore, at the moment I 
think it can only be suggested that TCF4 and VRK2 influence cell proliferation via 
different but functionally related pathways. However, it is noteworthy that DISC1, a gene 
that is disrupted by a chromosomal translocation co-segregating with schizophrenia and 
other major psychiatric disorders in a large Scottish family and one of the most widely 
studied genes in the context of schizophrenia, has been shown to be involved in the 
regulation of neuronal cell proliferation by participating in the GSK3b/β-catenin pathway 
(Mao et al., 2009). Therefore, TCF4 may be downstream of DISC1 and might perhaps 
influence proliferation through the same pathway. It is conceivable, therefore, that genes 
mediating the effect of schizophrenia susceptibility variants affect cell proliferation 
through more than a single pathway. Future studies should aim to provide more evidence 
for the involvement of both TCF4 and VRK2 on the WNT/TCF and MAPK pathway, 
attempt to clarify their interplay and how they relate to other known risk mediator genes, 
such as DISC1. 
 
Several studies have suggested cell proliferation is involved in the pathology of 
schizophrenia using neuronal nasal epithelium and histology of post-mortem tissues (Fan 
et al., 2012; Reif et al., 2006). There is evidence that drugs used to treat schizophrenia 
and bipolar disorder (another psychotic mental illness), such as valproic acid, olanzapine 
and others, affect cell proliferation (Dodurga et al., 2014; Kimoto et al., 2011; Kurihara et 
al., 2014; Niu et al., 2010; Schwarz et al., 2008). Interestingly, these drugs seem to target 
the same proliferation pathways linked to TCF4 and VRK2. For example, valproic acid 
can trigger phosphorylation of ERK interfering with the MAPK signalling pathway (Hao et 
al., 2004; Jung et al., 2008; Yuan et al., 2001). Additionally, valproic acid has been show 
to affect the WNT/ β-catenin signalling pathway by inhibiting GSK3β (Chen et al., 1999; 
Kao et al., 2013; Sintoni et al., 2013). Other antipsychotics have been reported to be 
involved in the regulation of the WNT pathway (Sutton and Rushlow, 2011). This opens 
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the possibility that VRK2 or TCF4 and its associated signaling pathways may mediate or 
be interesting targets for drugs to treat schizophrenia. I think it might the possible to 
combine the cellular models I have worked on to study TCF4 and VRK2 with animal 
models to devise a framework on which to test potential new drugs.  
My argument is as follows; some drugs use to treat schizophrenia have been shown to 
have an effect in proliferation and VRK2 and TCF4 have an effect on proliferation, as 
shown in this thesis. Moreover, the evidence also suggests an overlap on the pathways 
where these genes and some drugs act. Thus, it can be hypothesized that the risk and 
therapeutic effect of these genes and drugs, respectively, converge on the same 
pathways. It is important to note that the drugs are used in adulthood implying, at least, 
two things. First, the effect on proliferation mediated by TCF4 and VRK2 might be present 
in adulthood in the few brain regions where neurogenesis is still active, such as the 
subventricular zone (SVZ) and dentate gyrus (Reif et al., 2007). A second possibility is 
that the disease risk mediated by these genes is not increasing risk in adulthood but the 
drugs can compensate some of the pathology produced during foetal development and or 
pathology that is a consequence of the disease itself. Regardless of which model is 
correct, the fact that drugs do indeed improve schizophrenia symptoms shows that drugs 
targeting cell proliferation can be effective in treating the disease. This is in spite of us not 
fully understanding all the disease mechanisms nor the mechanisms of drug action or 
whether schizophrenia genetic susceptibility is mostly mediated during foetal 
development. A interesting example of this have been shown in a KO mouse model of 
Fragile-X syndrome, where drugs can revert the effect of the mutation in adult mice in 
spite being a bona fide example of a neurodevelopmental disorder (Gandhi et al., 2014; 
Sun et al., 2014). 
 
I translate this argument on the following idea. We can use the effect on cell proliferation 
on cell lines as a functional signature useful to identify new drugs to treat schizophrenia. 
Given the evidence presented above I suggest the knockdowns of TCF4 and VRK2 could 
be useful to this end. Therefore, we could test drugs on these cellular models and look for 
a reversal of the gene knockdowns on cell proliferation. If this is seen, we could think that 
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those drugs could have a therapeutic effect on schizophrenia. For example, known drugs 
targeting the WNT/TCF and MAPK pathway could be tested together for reversal of the 
effect on cell proliferation seen upon TCF4 or VRK2 knockdown. Targeting the same 
pathways where TCF4 and VRK2 act is not a requirement but could prioritize for more 
interesting drugs. Brzozka et al., (Brzózka et al., 2010) described a transgenic mouse for 
TCF4 that presents cognitive and sensorimotor impairments. This animal model could be 
used to test the drugs affecting proliferation in the cellular models to see if they bring 
about an improvement in behavioral outcomes. In addition, VRK2 is a kinase with 
reduced kinase promiscuity (Fedorov et al., 2007) making it the ideal candidate for 
development of specific inhibitors and for which selective drugs could be tested, perhaps 
also based on their effect on cell proliferation in the neural cell line model.  
 
I acknowledge limitations of the experimental models and results I have presented but I 
also think this thesis highlights additional potentially interesting avenues for future work 
as well as some important considerations. Data presented in Chapter 4 show the 
presence of cis-acting influences affecting VRK2 expression in dorsolateral prefrontal 
cortex (DLPFC) in adult human brain. However, the genotype at rs2312147, the SNP 
associated with schizophrenia, did not have a major effect on VRK2 allelic expression in 
this region of the adult brain. It is important to consider that effects of cis-regulatory 
variation can differ across brain regions (Buonocore et al., 2010). Given the evidence, 
presented in Chapter 5, that VRK2 knockdown affects neural cell proliferation, it may be 
informative to test effects of the GWAS risk variant on VRK2 expression in an adult brain 
region where neurogenesis continues, such as the dentate gyrus of the hippocampus. It 
is also important to point out that assessment of allelic expression carried out in the 
present study was limited to a single gene – VRK2. However further studies using RNA-
seq technology will allow assessment of allelic expression on a genome-wide scale 
(Pastinen, 2010).  
 
In the present study I provided evidence for the biological effect of TCF4 and VRK2 
knockdown in neural progenitor cell lines derived from human foetal brain. It is important 
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to consider some limitations of this model; for example, while celular models are a good 
approach to test the effect of one gene, they fail to capture all the complexity of the brain 
and psychiatric disorders. Furthermore, it is important to point out that effects observed in 
this study would be specific to cycling cells like neural progenitors. Because they are 
neural progenitor cells derived from human foetal brain, the cells used in these studies 
might not be relevant to mature cells of the adult brain.  
 
Additionally, my results also showed that the biological effect of TCF4 and VRK2 is 
heterogeneous in respect to cell lines and genes. Thus, it seems that in order to gain a 
more detailed understanding we may need to explore the use of additional cell lines. For 
instance, this could be achieved with studies in mature neuronal cells differentiated from 
these progenitors. One could also think of more complex but also realistic experimental 
models. For example those in which different mature cell lineages generate active 
functional synapses on which electrochemical properties of synapses and other cell 
physiological phenotypes could be measured. Perhaps in the future it will be possible to 
induce knockdown in cerebral organoids. Cerebral organoid permits in vitro assembly of a 
human embryonic brain rudiment that recapitulates the developing human cerebrum and 
yield mature cortical neuron subtypes (Lancaster et al., 2013; Muzio and Consalez, 
2013). Regardless, of the model I think it might be necessary to use additional and 
differentiated cell lineages and if possible study the effect of knockdown (or other 
intervention) on their functional interactions.  
 
I believe functional experiments aiming to identify the biological processes likely affected 
by alleles confering risk to schizophrenia may also have implication for the understanding 
of future genetic studies both in populations and in the case of personalised medicine. 
One can think of using the knowledge of the biological processes to prioritize genetic 
variants implicated in a disorder. For example, to date analyses of rare variants have 
been restricted to burden tests grouping all variants together. In order to link susceptibility 
alleles with biological mechanism or to practice stratified medicine we need to identify 
individual risk variants. Recognizing true susceptibility rare variation among the sea of 
Chapter 6: General Discussion 
 187 
rare variants in the human genome is currently a major challenge (MacArthur et al., 
2014). An interesting possibility is that the effect of both rare and common variants will 
converge on common biological processes. Therefore, as we characterise the biological 
role of genes in additional risk loci this information will serve as a framework to sieve 
human rare genetic variation and retain the most likely rare susceptibility alleles for 
further studies. For example, in a patient with schizophrenia and whole genome 
sequencing we could pay more attention or give more weight to rare potentially 
deleterious variation in genes known to affect cell proliferation or to be highly expressed 
during mid-foetal brain development. These ideas are already being applied to other 
human disease to prioritise variants for further research, for example to autism (Liu et al., 
2014), and might be important for the interpretation of personal genomes and quantitative 
personalised medicine.  
 
At the moment, the potential links between TCF4 and VRK with the WNT/TCF and MAPK 
pathways, respectively, are based on biochemical evidence gathered from other human 
cell types and other species. I have used this evidence to speculate on the possible 
mechanism underlying the effects on cell proliferation. However, it remains for future work 
to validate and extend knowledge of these biochemical interactions. This may be 
especially interesting as one attempts to validate links with other genes involved in 
schizophrenia that also affect cell proliferation, like DISC1.  
 
Finally, I used transcriptome profiling to better understand the molecular effect of VRK2 
knockdown. I think this is a valuable approach since it is genome-wide, requires no a 
priori hypotheses and enables comparison with other data generated at Dr. Bray’s lab on 
the same cell lines and other genes. However, given that VRK2 is a kinase it would be 
interesting to use other experimental approaches like phosphoproteomics to better 
understand VRK2’s kinase function and how it relates to MAPK and WNT/TCF pathways 
and genes in other schizophrenia associated loci. These studies combined with cell 
phenotype assays (e.g., proliferation) and direct trasncriptome profiling will complement 
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my findings and provide additional insights into VRK2’s regulated genes and targets and 
its biological function in the human brain. 
 
In summary, the series of studies presented in this thesis provide experimental evidence 
for the biological effect of TCF4 and VRK2 on cell proliferation in human neural progenitor 
cells, and evidence that schizophrenia risk variation at the VRK2 locus has a cis-effect on 
VRK2 expression during foetal brain development. These findings can be interpreted in 
the context of and support the neurodevelopmental hypothesis of schizophrenia. I 
highlight interesting implications of my results, some of which warrant future research to 
help dissect the molecular aetiology of schizophrenia and to develop models to bring new 
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Common SNPs in the transcription factor 4 (TCF4; ITF2, E2-2,
SEF-2) gene, which encodes a basic Helix-Loop-Helix (bHLH)
transcription factor, are associated with schizophrenia, confer-
ring a small increase in risk. Other common SNPs in the gene are
associated with the common eye disorder Fuch’s corneal dys-
trophy, while rare, mostly de novo inactivating mutations cause
Pitt-Hopkins syndrome. In this review, we present a systematic
bioinformatics and literature review of the genomics, biological
function and interactome of TCF4 in the context of schizophre-
nia. The TCF4 gene is present in all vertebrates, and although
protein length varies, there is high conservation of primary
sequence, including the DNA binding domain. Humans have
a unique leucine-rich nuclear export signal. There are two main
isoforms (A and B), as well as complex splicing generating many
possible N-terminal amino acid sequences. TCF4 is highly
expressed in the brain, where plays a role in neurodevelopment,
interacting with class II bHLH transcription factors Math1,
HASH1, and neuroD2. The Ca2þ sensor protein calmodulin
interacts with the DNA binding domain of TCF4, inhibiting
transcriptional activation. It is also the target of microRNAs,
including mir137, which is implicated in schizophrenia. The
schizophrenia-associated SNPs are in linkage disequilibrium
with common variants within putative DNA regulatory ele-
ments, suggesting that regulation of expression may underlie
association with schizophrenia. Combined gene co-expression
analyses and curated protein–protein interaction data provide a
network involving TCF4 and other putative schizophrenia sus-
ceptibility genes. These findings suggest new opportunities for
understanding the molecular basis of schizophrenia and other
mental disorders. ! 2012 Wiley Periodicals, Inc.
Key words: Pitt-Hopkins syndrome; Fuch’s corneal dystrophy;
genome-wide association; protein–protein interaction; gene
network
INTRODUCTION
The TCF4 gene on chromosome 18q21.2 (Entrez Gene ID 6925;
ensemble ENSG00000196628) encodes a basic helix-turn-helix
(bHLH) Ephrussi-box (‘‘E-box’’ or E-) protein transcription fac-
tor. The gene spans 437 kb and has 41 exons. It has multiple aliases
in addition to the official HUGO name TCF4 and is also known as
E2-2, ITF2, PTHS, SEF2, SEF2-1, SEF2-1A, SEF2-1B, bHLHb19,
MGC149723, andMGC149724. Thepleiotropic disease associations
of TCF4 include rare non-synonymous mutations and gene dele-
tions in Pitt-Hopkins syndrome (PHS), and common risk variants
for Fuch’s corneal dystrophy (FCD) and schizophrenia, which are
genetically distinct from each other. It should not be confused with
Additional supporting information may be found in the online version of
this article.
*Correspondence to:
Prof. David A. Collier, Social, Genetic and Developmental Psychiatry
Centre, King’s College London, Institute of Psychiatry, De Crespigny
Park, Denmark Hill, London SE5 8AF, UK.
E-mail: david.collier@kcl.ac.uk
Article first published online in Wiley Online Library
(wileyonlinelibrary.com): 5 November 2012
DOI 10.1002/ajmg.b.32109
How to Cite this Article:
Navarrete K, Pedroso I, De Jong S, Stefansson
H, Steinberg S, Stefansson K, Ophoff RA,
Schalkwyk LC, Collier DA. 2013. TCF4 (e2-2;
ITF2): A schizophrenia-associated gene with
pleiotropic effects on human disease.
Am J Med Genet Part B 162B:1–16.
! 2012 Wiley Periodicals, Inc. 1
Neuropsychiatric Genetics
TCF7L2 (transcription factor 7-like 2), another transcription factor
mapping to a different locus on chromosome10q25-25.3, that plays
a key role in theWnt-signaling pathway, which has also been called
TCF4, and has been associated with schizophrenia [Hansen et al.,
2011; Alkelai et al., 2012].
In the present archival review, we performed a systematic
literature search for publications describing the TCF4 protein,
using the terms E2-2, ITF2, PTHS, SEF2, SEF2-1, SEF2-1A,
SEF2-1B, bHLHb19, PHS, and FCD. The literature search was
updated upuntil July 9, 2012, and references collated (seeAppendix
given in Supporting Information for full list of references identified
for the study). Papers referring toTCF7L2 (butwhichused the term
TCF4)weremanually excluded from the list after reading the text to
determine this. Several papers whose subject was TCF4 (e2-2) were
incorrectly indexed with the term TCF7L2, including the original
paper describing the cloning of TCF4 (e2-2). Thesewere retained in
the list. Bioinformatic analysis was performed up until April 2012.
TCF4 AND HUMAN DISEASE
Pitt-Hopkins Syndrome
Non-synonymous mutations and deletions in the TCF4 gene are a
cause of PHS (MIM #610954), a rare autosomal dominant ence-
phalopathy caused largely by de novo mutations [Whalen et al.,
2012]. PHS was originally described in 1978 in two unrelated
patients with mental retardation, recurrent episodes of hyperven-
tilation, and a wide mouth [Pitt and Hopkins, 1978]. A series of
additional cases helped to refine the clinical features, which are
severe psychomotor delay, epilepsy, and daily bouts of diurnal
hyperventilation starting in infancy; mild postnatal growth retar-
dation; postnatal microcephaly; and distinctive facial features
[Singh, 1993; Van Balkom et al., 1998; Orrico et al., 2001; Peippo
et al., 2006; de Pontual et al., 2009]. Families describe their children
with PHS as creative and joyful (pitthopkins.org). Clinical study
finds that most have a smiling appearance, as well as anxiety,
stereotypicmovements, particularly of the arms,wrists, andfingers,
and hyperventilation thatmay be triggered by emotional situations
[Whalen et al., 2012]. Constipation is common, and there is
co-morbidity for the developmental disorder Hirschsprung disease
in PHS, a neurocristopathy characterized by the absence of enteric
ganglia along a variable length of the intestine.
Using systematic genome-wide BAC-array screening, de novo
microdeletions on chromosome 18q21.1, which include the TCF4
gene, were identified in PHS [Gustavsson et al., 1999; Amiel et al.,
2007; Brockschmidt et al., 2007; Zweier, 2007] and finemapping of
the deleted region led to the identification of heterozygous TCF4
mutations in non-deleted cases [Amiel et al., 2007; de Pontual et al.,
2009], including null alleles created by splice site, frameshift,
nonsense mutations, and missense mutations which change highly
conserved residues. Almost all mutations are de novo and private.
Point mutations account for 40% of these, mostly causing pre-
mature stop codons, indels 30%, and de novo gene deletions 30%.
Missense mutations are generally within the bHLH domain, a
mutational hotspot. There may also be attenuated loss of function
with a less severe phenotype: one parent carried a mosaic mutation
and suffered fromdepression and epilepsy [de Pontual et al., 2009].
Analysis of the effects of TCF4 mutations in PHS is consistent
with loss of function, with activation of a reporter construct
significantly and similarly impaired for nonsense, frameshift,
and missense TCF4 mutants when co-transfected with achaete-
scute complex homolog 1 (HASH1; ASCL1) cDNA [de Pontual
et al., 2009], a cofactor involved in activation of TCF4DNAbinding
[Persson et al., 2000]. The causative mutations in TCF4 that is
hemizygous deletion and inactivating mutations indicate that
PHS is caused by haploinsufficiency of the gene, that is it is highly
dosage-sensitive.
While TCF4 mutations are confirmed as the cause of PHS,
autosomal recessive disorders resembling PHS (Pitt-Hopkins-
like syndrome) are caused bymutations in NRXN1 andCNTNAP2
[Zweier et al., 2009; Blake et al., 2010]. Copy number variants
(CNVs) in both of these genes are also associated with schizophre-
nia andother neurodevelopmental disorders [Friedman et al., 2008;
Rujescu and Collier, 2009].
Schizophrenia
Genetic epidemiology studies of schizophrenia have consistently
shown a strong genetic component, with estimates of heritability at
up to 80% [Cardno et al., 2002; van Os and Kapur, 2009]. Multiple
genetic variants have been implicated in risk, including common
single nucleotide polymorphisms (SNPs) from genome-wide asso-
ciation with small effect-size and rare CNVs of moderate to large
effects [Rujescu and Collier, 2009], as well as environmental and
epigenetics factors [Pidsley and Mill, 2011]. To date, two inde-
pendent genetic loci in near TCF4 have been implicated in schiz-
ophrenia, one in intron three of the gene and one between the distal
end of TCF4 and the gene CCDC8, providing robust GWAS
evidence for association [Stefansson et al., 2009; Ripke et al.,
2011; Steinberg et al., 2011].
The initial association between TCF4 and schizophrenia was
with the SNP rs9960767, in intron three of the gene (P¼ 4.1" 10#9;
OR 1.23 [1.15, 1.32]) [Stefansson et al., 2009]. A second variant
(rs4309482) downstream the TCF4 gene reached a genome-wide
significance level in a follow-up study (P¼ 7.8" 10#9; 1.09 [1.06,
1.12]) [Steinberg et al., 2011], and a third variant (rs12966547) was
significantly associated with schizophrenia in a GWAS mega-
analysis from the psychiatric GWAS consortium (P¼ 2.60" 10#10;
OR 1.09 [1.06–1.12]) [Ripke et al., 2011]. A fourth variant,
rs17512836, has also been associated with schizophrenia from
the PGC schizophrenia analysis (P¼ 2.35" 10#8); after follow-
up this gave a combined P value of 1.05" 10#6 (OR 1.23
[1.14–1.31]) [Ripke et al., 2011; broadinstitute.org/mpg/ricopili/].
The TCF4 gene, the location of GWAS associated SNPs, and
their linkage disequilibrium (LD) with other SNPs at the locus is
shown in Figure 1. rs12966547 is physically (1.5 kb) very close to
rs4309482 and is in complete LD (r2¼ 1), so is effectively the same
marker. rs4309482 and rs12966547 are in very weak LD with
rs9960767 in the Caucasian population (D0¼ 0.05, r2¼ 0), that
is they are showing independent association signals with schizo-
phrenia. rs17512836 is likewise in very low LD with rs4309482 and
rs12966547 (D0¼ 0.02, r2¼ 0), but inmoderate LDwith rs9960767
(D0¼ 1, r2¼ 0.52), indicating the association signal there is not
independent.
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Both rs4309482 and rs12966547 lie approximately equidistant
from three genes: CCDC68 (coiled-coil domain containing 68, aka
cutaneous T-cell lymphoma associated antigen, CTLC SE57-1), a
gene with unknown function; a long intergenetic non-coding RNA
(ENST00000507267 or AC091103.1) overlapping TCF4 in the
opposite strand; and TCF4 itself. Therefore, in contrast with
PHS mutations, it is less certain from the GWAS results which
gene(s) these variants affect, as they are not obviously functional.
However, a parsimonious association with TCF4 can be hypothe-
sized given that (i) rs9960767 is in an intron of the TCF4 gene and
is in low LD with the other two TCF4 associated markers, (ii)
mutations in TCF4 are known to cause severe mental illness, and
(iii) TCF4 is target of micro-RNA 137, which has also been
associated with schizophrenia [Kwon et al., 2011; Ripke et al.,
2011]. Therefore, it is reasonable that the gene mediating the
genetic risk conferred by these variants is TCF4 and that the
GWAS-associated variants are tagging two independent TCF4
loci which have a functional effect on the gene in some way.
However, these SNPs do not shown any association with bipolar
affective disorder [Psychiatric Genetics Consortium Bipolar
GWAS; Sklar et al., 2011]; http://www.broadinstitute.org/mpg/
ricopili/), making them unusual in that many genome-wide sig-
nificant susceptibility loci for schizophrenia and bipolar disorder
reported to date cross-traditional diagnostic boundaries [Williams
et al., 2011a]. It is also interesting that both common and rare
variants affect the same gene and confer susceptibility to brain
disorders of varying severity, as it has been shown for other traits
[Johansen et al., 2010; Zaghloul and Katsanis, 2010].
Two earlier genetic studies, before the advent of GWAS, exam-
ined this locus in schizophrenia: one study examined an unstable
CTG repeat (CTG18.1) in an intron of TCF4 [McInnis et al., 2000]
which did not show association, and a second, cytogenetic, study of
families with schizophrenia or bipolar disorder found independent
pericentric inversions on chromosome 18 close to the TCF4 gene
(inv[18][p11.31;q21.2] and inv[18][p11.31;q21.1]) which could
conceivably affect gene function [Pickard et al., 2005].
Consistent with its involvement in schizophrenia pathogenesis,
blood TCF4 levels were found to be reduced during psychotic states
[Kurian et al., 2011], and a small study of post-mortem cerebellar
cortices of 14 schizophrenia patients and six controls also high-
lighted TCF4, but found up-regulation of expression in patients
[Mudge et al., 2008]. However, post-mortem brain mRNA-level
analyses of three brain regions, the dorsolateral prefrontal cortex
(DLPFC; Brodmann area BA46) [Narayan et al., 2008], the lateral
andcaudal superior temporal gyrus (BA22) [Barnes et al., 2011] and
the frontopolar prefrontal cortex (BA10) [Maycox et al., 2009],
found no association between schizophrenia and TCF4. These
discrepancies may well be explained by differences in expression
patterns among tissues and cell type. Nonetheless, it remains
unclear if mRNA expression changes are part of the schizophrenia
pathology. In order to gather additional evidence, we examined
TCF4 relative mRNA levels experimentally in lymphocytes from
FIG. 1. Association signals between the TCF4 markers rs4309482, rs12966547, rs9960767, and rs17512836. Figure obtained from PGC
schizophrenia analysis (broadinstitute.org/mpg/ricopili/).
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cases with schizophrenia (n¼ 106) and controls (n¼ 96), and
found approximately 20% lower expression in patients (fold
change¼ 0.84 and P-value¼ 2.13" 10#7, see Supplementary
Material and Methods Section for details). Williams et al.
[2011b] examined TCF4 cis-regulated variation in gene expression
for correlationwith one of the associated SNPs, rs9960767, using an
assay to detect differential allelic expression. They found no evi-
dence for cis-regulated mRNA expression related to genotype at
the schizophrenia associated SNP. However, they could not rule
out temporal- or tissue-specific effects on expression. A potential
limitation of these studies is that if TCF4 is highly dosage sensitive
and it may be possible that small changes in mRNA and protein
levels, well under those possible to detect with small samples sized
studies, could increase riskof psychiatric disorders throughchanges
in neurodevelopment. Future studies on larger sample sizes looking
at specific brain regions acrossdevelopmentwill beneeded to clarify
the role of mRNA-level changes in schizophrenia risk.
Fuch’s Corneal Dystrophy
Genetic variation within TCF4 has also been associated with FCD
[Baratz et al., 2010; Li et al., 2011; Kuot et al., 2012], a common
eye disease affecting about 5% of the population, and the leading
cause of corneal transplant (accounting for 10% of all corneal
dystrophies) [Lang andNaumann, 1987]; 80% of those affected are
female. FCD is characterized by the development of collagen-free
regions, which may be caused by cell death [Meek et al., 2003].
Baratz et al. [2010], in aGWAS study, showed that SNPs at theTCF4
locus were strongly associated with typical FCD, with an odds ratio
of 30 for homozygotes for the disease variants.Whilemanymarkers
showed association, the SNPs rs17595731 and rs613872, intronic
for TCF4, and rs9954153 and rs2286812, upstream of TCF4,
demonstrated independent signals across the gene and gave the
best case–control discrimination. rs613872 showed the strongest
evidence for association (P¼ 1" 10#18).
The FCD-associated variants appear partly independent of
schizophrenia associations, even though the FCD index SNP
rs613872 maps to the same intron of the gene as some of the
schizophrenia associations. rs613872 shows weak to moderate LD
with rs17512836 (D0¼ 1, r2¼ 0.25) and rs9960767 (D0¼ 0.65, 1,
r2¼ 0.20) but negligible LD with rs4309482 (D0¼ 0.07, r2¼ 0) and
rs12966547 (D0¼ 0.07, r2¼ 0). Given that schizophrenia and FCD
are common in the population (about 1%) andmay partially share
some genetic risk, it will be worth determining whether there is any
co-morbidity between these two disorders. However, there is no
evidence of this from the literature.
THE TCF4 GENE
TCF4 (immunoglobulin transcription factor 2; ITF2; SEF2; OMIM
*602272) was initially identified in 1990 through cloning and
sequencing of the cDNA, identified as encoding a HLH transcrip-
tion factor binding toEphrussi, or Ebox elements (themu-E5motif
of the immunoglobulin heavy chain enhancer and the kappa-E2
motif of the light chain enhancer) [Henthorn et al., 1990].TCF4was
independently identified by Corneliussen et al. [1991], who char-
acterized a protein family with homology to other bHLH tran-
scription factors through their binding to glucocorticoid response
element E-box motifs in the in the murine leukemia virus SL3-3
enhancer. Corneliussen et al. called the newprotein family SEF2, for
‘‘SL3-3 enhancer factors’’; TCF4 was named SEF2-1B (667 amino
acids). They also identified multiple splice variants. Pscherer et al.
[1996] identified themurine homologue of TCF4 (SEF2-1B;mouse
Sef2) through its binding to the E box of the somatostatin receptor
(SSTR2) initiator element, where it can recruit the basal tran-
scription factor TFIIB through physical interaction with SEF2.
Comparative Genomics of TCF4
Comparative genomic analyses on 14 representative vertebrates
showed that the lengthof theTCF4gene greatlydiffers evenbetween
closely related species, for example medaka and fugu and mouse
and rat, probably as a result of the extent of repeats. We observed a
trend for an increase in the size of the gene from fish (36.2 kb) to
human (437 kb), which could be explained under neutral evolution
[Lynch, 2007]. The length of deduced human proteins from alter-
native TCF4 transcripts based on the Ensembl annotation is
between 511 and 773 amino acids. Although the length of the
deduced protein differs across species there is high sequence
identity of the primary sequence, including the DNA binding
domain Helix-loop-helix (Pfam domain id: PF00010) (Table I).
Supplementary Figure 1 shows an alignment of TCF4 protein
sequences of 14 vertebrate species. The bHLH domain is conserved
among these species as well as an element reported to play an
important role the activity of the protein [Herbst and Kolligs,
2008]. Only the Ensembl database annotates a longer N-terminal
region that includes a signal peptide region in a human
(ENSP00000381382) and chimpanzee (ENSPTRP00000040814)
isoforms (amino acids position 1–31). We performed analyses
with a suite of bioinformatics tools, as described by Emanuelsson
et al. [2007] to predict the function of this N-terminal region and
the subcellular localization of TCF4 in human and chimpanzee.We
confirmed that both the human (amino acids position 1–31) and
chimpanzee (amino acids position 1–27) sequences have predicted
signal peptides (Supplementary Table I; Supplementary Figs. 2–4).
For the human protein, a leucine-rich nuclear export signal (amino
acid position 14) was also predicted by the software NetNES [la
Cour et al., 2004]. Proteins having this signal can shuttle back and
forth between the nuclear and cytoplasmic compartments many
times during their life cycle [Pemberton and Paschal, 2005]. In a
recent study by Sepp et al. [2011] experimental evidence demon-
strated TFC4 in fact does shuttle from the nucleus to the cytoplasm.
They showed that full-length TCF4 isoforms that have longer
N-termini were restricted to cell nucleus whereas other isoforms
localized to both the nucleus and the cytoplasm, and found a
nuclear localization signal in the protein in exons 8–9.
In addition to protein motifs, non-coding sequence nearby
genes can have important regulatory functions, such as driving
expression or modulating splicing, and represent an important
source of information to understand gene function. These regu-
latory sequences can be identified by cross speciesDNA alignments.
We used the VISTA genome browser [Frazer et al., 2004] and
identified 365 ECRs (evolutionarily conserved sequences) between
human and mouse with an average identity of approximately 75%
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(Supplementary Table II). When more genetically distant species
(human, dog, mouse, and opossum) were employed in a cross-
species sequence comparison, all exons appear highly conservedbut
only a few non-exonic ECRs are present (Supplementary Fig. 5).
Four ECRs conserved between the human and mouse genome
sequences have been tested as part of the vista enhancer project
[Visel et al., 2007] (Supplementary Table III). The human element
hs376 (chr18:51,240,623–51,242,077 on human genome assembly
hg19) is located in intron 5 of TCF4 and was shown to drive
expression of a reporter gene in the nervous system during mouse
development, including the hindbrain (rhombencephalon), mid-
brain (mesencephalon), and neural tube (Supplementary Fig. 6).
Interestingly, we found reported genetic variation within this
regulatory element (SupplementaryTable IV) and several predicted
transcription factor binding sites (Supplementary Fig. 7) for
CREB1, ZEB1, and CUX1 among others. Interestingly, CUX1
binding to theTCF4genepromoter hasbeenproved experimentally
by Harada et al. [2008] where chromatin affinity experiments were
performed in HEK293 cell line. We also found four experimentally
identified transcription factors binding sites from the ENCODE
Chip-seq data: REST (NRSF), NFKB1, SPI1 (PU.1), and POU2F2
[Euskirchen et al., 2007; Robertson et al., 2007; Rozowsky et al.,
2009] (Supplementary Fig. 7). Some of these transcriptions factors
are known to be important in neurogenesis and neuronal plasticity,
like REST and CREB1 [Dworkin and Mantamadiotis, 2010;
Gao et al., 2011; Merz et al., 2011; Rossbach, 2011]. Further
study of these ECRs and the potential regulatory links revealed
by growing functional genomics informationmay shed light on the
regulation of TCF4 expression and its function on the central
nervous system (CNS).
THE TCF4 PROTEIN
E-proteins comprise a family of class I bHLH transcription
factors homologous to the drosophila protein ‘‘daughterless’’
[Lazorchak et al., 2005; Murre, 2005] and include E12 and E47
(encoded by a single gene, E2a), HEB and TCF4 (E2-2) which form
homodimers or heterodimers with other proteins in order to
enable DNA binding. They have no known DNA binding activity
as monomers. Class I bHLH transcription factors are expressed
in a ubiquitous pattern and are able to dimerize efficiently
with tissue-restricted class II factors to activate gene expression
[Murre et al., 1989]. They recognize a palindromic binding site
(‘‘CANNTG’’), first identified in immunoglobulin enhancers, and
have a preference for C or G in the central bases. Because
each partner contributes a specific DNA recognition half-site,
different class I and class II heterodimers can provide distinct
E box binding specificities.
Multiple alternatively spliced transcript variants that encode
different TCF4 proteins have been described, with two main
isoforms, E2-2A and E2-2B. E2-2B is a transcriptional repressor
and a downstream target of the TCF/b-catenin complex
[Petropoulos, 2000; Kolligs et al., 2002] whereas E2-2A is a
transcriptional regulator with diminished or absent repressor
capacity [Skerjanc et al., 1996; Furumura, 2001]. For example,
the E2-2B isoform can repress the brain-specific FGF1 (fibroblast
growth factor 1) by binding to an imperfect E-box in the
promoter [Liu et al., 1998] while the E2-2A isoform has no
activity. Likewise, interaction of E2-2B protein with MyoD can
inhibit its activity by forming an inactive heterodimer [Skerjanc
et al., 1996].
TABLE I. TCF4 Gene in 14 Species
Species Gene ID


















Human ENSG00000196628 413.6 23.7 2,322 773 100 55 Ensembl
Chimpanzee ENSPTRG00000010040 412.5 22.6 2,259 99 752 96 56 91 Ensembl
Orangutan ENSPPYG00000009175 361.4 20.3 2,016 99 671 100 55 100 Ensembl
Rhesus ENSMMUG00000012001 360.8 19.3 2,016 98 671 99 55 100 Ensembl
Mouse ENSMUSG00000053477 340.4 11.3 2,013 92 670 98 55 100 Ensembl
Rat ENSRNOG00000012405 340.1 11.0 1,758 90 585 96 55 100 Ensembl
Dog ENSCAFG00000000140 235.0 14.0 1,857 94 618 98 55 100 Ensembl
Horse ENSECAG00000017265 345.8 17.0 2,049 96 682 98 55 100 Ensembl
Lizard ENSACAG00000008863 268.2 3.0 1,875 85 624 94 55 100 Ensembl
Platypus ENSOANG00000003082 157.2 23.4 1,647 87 548 96 55 100 Ensembl
Opossum ENSMODG00000020455 223.0 59.7 1,626 90 541 97 55 100 Ensembl
Xenopus ENSXETG00000019086 31.4 35.4 1,464 80 487 90 55 100 Ensembl
Medaka ENSORLG00000015062 31.3 7.0 1,644 71 547 72 56 98 Ensembl
Fugu ENSTRUG00000002569 36.2 7.0 1,581 71 526 75 56 94 Ensembl
rhesus, rhesus macaque; xenopus, xenopus tropicalis; bHLH, basic helix loop helix domain.
aThe proportion (%) of repetitive sequences identified by the Repeat Masker in UCSC.
bIdentity was calculated by comparing with the human TCF4 sequence.
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BIOLOGICAL FUNCTIONS AND INTERACTIONS
OF TCF4
TCF4 is widely expressed in human tissues and appears to be
involved in multiple biological processes, including plasmacytoid
dendritic cell development [Cisse et al., 2008; Ghosh et al., 2010;
Watowich and Liu, 2010], sertoli cell development [Muir et al.,
2006], B and T lymphocyte development [Bergqvist et al., 2000;
Engel and Murre, 2001; Quong et al., 2002; de Pooter and Kee,
2010], thymocyte development [Wikstrom et al., 2008], the
epithelial-mesenchymal transition (EMT) [Sobrado et al., 2009],
the maintenance of the properties of corneal epithelial stem cells
during corneal epithelial development [Bian et al., 2010; Lu et al.,
2012], and brain development (see below).
In EMT, a process that allows cell migration during embryonic
development and tumor invasion, TCF4 can act as an E-cadherin
repressor. Functional loss of the cell–cell adhesion molecule
E-cadherin is an essential event in EMT and transcriptional repres-
sion has emerged as the main regulatory mechanism. E-cadherin
repression mediated by TCF4 is indirect and independent of
proximal E-boxes of the promoter [Sobrado et al., 2009]. Because
of the potential role of TCF4 in tumor invasion, TCF4 has been
examined in cancer, including estrogen receptor negative breast
cancer [Appaiah et al., 2010; Brody and Witkiewicz, 2010] and
is activated in human cancers with beta-catenin deficits [Kolligs
et al., 2002].
TCF4 (E2-2.1) is also an essential molecular regulator of the
plasmacytoid dendritic cell (PDC) lineage [Cisse et al., 2008;
Nagasawa et al., 2008; Esashi and Watowich, 2009], cells which
play a central role in the defense against viruses through rapidly
producing interferon I [Cervantes-Barragan et al., 2012]. TCF4
shows high expression in PDCs relative to other immune cells and
regulates terminal development and interferon production by
controlling PDC-related genes. Impairment of TCF4 (E2-1.1) leads
to a reduced number and abnormal cell surface of PDCs, which
is thought to be the basis for persistent respiratory infection in
patients with PHS.
TCF4mayalso involved in regulationof calciumsignaling in cells
through its interaction with calmodulin. TCF4 along with the E2A
proteins E12 and E47 bind calmodulin in vitro at physiologically
relevant calmodulin concentrations [Corneliussen et al., 1994] in
an interaction modulated by sequences directly N-terminal to the
basic domain. This results in inhibition of DNA binding in vitro.
Increased intracellular Ca2þ concentration potently inhibits the
transcriptional activity of TCF4 on an E-box containing reporter
plasmid, as does calmodulin overexpression. Thus Ca2þ signaling
may inhibit the transcriptional activity of E-proteins, including
TCF4, by establishing an E-protein-calmodulin complex that
prevents the E-protein from interaction with its target DNA
[Saarikettu, 2004].
TCF4 expression in the brain is likely to play a major role
in neurodevelopment, especially as haploinsufficiency has been
associated with PHS and common variants in or near the gene
confer risk of schizophrenia. However, there is a paucity of infor-
mation on the role of TCF4 in the CNS. TCF4 is known to be
important in the differentiation of glial cells, especially the matu-
ration of oligodendrocyte progenitors In the postnatal spinal cord
TCF4 expression is exclusive to oligodendrocyte lineage cells and
decreases as myelination proceeds, whereas in the brain, TCF4 is
also expressed in neurons, especially in the thalamus [Fu et al.,
2009].
TCF4 is known to interact with several class II bHLH tran-
scription factor genes involved in neurodevelopment: Math1,
a proneural protein expressed in the differentiating neuroepithe-
lium [Ross et al., 2003; Flora et al., 2007; Gohlke et al., 2008];
HASH1, a protein necessary for the formation of distinct neuronal
circuits within theCNS, especially the telencephalon [Persson et al.,
2000]; neuroD2, which plays important roles in neuronal differ-
entiation and survival [Ravanpay and Olson, 2008; and Id1,
a homologue of the drosophila daughterless and emc loci, which
are required for correct patterning in neurogenesis [Einarson and
Chao, 1995]. TCF4 is also the only transcription factor showing
complete co-expression with Olig2 [Fu et al., 2009], an essential
regulator of ventral neuroectodermal progenitor cell fate and
a requirement for oligodendrocyte andmotor neurondevelopment
[Othman et al., 2011; Panman et al., 2011]. Taken together, these
data suggest that TCF4 is involved in an intricate combinatorial
regulatory circuit during CNS development. Ravasi et al. [2010]
support amodel inwhich the combinatorial nature of transcription
factors rather than their expression in isolation is the main deter-
minant of tissue specificity and the functionality of transcription
factors complexes is associated with their conservation across
species. Ravasi et al. [Ravasi et al., 2010] show that TCF4 is part
of conserved transcription factor complex of proteins co-expressed
in cerebellum across human and mouse.
Math1 is highly expressed in proliferating progenitors of the
rhombic lip, a specialized neuroepithelium in the developing
dorsal hindbrain [Akazawa et al., 1995; Ben-Arie et al., 1996],
and is also required for the differentiation of most cerebellar
and pre-cerebellar structures [Ben-Arie et al., 1997; Wang et al.,
2005]—for example, Math1 knockout mice lack all cerebellar
granule neurons. It is important to note that cerebellar expression
of TCF4 is very high [Sepp et al., 2011] and could relate to Math1.
TCF4 also forms a functional complex with HASH-1, and thus
appears to be involved in the development of specific parts of
the central and peripheral nervous systems [Persson et al., 2000].
The HASH-1/TCF4 complex binds an E-box (CACCTG) in vitro
and is one of the major HASH-1 interacting proteins in extracts
from neuroblastoma cells. HASH-1 (MASH-1 in mouse) is a
transcription factor homologous to the drosophila ‘‘achaete-scute
homolog-1’’ and is essential for correct development of olfactory
and most peripheral autonomic neurons, and for the formation
of distinct neuronal circuits within the CNS [Persson et al., 2000].
The E proteins E12, HEB, and TCF4 all interact with neuroD2,
and heterodimers bind a neuroD2 preferred E-box. These com-
plexes have a comparable ability to induce neurogenesis, indicating
a similar baseline biological activity [Ravanpay and Olson, 2008].
NeuroD2 has been reported to play a critical role in the induction
of neuronal differentiation, the promotion of neuronal survival,
and development of thalamocortical communication [Farah et al.,
2000; Olson et al., 2001; Ince-Dunn et al., 2006; Lin et al., 2006;
Noda et al., 2006].
Brockschmidt et al. [2011] performed knockdown of TCF4 in
zebrafish embryos,which resulted indevelopmental delayordefects
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in terminal differentiation of brain and eyes. The authors conclude
that TCF4-knockdown in zebrafish embryos did not seem to affect
early neural patterning and regionalization of the forebrain, but
maybe involved in later aspects of neurogenesis anddifferentiation.
HUMAN TCF4 EXPRESSION
Inspection of public databases showed that TCF4 is expressed at
detectable levels acrossmany tissues (Supplementary Figs. 8 and 9).
However, it expression is high in prefrontal cortex, fetal brain, and
BDCA4þ dendritic cells. We explored the Human Brain Tran-
scriptome dataset, which has expression data of TCF4 across several
brain regions and developmental stages [Kang et al., 2011], and we
also examined the Sestan Lab Human Brain Atlas Microarrays
dataset [Johnson et al., 2009] to explore the expression pattern of
TCF4 inhumanbrain.We found thatTCF4hashigher expression in
neocortex and hippocampus compared with striatum, thalamus,
and cerebellum and that its expression seems to be higher at early
stages of development (Fig. 2; Supplementary Table V). These brain
areas have been implicated with schizophrenia by neuropsycho-
logical neuroimaging and post mortem histology and neurochem-
ical studies [Heckers, 1997; Harrison, 2004; Boyer et al., 2007;
Casanova et al., 2008; Lewis and Gonzalez-Burgos, 2008; Zierhut
et al., 2010].
de Pontual et al. [2009] found that TCF4 is highly expressed
throughout the human CNS development and the sclerotomal
component of the somites from Carnegie stage C13 28–32 days
postfertilization (dpf). TCF4 expression continues into adult life,
expressed in lymphocytes, fibroblasts, gut, muscle, but not the
heart. Sepp et al. [2011] used RT-PCR to detect TCF4 transcripts
and also found widespread expression, including testis, placenta,
prostate, and in postmortem adult human brain, where they found
particularly high expression, especially in the cerebellum.
TCF4 Transcripts
The TCF4 gene has numerous exons and produces several tran-
scripts. Currently twohuman transcripts (isoformsTCF4A [ITF2A;
SEF2-1A] and the canonical sequence TCF4B [ITF2B; SEF2-1B];
accession numbers NM_001083962.1 and NM_003199.2) are
commonly referred to in the literature, along with a third known
isoform SEF2-1D (TCF4D). Likewise, two transcripts of human
TCF4 are annotated in the NCBI Entrez database, but four
in Ensembl, 10 in UCSC and 38 in NCBI AceView database
(version April 2007) [Thierry-Mieg and Thierry-Mieg, 2006].
More than 459 mRNA or EST sequences are related to human
TCF4. Forty one splice variants are recorded at Ensembl’s latest
version (version 66), many of which are derived from RNA-seq
(de novo sequencing of transcripts [Ozsolak and Milos, 2011])
experiments from the Illumina Body Map and ENCODE projects
and therefore the splice junctions are likely to be real. Increasing
availability of RNA-seq data will help to elucidate the full coding
potential of the gene as well as possible transcriptional biases for
different isoforms on specific tissues.
Transcripts have been experimentally verified in mice [Brzozka
et al., 2010], rat [Yoon and Chikaraishi, 1994], and humans
[Pscherer et al., 1996]. Sepp et al. [2011] used RT-PCR in a detailed
bioinformatic and experimental study ofTCF4.Theydemonstrated
the existence of several 50 exons that potentially yield 18 different
N-termini in TCF4 proteins, and alternative splicing of several
FIG. 2. Expression of TCF4 across several brain regions and developmental stages. Data obtained from the Human Brain Transcriptome dataset and
the Sestan Lab Human Brain Atlas Microarrays dataset. TCF4 has higher expression in neocortex and hippocampus compared with striatum,
thalamus, and cerebellum and it expression seems to be higher at early stages of development.
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internal exons that may give rise to further isoforms. All the
isoforms contain transactivation domain AD2 and the bHLH
domain, however, only the isoforms with the longest N-terminal
have the amino-terminal transactivation domain AD1. AD1 and
AD2are able toactivate transcription individually and together they
act synergistically [Sepp et al., 2011].
Some of these isoforms contain a nuclear localization signal
(NLS) and are only found in the nucleus, whereas others are also
found in the cytoplasm. Isoforms without an NLS may rely on
binding to bHLHpartner proteins, such asNeuroDwhich contains
an NLS, in order to enter the nucleus. Sepp et al. [2011] also
conclude that isoforms lacking NLS can be exported from the
nucleus by heterodimerization with nuclear export signal (NES)
containing partner proteins. In the present study, we also detected
a leucine-rich NES (amino acid position 14), which could also
explain its export from the nucleus. In Supplementary Table VI,
we provide identifier mapping for isoforms across different data-
bases that can be useful for researchers aiming to use information
across these databases.
Potential miRNA Regulation
TCF4 is known to be regulated by at least two differentially
expressed microRNAs, miR-221 and miR-222, which regulate
plasmacytoid versus conventional dendritic cell development
[Kuipers et al., 2010].MicroRNAs are likely to confer tissue-specific
fine-tuning of TCF4 expression, for example in neurons. In order to
explore this, we used the TargetSCAN [Lewis et al., 2005] database
to identify predicted miRNA binding sites in the TCF4 UTR
conserved regions. There were 45 miRNA predicted binding sites
conserved across vertebrates.Of them, 37 have been associatedwith
human diseases and 30 specifically with CNS disorders (Table II).
Interestingly, hsa-mir-106a/b, hsa-mir-7-1/2/3, hsa-mir-92a-1/2,
hsa-mir-92b, and hsa-mir-20a/b have been associated with schiz-
ophrenia and autism [Perkins et al., 2007; Abu-Elneel et al., 2008;
Talebizadeh et al., 2008]. Furthermore, a genetic variant near hsa-
mir-137 has been associated with schizophrenia at genome-wide
significant level [Ripke et al., 2011]. The targeting of has-mir-137
with TCF4 has been confirmed by Kwon et al. [2011]. hsa-mir-155
has been also validated experimentally according to the database
mirWalk [Dweep et al., 2011] (http://www.ma.uni-heidelberg.de/
apps/zmf/mirwalk/mirnatargetpub.html).
SNPs in TCF4
Wefound18,636SNPs (db130) in the locus,whichwedefinedas the
geneboundaries plus approximately 2Mb ineachdirection to cover
all proximal haplotype blocks (chr 18: 49.019.029–52.414.148,
human assembly hg18). Of them, 4,417 and 6,762 have been
genotyped by theHapMap and 1,000 genomes project, respectively,
and 2,706 in both. We used Galaxy tools [Blankenberg et al., 2010]
to intersect these SNPs with a set of putative and validated DNA
functional elements and found that 12,500 SNPs (67%) are within
potentially regulatory regions, including multispecies conserved
sequences and known protein binding sites, and 64 were
within exons (Fig. 3). Among the latter, 29 were validated non-
synonymous SNPs, as listed in the UCSC genome browser
(Supplementary Table IX).
Williams et al. [2011b] useddata from the 1,000 genomes project
to identify non-synonymous coding variants in the TCF4 gene, but
did not find any evidence for association and conclude that
association between schizophrenia and TCF4 is not mediated
by a relatively common non-synonymous variant. They also
performed allele-specific expression analysis using human post
mortem brain samples, but found no evidence for cis-regulated
mRNA expression related to genotype at the schizophrenia-
associated SNP.
Eighty-eight out of the 4,417 SNPs genotyped by HapMap
were both in high LD (r2> 0.8) with the SNPs associated with
schizophrenia, rs4309482 and rs9960767, and within potentially
regulatory sites (Table III), suggesting that the disease-
susceptibility alleles may capture variants influencing gene
expression. To test this we looked at eQTL dataset at http://
eqtl.uchicago.edu/Home.html [Veyrieras et al., 2008] where we
found one eQTLmapping TCF4 gene region, rs1261085. However,
this eQTL showed low LD with the three schizophrenia-associated
SNPs, for example with rs996076 had an r2 of 0.073, and an r2 of
0.003 with rs4309482 and rs12966547.
CO-EXPRESSION AND PROTEIN–PROTEIN
INTERACTION NETWORKS OF TCF4
We used network biology information to help understand the
function of TCF4 by using higher-level biological information
[Geschwind and Konopka, 2009]. Gene co-expression networks
derived from gene-expression analysis of human brains [Oldham
et al., 2008] revealed 139 genes tightly co-expressed with TCF4.
These genes were analyzed by gene-set enrichment analysis
withMetaCore (GeneGO, Inc.) showing that they are characterized
by specific biological processes including Alpha-2 adrenergic
receptor activation of mitogen-activated protein kinase 1 and 3
(MAPK1/3) (P-value¼ 1.5" 10#3), WNT signaling pathway
(P-value 5.9" 10#3) and cell adhesion/synaptic contact (P-value
3.0" 10#3) (Supplementary Table VII). It is interesting that
some of them have been previously associated with schizophrenia,
such as the WNT signaling pathway [Cotter et al., 1998; Miyaoka
et al., 1999; Freyberg et al., 2010] and cell adhesion/synaptic
contact [Vawter, 2000; Gross et al., 2003; Eastwood, 2004; Stephan
et al., 2009; Hayashi-Takagi and Sawa, 2010; O’Dushlaine et al.,
2011].
In addition, we used GeneGO Metacore (GeneGo, Inc.)
manually curated information to identify TCF4 interacting part-
ners, based on physical or regulatory interactions, that are also
known to be associated with schizophrenia. We identified six
proteins, namely TP53, NR3C1, AR, CTNNB1, ESR1, and
EGFR, known to regulate or interact with TCF4 and further seven
from among the co-expression partners, that is GSK3b, NRXN1,
GABRA1, MILL, GRIA3, GNAL, and ADRA2A. We used the
manually curated interactions and the co-expression results to
build a network of schizophrenia susceptibility genes around
TCF4 (Fig. 4). This sheds light on its relationships with known
disease susceptibility genes.
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SUMMARY AND FUTURE DIRECTIONS
TCF4 is still a poorly characterized gene in terms of function and
biology. However, the compelling evidence for genetic association
of TCF4with schizophrenia calls for additional detailed studies. For
example, the current literature only refers to three protein isoforms
at themost, but there is experimental evidence formanymore [Sepp
et al., 2011]. Future studies will benefit from a careful dissection of
the functional differences between TCF4 splice variants, especially
since they differ in functional motifs. This potential array of
different protein products from the TCF4 gene may account for
its pleiotropic associations with disease.
Although the role of TCF4 during development has not been
elucidated, it seems plausible, based on its known interactions with
TABLE II. Predicted Conserved miRNA Target Sites in TCF4
miRNA Disease Reference
hsa-mir-106a/hsa-mir-106b Schizophrenia, alzheimer disease,
autistic disorder, glioma
[Abu-Elneel et al., 2008;
Hebert et al., 2009;
Lavon et al., 2010;
Perkins et al., 2007]
hsa-mir-7-1/hsa-mir-7-2/hsa-mir-7-3 Schizophrenia, autistic disorder [Abu-Elneel et al., 2008;
Perkins et al., 2007]
hsa-mir-92a-1/hsa-mir-92a-2/hsa-mir-92b Schizophrenia, autistic disorder,
medulloblastoma, brain neoplasms
[Nass et al., 2009;
Northcott et al., 2009;
Perkins et al., 2007;
Talebizadeh et al., 2008;
Uziel et al., 2009]
hsa-mir-20a/hsa-mir-20b Schizophrenia, alzheimer disease,
medulloblastoma, glioma, glioblastoma
[Ernst et al., 2010;
Hebert et al., 2009;
Lavon et al., 2010;
Northcott et al., 2009;
Perkins et al., 2007;
Uziel et al., 2009]
hsa-mir-93 Autistic disorder, glioma [Abu-Elneel et al., 2008;
Lavon et al., 2010]
hsa-mir-129-1/hsa-mir-129-2 Autistic disorder [Abu-Elneel et al., 2008]
hsa-mir-363 Autistic disorder [Talebizadeh et al., 2008]
hsa-mir-193b Autistic disorder [Abu-Elneel et al., 2008]
hsa-mir-17 Alzheimer disease, medulloblastoma,
glioma, glioblastoma
[Ernst et al., 2010;
Hebert et al., 2009;
Lavon et al., 2010;
Northcott et al., 2009;
Uziel et al., 2009]
hsa-mir-139 Neurodegenerative diseases [Saba et al., 2008]
hsa-mir-155 Down syndrome, cerebral hemorrhage,
stroke, glioblastoma
[Care et al., 2007;
Li et al., 2009;
Liu et al., 2010;
Sethupathy et al., 2007]
hsa-mir-124-1/hsa-mir-124-2/hsa-mir-124-3 Glioblastoma, medulloblastoma,
stroke, cocaine-related disorders
[Chandrasekar and Dreyer, 2009;
Laterza et al., 2009;
Pierson et al., 2008;
Silber et al., 2008]
hsa-mir-128-1/hsa-mir-128-2 Neuroblastoma [Evangelisti et al., 2009]
hsa-mir-137 Glioblastoma [Silber et al., 2008]
hsa-mir-141 ACTH-secreting pituitary adenoma [Amaral et al., 2009]
hsa-mir-145 ACTH-secreting pituitary adenoma,
atherosclerosis
[Amaral et al., 2009;
Zhang, 2009]
hsa-mir-183 Glioma [Lavon et al., 2010]
hsa-mir-200a Meningioma [Poethig, 2009]
hsa-mir-221 Astrocytoma [Conti et al., 2009]
hsa-mir-367 Glioma [Lavon et al., 2010]
miRNA potentially regulating TCF4 and associated with CNS diseases.
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Math1, HASH1, and neuroD2, to suggest that TCF4 plays an
important role during CNS development. Because of its interaction
with calmodulin and involvement in calcium signaling, TCF4
may also be involved in acute functional effects in neurons. The
advent of second generation sequencing technologies will allow a
more thorough study of transcription factor binding site targets
of TCF4, using methods such as ChIP-seq, as well as isoform
abundance at different points during development of CNS
tissues using RNA-Seq. These analyses will reveal further
information on the TCF4 biological regulatory network, the role
of the protein in brain development and function and, in turn,
TCF4’s involvement in psychiatric and neurodevelopmental
disorders.
The role of TCF4 in brain neural function, especially in relation
to schizophrenia, also needs to be elucidated. For example, pre-
liminary studies are examining the role of TCF4 polymorphisms on
putative endophenotypes of schizophrenia have shown an effect on
sensory gating, as measured by the P50 suppression of the auditory
evoked potential [Quednow et al., 2012], and on prepulse inhib-
ition of the acoustic startle response, a different measurement of
sensorimotor gating [Quednow et al., 2011]. These studies
may provide important information on the relationship between
TCF4 risk polymorphisms and neuropsychiatric dysfunctions
in schizophrenia.
Our scan for putative functional genetic variants revealed that
several common SNPs are both within likely functional DNA
elements and in LD with SNPs associated to schizophrenia. In
linewith thesefindings, oneof these elements is known todrive gene
expression in mouse CNS. Additional studies exploring the func-
tion of these DNA sequences can provide clues as to which tran-
scription factors are regulatingTCF4 and in turn howTCF4 is being
integrated into wider regulatory processes. In addition, TCF4
transcripts have several potential binding sites for miRNAs whose
expression has been associated with mental illnesses. Additional
validation of these regulatory links is warranted and could provide
important clues between TCF4 and other genes underlying risk of
mental disorders. Thus, the informationwe have compiled suggests
it may be possible to use additional targeted functional studies to
start drawing a functional network relating TCF4 to other key
molecular players in brain development and mental illness. Fur-
thermore, we showed that by compiling gene-expression data and
protein–protein interaction information TCF4 is readily linked to
other genes associatedwith schizophrenia.Amajor challengewill be
to understand the mechanisms relating these genes and in which
context, for example cell type or developmental stage, their inter-
actions are important as mediators of risk for schizophrenia. This
effort will need to be undertaken by a wide community applying a
plethora of experimental approaches. Nonetheless, this represents
that the start of a path lead to biological understanding and possibly
new treatments for schizophrenia and other psychiatric disorders.
TABLE III. Putative Functional SNPs in LD With Schizophrenia Associated SNPs
SNP 1 SNP ID Position r-square Functional element
rs4309482 rs4309482 50901467 1 Nucleosome occupancy (MEC)
rs12966547 50903015 1 phastConsElements28wayPlacMammal,
phastConsElements28way,
Nucleosome occupancy (MEC)
rs4801131 50903698 1 Nucleosome occupancy (MEC)
rs4131791 50898869 1 Nucleosome occupancy (MEC)
rs9960767 rs9960767 51306000 1 Nucleosome occupancy (MEC), Sunny RBP
rs12327270 51319071 1 phastConsElements28wayPlacMammal,
phastConsElements28way, Nucleosome occupancy (MEC),
Regulatory Potential 7x, Gis Chip (c-Myc), Sunny RBP
rs10401120 51343496 0.867 Nucleosome occupancy (MEC), Sunny RBP
FIG. 3. Summary of the strategy used to find the 88 potentially
regulatory SNPs in LD with the SNPs associated with
schizophrenia.
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Supplementary Table I.  Output from the TargetPserver, tested on TCF4 sequences (four 
sequences from Human and one from Chimpanzee). The “Loc” column contains the prediction of 
N-terminal sorting signal: “S” for secretory. 
________________________________________________________________________ 
 
### targetp v1.1 prediction results ################################## 
Number of query sequences:  5 
Cleavage site predictions included. 
Using NON-PLANT networks. 
 
Name                  Len            mTP     SP  other  Loc  RC  TPlen 
---------------------------------------------------------------------- 
Chimpanzee            752          0.041  0.856  0.122   S    2     27 
ENSP00000381382       773          0.041  0.858  0.114   S    2     31 
ENSP00000348374       667          0.106  0.038  0.896   _    2      - 
ENSP00000346440       671          0.106  0.038  0.896   _    2      - 
ENSP00000409447       511          0.091  0.094  0.893   _    2      - 
---------------------------------------------------------------------- 





























Supplementary Table II Multi-species conserved sequences (MCS) in the comparison of 
human and mouse TCF4 genes.  
  
start end Length (bp) Identity (%) Region SNP 
51049707 51049893 190 71.60 intron 17  
51050347 51050466 125 72.00 intron 17  
51050514 51050737 224 80.80 intron 17  
51050991 51051461 474 85.00 intron 16  
51052323 51052683 377 76.90 intron 16  
51053084 51053695 665 84.50 intron 15  
51055983 51056095 113 71.70 intron 15 rs10515969, rs7237259 
51057819 51058316 501 83.60 intron 15  
51058549 51058776 229 72.50 intron 15  
51061146 51061260 118 70.30 intron 15  
51061438 51061818 392 82.40 intron 15  
51062110 51062428 335 71.60 intron 15  
51062616 51063330 717 76.70 intron 15  
51063434 51063696 265 85.30 intron 15  
51064989 51065099 114 70.20 intron 15  
51065437 51065572 138 68.80 intron 15  
51067615 51067721 107 69.20 intron 15  
51068360 51068476 117 68.40 intron 15  
51069305 51069423 119 70.60 intron 15  
51069578 51070192 626 71.90 intron 15  
51070216 51070332 124 75.00 intron 15  
51070797 51071449 674 81.00 intron 15  
51072492 51072588 98 71.40 intron 15  
51073030 51073351 327 75.50 intron 14  
51073030 51073351 327 75.50 intron 14  
51073923 51074017 96 70.80 intron 14  
51073923 51074017 96 70.80 intron 14  
51074094 51074290 202 77.20 intron 14  
51074960 51075093 134 72.40 intron 14  
51075309 51075410 102 70.60 intron 14  
51076233 51076561 339 80.50 intron 13  
51077556 51077727 172 71.50 intron 13  
51079589 51079694! 108! 87.00! intron 12!  
51079589 51079694 108 87.00 intron 12  
51079763 51080040 285 86.70 intron 11  
51082378 51082818 446 76.70 intron 11  
51083072 51083458 390 71.80 intron 11  
51083508 51083619 116 71.60 intron 11  
51083686 51083817 135 71.10 intron 11  
51083881 51084313 471 72.20 intron 11  
51085262 51085700 453 76.40 intron 11  
51086019 51086116 98 71.40 intron 11  
51086372 51086853 490 78.40 intron 11  
51087603 51087706 104 71.20 intron 11  
51087779 51087903 129 69.80 intron 11  
51088271 51088381 113 71.70 intron 10  
51090237 51090575 356 71.60 intron 10  
51091211 51091426 218 74.30 intron 10  
51091655 51091956 307 75.90 intron 10  
51092437 51092597 161 71.40 intron 10  
51093003 51093139 138 71.00 intron 10  
51093516 51093772 267 70.80 intron 10  
51093982 51094199 226 79.60 intron 9  
51095494 51095980 503 76.30 intron 9  
51096138 51096373 241 69.70 intron 9  
51098382 51098997 637 78.30 intron 8  
51099001 51099258 264 75.80 intron 8  
51104202 51104301 101 70.30 intron 8  
51107153 51107366 214 72.90 intron 8  
51107382 51107644 266 75.90 intron 8  
51107700 51108040 348 71.80 intron 8  
51108205 51108313 112 69.60 intron 8  
51109523 51109936 436 77.10 intron 8  
51110274 51110405 132 68.20 intron 8  
51110474 51110647 181 69.10 intron 8  
51111275 51111373 100 70.00 intron 8  
51111492 51111640 149 67.10 intron 8  
51114275 51114582 312 80.80 intron 8  
51114809 51115438 638 80.30 intron 8  
51115461 51115560 105 71.40 intron 8  
51116514 51116706 196 69.90 intron 8  
51116867 51116969 104 75.00 intron 8  
51118287 51118437 153 69.30 intron 8  
51118478 51118603 129 79.80 intron 8  
51118624 51119442 862 80.70 intron 8  
51119469 51120022 576 79.00 intron 8  
51120105 51120371 270 78.10 intron 8  
51120572 51121022 454 78.60 intron 8  
51123111 51123455 353 90.10 intron 8  
51123456 51123584 131 78.60 intron 8  
51123685 51123888 205 74.10 intron 8  
51124086 51124191 107 74.80 intron 8  
51124422 51125319 916 87.40 intron 8  
51125402 51126023 632 74.80 intron 8  
51128561 51128810 267 69.70 intron 8  
51129197 51129329 137 73.70 intron 8  
51129690 51129819 132 69.70 intron 8  
51130012 51130361 351 74.10 intron 8  
51130717 51130944 233 73.40 intron 8  
51130984 51131688 725 75.40 intron 8  
51132275 51132825 587 77.90 intron 8  
51132831 51132946 128 69.50 intron 8  
51132949 51133359 428 73.80 intron 8  
51134184 51134279 104 70.20 intron 8  
51134417 51134515 99 74.70 intron 8  
51135185 51135415 243 74.90 intron 8  
51135573 51135723 151 69.50 intron 8  
51136091 51136459 373 81.00 intron 8  
51136718 51136867 155 71.60 intron 8  
51136993 51137369 388 75.50 intron 8  
51137403 51138191 790 80.00 intron 8  
51138887 51139597 738 73.20 intron 8  
51139750 51140305 561 88.10 intron 8  
51140358 51140843 504 85.10 intron 8  
51141005 51141113 114 71.90 intron 8  
51141180 51141336 157 73.20 intron 8  
51141350 51142013 666 82.00 intron 8  
51142085 51142203 120 71.70 intron 8  
51142358 51142691 340 74.40 intron 8  
51144220 51144354 136 69.90 intron 8  
51144980 51145086 112 73.20 intron 8  
51145125 51145204 85 75.30 intron 8  
51145747 51145910 165 77.00 intron 8  
51146634 51146771 138 81.90 intron 8  
51147026 51147275 258 72.90 intron 8  
51150277 51150374 100 70.00 intron 8  
51150663 51150821 159 67.30 intron 8  
51151405 51151541 139 71.20 intron 8  
51151552 51151647 100 72.00 intron 8  
51151909 51152141 235 68.90 intron 8  
51152320 51152429 114 71.10 intron 8  
51152811 51153007 198 73.20 intron 8  
51153050 51153754 712 80.30 intron 8  
51154025 51154204 180 75.00 intron 8  
51154836 51155456 625 94.90 intron 8  
51155458 51155940 489 77.70 intron 8  
51156127 51156242 134 76.90 intron 8  
51156245 51156722 480 84.40 intron 8  
51156745 51156862 118 69.50 intron 8  
51157156 51157491 339 95.90 intron 8  
51157560 51157675 119 77.30 intron 8  
51157934 51158049 116 72.40 intron 8  
51158348 51158454 107 70.10 intron 8  
51160581 51160677 102 70.60 intron 8  
51160904 51161329 431 79.10 intron 8  
51161420 51161523 104 71.20 intron 8  
51162698 51162802 113 73.50 intron 8  
51164486 51164582 101 70.30 intron 8  
51165167 51165261 100 70.00 intron 8  
51167096 51167261 166 69.90 intron 8  
51167280 51167733 470 79.10 intron 8  
51167805 51167892 88 77.30 intron 8  
51168126 51168435 312 84.90 intron 7  
51168488 51168587 103 70.90 intron 7  
51169233 51169359 131 70.20 intron 6  
51169876 51170040 177 74.60 intron 6  
51170043 51170582 540 95.90 intron 6  
51171081 51171198 123 73.20 intron 6  
51171271 51171388 118 68.60 intron 6  
51171440 51171583 148 69.60 intron 6  
51171673 51171952 285 78.90 intron 6  
51172050 51172178 130 71.50 intron 6  
51172676 51173038 365 82.20 intron 6  
51173075 51173949 890 79.00 intron 6  
51174258 51174357 101 70.30 intron 6  
51175041 51175361 322 74.20 intron 6  
51175501 51175601 101 70.30 intron 6  
51175789 51175971 189 72.00 intron 6  
51177714 51177813 100 70.00 intron 6  
51180080 51180197 118 68.60 intron 6  
51180838 51181188 353 73.10 intron 6  
51185607 51185726 120 70.80 intron 6 rs8092679 
51187562 51187718 158 69.00 intron 6  
51187839 51188132 310 76.10 intron 6  
51196322 51196461 149 65.80 intron 6  
51200933 51201074 142 68.30 intron 6 rs9646596, rs17594301, rs1788025 
51202334 51202632 303 73.30 intron 6  
51204105 51204224 122 69.70 intron 6 rs9950000 
51204271 51204368 99 70.70 intron 6  
51205030 51205162 135 69.60 intron 6 rs9958125, rs9320010 
51205471 51206107 641 81.90 intron 6  
51208087 51208186 100 71.00 intron 6  
51209211 51209429 220 73.20 intron 6 rs17594526 
51212022 51212529 512 82.20 intron 6  
51212754 51212878 125 76.80 intron 6  
51213962 51214190 233 75.50 intron 6  
51217758 51217894 137 73.00 intron 6 rs11152369, rs1759472, rs17594665, rs17089778 
51218083 51218146 64 98.40 intron 6  
51218413 51218633 225 72.90 intron 6 rs17509991 
51219030 51219467 446 74.00 intron 6  
51219582 51219674 94 71.30 intron 6  
51219749 51220491 776 79.60 intron 6 rs17510124 
51221076 51221564 501 76.80 intron 6 rs2958178 
51221748 51222283 556 82.70 intron 5  
51222704 51222816 115 70.40 intron 5  
51224012 51224634 631 86.10 intron 5  
51224693 51225473 796 76.10 intron 5  
51225584 51225746 163 76.70 intron 5  
51225765 51225842 97 71.10 intron 5  
51226459 51226663 207 74.40 intron 5  
51226883 51226989 107 72.00 intron 5 rs10503001 
51227021 51227494 481 78.40 intron 5 rs17089789 
51229257 51229614 359 85.00 intron 5  
51233611 51233787 185 68.10 intron 5  
51233818 51233910 93 71.00 intron 5  
51234579 51234670 93 72.00 intron 5  
51234841 51235407 580 82.20 intron 5  
51236238 51236559 324 74.70 intron 5 rs11873788, rs17089803 
51237168 51237375 209 72.70 intron 5  
51237773 51238363 617 69.90 intron 5  
51238966 51239112 159 74.20 intron 5  
51239154 51239273 120 83.30 intron 5  
51239661 51239837 180 70.00 intron 5  
51239911 51240028 121 70.20 intron 5  
51240164 51240328 168 71.40 intron 5  
51240348 51241258 954 83.80 intron 5  
51241259 51241502 248 86.30 intron 5  
51241503 51242386 908 81.10 intron 5  
51242493 51242628 136 72.80 intron 5  
51243191 51243288 99 70.70 intron 5  
51243388 51243586 203 78.80 intron 5  
51243620 51243717 105 75.20 intron 5  
51243775 51244291 534 79.80 intron 5  
51244371 51244954 593 80.30 intron 5  
51245611 51245718 108 71.30 intron 5  
51248095 51248211 117 70.10 intron 5 rs8086206, rs9320016 
51248297 51248392 100 70.00 intron 5  
51254304 51254636 340 73.80 intron 5  
51255339 51255477 140 68.60 intron 5  
51255651 51255811 172 68.00 intron 5  
51258583 51258684 102 70.60 intron 5 rs17595731 
51258721 51258819 99 70.70 intron 5  
51259370 51259799 432 77.30 intron 5  
51260184 51260941 772 77.20 intron 5  
51261362 51261489 129 69.80 intron 5  
51262263 51262412 150 68.70 intron 5  
51262940 51263057 121 70.20 intron 5  
51265920 51266217 308 73.40 intron 5  
51266507 51266822 321 74.50 intron 5  
51266952 51267159 212 75.00 intron 5  
51267676 51267892 219 70.30 intron 5  
51267983 51268148 166 71.70 intron 5  
51270389 51270573 187 73.80 intron 5  
51271459 51271575 118 72.00 intron 5  
51274038 51274192 157 71.30 intron 5  
51274209 51274566 363 84.60 intron 5  
51274769 51274920 153 70.60 intron 5  
51276229 51276546 318 80.80 intron 5  
51276859 51277448 597 78.60 intron 5  
51278230 51278668 449 71.70 intron 5 rs17089826 
51280222 51280342 123 74.80 intron 4  
51280913 51281154 246 73.20 intron 4  
51282367 51282590 224 92.90 intron 3  
51282591 51282763 178 74.20 intron 3  
51283334 51283636 304 76.60 intron 3  
51283678 51283923 246 69.90 intron 3  
51284903 51285223 330 78.80 intron 3  
51285287 51285386 104 73.10 intron 3  
51285451 51285566 117 71.80 intron 3  
51287955 51288241 301 71.80 intron 3 rs17511376 
51288842 51288962 125 69.60 intron 3  
51289207 51289513 308 85.70 intron 3  
51291454 51291598 150 75.30 intron 3  
51291798 51292283 486 86.00 intron 3 rs17596267 
51295394 51295499 106 74.50 intron 3 rs12326678 
51296229 51296854 639 79.20 intron 3  
51297956 51298330 377 75.10 intron 3 rs17511755, rs8090422, rs8086784 
51302043 51302389 362 71.30 intron 3  
51302393 51302504 114 71.10 intron 3  
51304125 51304288 167 70.70 intron 3  
51305937 51306112 178 71.30 intron 3 rs9960767 
51306134 51306261 128 88.30 intron 3  
51306263 51306481 239 74.50 intron 3  
51306482 51306616 139 71.20 intron 3  
51307015 51307114 100 70.00 intron 3  
51308104 51308216 113 68.10 intron 3 rs2924333 
51308225 51308332 109 72.50 intron 3  
51309043 51309143 101 71.30 intron 3  
51309206 51310328 1136 78.50 intron 3  
51312137 51312230 96 72.90 intron 3 rs2958187 
51312573 51312885 314 79.90 intron 3  
51313088 51313346 261 75.10 intron 3  
51313593 51313855 270 74.10 intron 3  
51314366 51314663 299 80.90 intron 3  
51314673 51315159 495 70.50 intron 3  
51315256 51315406 152 71.70 intron 3  
51315418 51315800 387 76.50 intron 3  
51315830 51315952 124 71.80 intron 3  
51316029 51316395 373 74.80 intron 3  
51317454 51317608 158 74.10 intron 3 rs17596974 
51318524 51319116 609 79.60 intron 3 rs12327270, rs2958189 
51319413 51320056 661 73.10 intron 3  
51320753 51320877 125 68.80 intron 3  
51320957 51321301 353 74.20 intron 3  
51321800 51321895 96 70.80 intron 3  
51322999 51323647 657 83.10 intron 3 rs2958158 
51324689 51324784 96 70.80 intron 3  
51326723 51326857 138 70.30 intron 3 rs2924338 
51326928 51327053 127 71.70 intron 3  
51327069 51327199 135 72.60 intron 3  
51327283 51327423 142 69.00 intron 3  
51328072 51328251 182 69.20 intron 3  
51328713 51328905 195 71.30 intron 3  
51329036 51329354 322 85.70 intron 3  
51329356 51329551 196 71.90 intron 3  
51331730 51331936 209 80.90 intron 3  
51332038 51332540 506 72.90 intron 3  
51336093 51336242 150 68.00 intron 3 rs12606243, rs624244 
51338285 51338917 647 81.00 intron 3  
51339171 51339244 74 82.40 intron 3  
51339296 51339745 471 70.90 intron 3  
51342793 51343187 398 82.20 intron 3  
51345824 51346201 397 71.30 intron 3 rs10401120 
51346513 51346622 110 71.80 intron 3  
51347795 51347953 161 70.80 intron 3  
51348404 51348976 579 82.60 intron 3  
51350709 51350817 109 69.70 intron 3  
51351270 51351379 115 73.00 intron 3  
51351484 51351769 288 82.30 intron 3  
51351824 51351919 96 71.90 intron 3  
51352019 51352113 100 72.00 intron 3  
51353502 51353601 100 70.00 intron 3  
51353752 51353848 101 70.30 intron 3  
51353901 51354358 472 71.40 intron 3  
51354600 51354837 241 69.70 intron 3  
51356319 51356538 223 80.70 intron 3  
51356636 51356735 100 71.00 intron 3  
51357587 51357817 235 74.00 intron 3 rs17597926 
51359367 51359610 249 74.30 intron 3  
51359698 51359797 100 71.00 intron 3  
51359912 51360009 100 70.00 intron 3  
51360249 51360339 94 72.30 intron 3  
51361436 51362227 801 83.40 intron 3  
51362427 51362531 105 72.40 intron 3  
51363351 51363456 109 69.70 intron 3  
51364846 51365123 282 86.20 intron 3  
51365412 51365556 148 69.60 intron 3  
51365958 51366251 307 69.40 intron 3  
51366319 51366708 401 79.80 intron 3  
51368799 51369023 229 80.30 intron 3  
51369581 51369684 105 71.40 intron 3  
51370876 51371166 295 81.70 intron 3  
51373371 51373618 250 71.60 intron 3  
51373812 51373949 140 73.60 intron 3  
51373954 51374456 504 91.70 intron 3  
51377314 51377813 502 79.70 intron 3  
51377977 51378356 395 75.70 intron 3  
51380267 51380399 134 72.40 intron 3  
51380443 51380546 106 71.70 intron 3  
51392245 51392430 186 70.40 intron 3  
51394439 51394534 99 70.70 intron 3  
51395534 51395816 296 71.60 intron 3  
51395843 51396467 635 80.30 intron 3  
51396822 51397329 516 76.90 intron 3  
51397474 51397687 230 70.90 intron 3  
51397734 51398621 907 80.30 intron 3  
51398696 51398969 281 71.50 intron 3  
51400459 51400937 479 79.30 intron 3  
51401085 51401219 135 68.90 intron 3  
51401326 51401499 176 71.00 intron 3  
51401752 51401863 119 69.70 intron 3  
51402302 51402699 400 71.50 intron 3  
51402713 51403034 334 71.90 intron 3  
51403062 51403255 196 69.90 intron 3  
51403342 51403508 174 74.70 intron 3  
51403582 51403731 150 79.30 intron 2  
51403815 51404078 272 76.50 intron 2  
51404129 51404341 219 80.40 intron 2  
51404452 51404761 322 75.20 intron 2  
51405004 51405273 303 72.90 intron 2  
51405366 51405366 502 80.70 intron 1  
51405840 51405974 139 68.30 intron 1  











































ID Human (hg19)  Mouse (mm9)  Expression 
 Coordinates Bracketing Genes Coordinates Bracketing Genes  

















































chromStart chromEnd name class valid func locType 
51240647 51240648 rs2958170 single by-cluster,by-2hit-2allele,by-1000genomes intron exact 
51241299 51241299 rs35586642 insertion unknown intron between 
51241402 51241402 rs10623644 mixed unknown intron between 
51241403 51241403 rs33992145 mixed unknown intron between 
51241411 51241411 rs56100102 insertion unknown intron between 
51241412 51241412 rs67607050 insertion unknown intron between 
51241646 51241648 rs71875260 deletion unknown intron range 
51241654 51241658 rs35538327 deletion unknown intron range 
51241655 51241656 rs2919445 single by-cluster,by-2hit-2allele intron exact 
51241655 51241659 rs34425939 deletion unknown intron range 
51241655 51241657 rs56336951 deletion unknown intron range 
51241657 51241658 rs72926988 single by-1000genomes intron exact 
51242057 51242058 rs9959527 single by-hapmap intron exact 
Supplementary Table V.  Expression pattern of TCF4 in human brain. Data were retrieved 







































From tissue (no strict 





















1 to 408091 










20 158 mandible, pooled (81), 
brain (26), eye (10), 
germinal center B cell (9) 










47400 to 413697 




18 24 brain (4), B cells (ramos 
cell line) (2), frontal 









  18 4 embryonic stem cells, 
embryoid bodiesderived from 
H1, H7 and H9 cells (2), B 
cells (ramos cell line) 
















16 7 brain (3), neuroblastoma, 
cell line (2), dorsal root 
ganglia (1), embryonic stem 
cells, embryoid 
bodiesderived from H1, H7 
and H9 cells (1) and 5 
other tissues 





  9 2 lymph (4) 
 
5' stop 3' stop AW575235 
AW402684 








13 61 bone marrow (12), normal 
nasopharynx (12), brain 
(9), lung (4) and 22 other 
tissues 













2 brain (2), neuroblastoma 
(2), neuroblastoma cells 
(2), whole embryo, mainly 







3' stop AL518902 
AL518903 
333407 to 408338 
jApr07 
  
  13 4 dorsal root ganglia (1), 
neuroblastoma (1) 









14 94 brain (14), whole brain 
(7), kidney (4), lung (4) 
and 53 other tissues 
5' stop  validated 
polyA  
AB209741 234177 to 408913 
lApr07 
  
  6 2 bone (1), ovary (pool of 3) 
(1), subchondral bone (1) 
no evidence
  
3' stop BM805150 
BU615862 
378533 to 408182 
mApr07    12 7 brain (2), heart (2), liver 
and spleen (2)  




47837 to 374938 
nApr07 
  
  9 2 chondrosarcoma grade II 
(1), left pelvis (1) 








  12 9 nervous normal (3), testis 
(2), amygdala (1), pooled 
human melanocyte, fetal 
heart, andpregnant uterus 




3' stop  CR933675 
DB443719 
56 to 371422 
pApr0 
  




Partial BQ435271 314288 to 381497 
qApr07 
  
  9 2 coronary artery (1), 
leiomyosarcoma cell line 
(1), uterus (1) 
no evidence Partial BG337255 
BP206418 
47829 to 360321 
rApr07 
  
  7 20 brain (11), hippocampus 
(4), amygdala (2), ovary 
(1) and 4 other tissues 
capped  Partial DB727900 232265 to 366170 




213731 to 366086 
tApr07 
  
  7 1 muscle (1), 
rhabdomyosarcoma (1) 




  9 18 brain (10), dorsal root 
ganglia (1), embryonic stem 
cells, cell lines H1, H7, 
andh9 (1), thyroid (1) and 





46218 to 304639 
vaApr07 
  
   7 1 testis (1)  5' stop Partial BG773334 155790 to 356460 
vbApr07    6 2 coronary artery (1), eye 
(1), rpe/choroid (1) 




  8 2 embryonic stem cell, 
retinoic acid andmitogen-
treated hes cell line H7 
(1), lung (1) 
5' stop  Partial CN404348 49909 to 356415 
vdApr0    5 1 testis (1) capped  Partial DB040143 81 to 171913 
veApr07 
  
  7  2 cerebrum (1), coronary 
artery (1) 
5' stop Partial BP211580 47460 to 285135 
vfApr07    7 1 cerebrum (1) 5' stop  Partial BP214032 314733 to 378655 
vgApr07    4 1  no evidence 3' stop AA394023 403453 to 408025 
vhApr07    5 1 brain (1) 5' stop 3' stop BP230382 284042 to 360379 
viApr07    6 3 brain (3) 5' stop  Partial CB155670 232329 to 366088 
vjApr07    5 3 brain (3) 5' stop  3' stop BP348534 232368 to 360368 
 
 




vkApr07    5 2 embryo, 8 weeks (1), normal 
nasopharynx (1)  
5' stop  Partial CD691430 213760 to 356477 
vlApr07    7 1 testis (1) capped  Partial DB055535 137 to 285034 








No evidence BG546663 46252 to 47319 




  1 1 whole embryo, mainly head 
(1)  




  1 1 head neck (1)  no evidence No evidence BG993333 304940 to 305222 
Supplementary Table VII, Enrichment analysis for the genes that are coexpresed with 
TCF4 in human cortex.  
 
 
Pathway p-value Network objects Genes tissue 




receptor activation of MAPK1/3 
0.001489 3/28 Alpha-2A adrenergic receptor; G-protein alpha-o; PI3K 
reg class IA (p85-alpha) 
Cortex 
G-protein signaling_Rac3 regulation 
pathway 
0.002907 2/10 ABLIM1; Neurabin-1 Cortex 
Cell cycle_Nucleocytoplasmic transport 
of CDK/Cyclins 
0.003535 2/11 GSK3 beta; Karyopherin beta 1 Cortex 
Cytoskeleton remodeling_ACM3 and 
ACM4 in keratinocyte migration 
0.004962 2/14 ACM3; G-protein alpha-o Cortex 
Development_WNT signaling pathway. 
Part 2 
0.005864 3/45 GSK3 beta; ITF2; PP2C alpha Cortex 
Cell adhesion_Synaptic contact 0,002909 6/127 CASK; GABA-A receptor alpha-1 subunit; GABA-A 
receptor alpha-2 subunit; GluR3; Neurexin 1-alpha; 
Neurexin 1-beta 
Cortex 
Reproduction_Progesterone signaling 0,006381 6/156 DYNC1I1; GABA-A receptor alpha-1 subunit; GABA-
A receptor alpha-2 subunit; GSK3 beta; NCOA3 




Supplementary Table VIII UCSC Tables used to define functional regions within TCF4.  
 
Name of the track Description 
Vertebrate Multiz Alignment & PhastCons Conservation (28 
Species)  
This track shows multiple alignments of 28 vertebrate species and two 
measures of evolutionary conservation -- conservation across all 28 
species and an alternative measurement restricted to the placental mammal 
subset (17 species plus human) of the alignment. These two measurements 
produce the same results in regions where only mammals appear in the 
alignment. For other regions, the non-mammalian species can either boost 
the scores (if conserved) or decrease them (if non-conserved). The 
mammalian conservation helps to identify sequences that are under 
different evolutionary pressures in mammalian and non-mammalian 
vertebrates. 
 
Human mRNAs from GenBank  The mRNA track shows alignments between human mRNAs 
in GenBank and the genome. 
Human ESTs Including Unspliced  This track shows alignments between human expressed sequence tags 
(ESTs) in GenBank and the genome. 
EvoFold Predictions of RNA Secondary Structure This track shows RNA secondary structure predictions made with the 
EvoFold program, a comparative method that exploits the evolutionary 
signal of genomic multiple-sequence alignments for identifying conserved 
functional RNA structures. 
Non-coding RNA Genes (dark) and Pseudogenes (light) This track shows the location of non-protein coding RNA genes and 
pseudogenes. 
FirstEF: First-Exon and Promoter Prediction This track shows predictions from the FirstEF (First Exon Finder) 
program. Three types of predictions are displayed: exon, promoter and 
CpG window.  
Vista HMR-Conserved Non-coding Human Enhancers from 
LBNL 
The VISTA Enhancer Browser identifies distant-acting transcriptional 
enhancers in the human genome by coupling the identification of 
evolutionary conserved non-coding sequences with a moderate throughput 
mouse transgenesis enhancer assay. 
TargetScan miRNA Regulatory Sites This track shows conserved mammalian microRNA regulatory target sites 
for conserved microRNA families in the 3' UTR regions of Refseq Genes, 
as predicted by TargetScanS. 
ENCODE NHGRI Elnitski Bidirectional Promoters Annotation of bidirectional promoters, using in silico approaches.  
CpG Islands (Islands < 300 Bases are Light Green) This track shows CpG islands regions. 
Eur. Inst. Oncology/J. C. Venter Inst. Nuclease Accessible Sites  The track annotates the location of NAS in the genome of human CD34+ 
and CD34- cells in the form of tags, generated by NA-Seq and obtained 
by merging NAS within 600 bp.  
Eponine Predicted Transcription Start Sites  The Eponine program provides a probabilistic method for detecting 
transcription start sites (TSS) in mammalian genomic sequence, with good 
specificity and excellent positional accuracy. 
Regulatory elements from ORegAnno  This track displays literature-curated regulatory regions, transcription 
factor binding sites, and regulatory polymorphisms 
from ORegAnno (Open Regulatory Annotation).  
SwitchGear Genomics Transcription Start Sites  This track describes the location of transcription start sites (TSS) 
throughout the human genome along with a confidence measure for each 
TSS based on experimental evidence.  
FOX2 adaptor-trimmed CLIP-seq reads  The FOX2 CLIP-seq track shows adaptor-trimmed CLIP-seq reads that 
mapped uniquely to the repeat-masked human genome (hg17). The reads 
were converted to hg18 coordinates using the UCSC LiftOver tool. Reads 
on the forward strand are displayed in blue; those on the reverse strand are 
shown in red. 
NKI Nuclear Lamina Associated Domains (LaminB1 DamID) 
Tracks 
The LaminB1 track shows a high resolution map of the interaction sites of 
the entire genome with Lamin B1, (a key NL component) in human 
fibroblasts.. 
Uppsala University ChIP-chip Tracks  This super-track combines related tracks of genome-wide ChIP-chip data 
generated by the Wadelius lab at Uppsala University, Sweden. These 
tracks display localization of two transcription factors (USF1 and USF2) 
and acetylated histone H3 (H3ac) in a liver cell line (HepG2), as assayed 
by Affymetrix arrays tiled at 35 bp resolution. For each factor, the average 
probe level intensities as well as identified positive regions are presented.  
ENCODE Transcription Factor Binding Sites by ChIP-seq from 
Yale/UC-Davis/Harvard  
 
This track shows probable binding sites of the specified transcription 
factors (TFs) in the given cell types as determined by chromatin 
immunoprecipitation followed by high throughput sequencing (ChIP-Seq). 
ENCODE Open Chromatin, Duke/UNC/UT  These tracks display evidence of open chromatin in multiple cell types 
from the Duke/UNC/UT-Austin/EBI ENCODE group. Open chromatin 
was identified using two independent and complementary methods: 
DNaseI hypersensitivity (HS) and Formaldehyde-Assisted Isolation of 
Regulatory Elements (FAIRE), combined with chromatin 
immunoprecipitation (ChIP) for select regulatory factors. Each method 
was verified by two detection platforms: Illumina (formerly Solexa) 
sequencing by synthesis, and high-resolution 1% ENCODE tiled 
microarrays supplied by NimbleGen. 
ENCODE Univ. Washington DNaseI Hypersensitivity by Digital 
DNaseI  
This track shows DNaseI sensitivity measured genome-wide in 
different cell lines using the Digital DNaseI methodology, and DNaseI 
hypersensitive sites. For each experiment (cell type) this track shows 
DNaseI hypersensitive zones (HotSpots) and hypersensitive sites (Peaks) 
based on the sequencing tag density (Signal). 
ENCODE Univ. Washington Digital DNase Genomic 
Footprinting  
This track, produced as part of the ENCODE Project, contains deep 
sequencing DNase data that will be used to identify sites where regulatory 
factors bind to the genome (footprints). 
UW Predicted Nucleosome Occupancy Tracks  This track contains predicted nucleosome occupancy scores produced by 
three different computational models. Each model can predict regions of 
high and low nucleosome occupancy, one model (MEC) excels at 
recognizing regions of low nucleosome occupancy, whereas the other two 
(A375 and Dennis) are better at recognizing regions of high nucleosome 
occupancy. 
ENCODE SUNY Albany RNA Binding Proteins by RIP-chip  This track shows expression of target RNA binding proteins (RBPs) as 
measured by RNA-binding protein immunoprecipitation-microarray 
profiling (RIP-chip) using different RIP antibodies in multiple cell lines. 
GIS ChIP-PET This track shows binding sites for p53, STAT1, c-Myc, histone 
modifications H3K4me3 and H3K27me3, as determined by chromatin 
immunoprecipitation (ChIP) and paired-end di-tag (PET) sequencing. 
ESPERR Regulatory Potential (7 Species)  This track displays regulatory potential (RP) scores computed from 
alignments of human, chimpanzee (panTro2), macaque (rheMac2), mouse 
(mm8), rat (rn4), dog (canFam2), and cow (bosTau2). 
RP scores compare frequencies of short alignment patterns between 
known regulatory elements and neutral DNA. 
HMR Conserved Transcription Factor Binding Sites  This track contains the location and score of transcription factor binding 
sites conserved in the human/mouse/rat alignment. 
Ludwig Institute/UC San Diego TAF1 Binding in Fibroblasts 
Tracks  
This super-track combines related tracks of genome-wide ChIP-chip data 
generated by the Ludwig Institute/UC San Diego ENCODE group. These 
tracks show TAF1 binding in fibroblastoid (IMR90) cells as assayed by 





















Supplementary Table IX SNP within exons in TCF4 gene region (chr. 18: 49019029 – 










Consequence to transcript  
rs72496679 chr18 49036588 49095837 WITHIN_NON_CODING_GENE 
rs34573287 chr18 49085952 49085952 NON_SYNONYMOUS_CODING 
rs2271042 chr18 49086069 49086069 NON_SYNONYMOUS_CODING 
rs35691189 chr18 49102465 49102465 NON_SYNONYMOUS_CODING 
rs2278339 chr18 49120192 49120192 NON_SYNONYMOUS_CODING 
rs3764495 chr18 49166492 49166492 SYNONYMOUS_CODING 
rs984274 chr18 49190932 49190932 NON_SYNONYMOUS_CODING 
rs34395300 chr18 49190991 49190991 SYNONYMOUS_CODING 
rs35891220 chr18 49230895 49230895 SYNONYMOUS_CODING 
rs34075746 chr18 49239605 49239605 SYNONYMOUS_CODING 
rs2270950 chr18 49239778 49239778 NON_SYNONYMOUS_CODING 
rs71679147 chr18 49275215 49285157 SYNONYMOUS_CODING 
rs72918275 chr18 49279741 49279741 SYNONYMOUS_CODING 
rs9957887 chr18 49922777 49922777 MISSENSE 
rs61753467 chr18 49944955 49944955 SYNONYMOUS_CODING 
rs10584411 chr18 50049957 50049957 NON_SYNONYMOUS_CODING 
rs74180463 chr18 50049958 50049960 NON_SYNONYMOUS_CODING 
rs3729509 chr18 50049964 50049966 FRAMESHIFT 
rs60948705 chr18 50049964 50049964 FRAMESHIFT 
rs3730669 chr18 50050000 50050000 SYNONYMOUS_CODING 
rs3218778 chr18 50054337 50054337 NON_SYNONYMOUS_CODING 
rs3218785 chr18 50058216 50058218 NON_SYNONYMOUS_CODING 
rs3218788 chr18 50061120 50061120 SYNONYMOUS_CODING 
rs3218784 chr18 50061257 50061257 NON_SYNONYMOUS_CODING 
rs3218783 chr18 50063233 50063233 STOP_GAINED 
rs35830201 chr18 50063361 50063361 SYNONYMOUS_CODING 
rs11558769 chr18 50067700 50067700 NON_SYNONYMOUS_CODING 
rs35602237 chr18 50067729 50067729 SYNONYMOUS_CODING 
rs3730773 chr18 50067759 50067759 SYNONYMOUS_CODING 
rs56152401 chr18 50072250 50072250 STOP_GAINED 
rs3730823 chr18 50074032 50074032 NON_SYNONYMOUS_CODING 
rs3218786 chr18 50074206 50074206 NON_SYNONYMOUS_CODING 
rs55920515 chr18 50074207 50074207 NON_SYNONYMOUS_CODING 
rs3218787 chr18 50074289 50074289 NON_SYNONYMOUS_CODING 
rs8305 chr18 50074802 50074802 NON_SYNONYMOUS_CODING 
rs2917782 chr18 50109718 50109718 NON_SYNONYMOUS_CODING 
rs73958758 chr18 50112153 50112153 STOP_GAINED 
rs17470798 chr18 50112194 50112194 SYNONYMOUS_CODING 
rs17292725 chr18 50134886 50134886 STOP_GAINED 
rs3819129 chr18 50141022 50141022 NON_SYNONYMOUS_CODING 
rs1657904 chr18 50141120 50141120 SYNONYMOUS_CODING 
rs1657907 chr18 50142166 50142166 NON_SYNONYMOUS_CODING 
rs16958096 chr18 50142313 50142313 NON_SYNONYMOUS_CODING,SPLICE_SITE 
rs73958766 chr18 50146113 50146113 SYNONYMOUS_CODING 
rs35428499 chr18 50409545 50409545 NON_SYNONYMOUS_CODING 
rs35802037 chr18 50416121 50416121 SYNONYMOUS_CODING 
rs9947055 chr18 50416305 50416305 NON_SYNONYMOUS_CODING 
rs3764511 chr18 50697671 50697671 SYNONYMOUS_CODING 
rs9966265 chr18 50702595 50702595 NON_SYNONYMOUS_CODING 
rs73956736 chr18 50707543 50707543 NON_SYNONYMOUS_CODING 
rs34751112 chr18 50737542 50737542 NON_SYNONYMOUS_CODING 
rs1344011 chr18 50756185 50756185 SYNONYMOUS_CODING 
rs17852674 chr18 50756185 50756186 FRAMESHIFT 
rs4638673 chr18 50756260 50756260 SYNONYMOUS_CODING 
rs4294894 chr18 50756265 50756265 NON_SYNONYMOUS_CODING 
rs72928889 chr18 50756276 50756276 NON_SYNONYMOUS_CODING 
rs61743412 chr18 50760942 50760942 SYNONYMOUS_CODING 
rs8766 chr18 51046528 51046528 SYNONYMOUS_CODING 
rs71368997 chr18 51047271 51047271 SYNONYMOUS_CODING 
rs11660217 chr18 51072725 51072725 NON_SYNONYMOUS_CODING 
rs9947593 chr18 51599392 51599392 WITHIN_NON_CODING_GENE 
rs10502989 chr18 50195818 50195819 UNKNOWN 
rs16958240 chr18 50196362 50196363 UNKNOWN 





Supplementary Figure 1 Alignment of the 14 TCF4 amino acid sequences. Intron positions are 
indicated by arrows. The positions of the introns were defined by the human sequence isoform 
ENST00000398339. The predicted signal peptide domain is labeled by a purple line, the CE 
element is labeled by an orange line and the Helix-loop-helix domain is labeled by a red thick 
line. One nonsynonymous SNP (rs11660217) in isoform is indicated. 
 
 Helix-loop-helix domain 








>Chimpanzee            length = 70 
# Measure  Position  Value  Cutoff  signal peptide? 
  max. C    25       0.148   0.32   NO 
  max. Y    28       0.257   0.33   NO 
  max. S    11       0.823   0.87   NO 
  mean S     1-27    0.588   0.48   YES 
       D     1-27    0.423   0.43   NO 
# Most likely cleavage site between pos. 27 and 28: NYS-KM 
 
 
Supplementary Figure 2 SignalP-NN results for Human and Chimpanzee TCF4 sequences.  
The graphical output of SignalP-NN shows C-, S- and Y- score. The cleavage site is predicted to 








>ENSP00000381382       length = 70 
# Measure  Position  Value  Cutoff  signal peptide? 
  max. C    32       0.262   0.32   NO 
  max. Y    32       0.363   0.33   YES 
  max. S    11       0.883   0.87   YES 
  mean S     1-31    0.602   0.48   YES 
       D     1-31    0.482   0.43   YES 









































Supplementary Figure 3. SignalP-HMM result for Human and Chimpanzee TCF4 sequences.  










































Prediction: Signal anchor 
Signal peptide probability: 0.082 
Signal anchor probability: 0.591 




















































Prediction: Signal anchor 
Signal peptide probability: 0.201 
Signal anchor probability: 0.582 
Max cleavage site probability: 0.092 between pos. 31 and 32 
 
 
Supplementary Figure 4. The graphical output of TMHMM shows the probabilities for 
transmembrane, inside (i.e., cytoplasmatic), and outside (i.e., luminal or exterior) regions for 
Human and Chimpanzee TCF4 sequences. 
 
# Human-773 Length: 773 
# Human-773 Number of predicted TMHs:  0 
# Human-773 Exp number of AAs in TMHs: 3.51425 
# Human-773 Exp number, first 60 AAs:  3.46179 
# Human-773 Total prob of N-in:        0.18192 






# Chimpanze-752 Length: 752 
# Chimpanze-752 Number of predicted TMHs:  0 
# Chimpanze-752 Exp number of AAs in TMHs: 2.39919 
# Chimpanze-752 Exp number, first 60 AAs:  2.36479 
# Chimpanze-752 Total prob of N-in:        0.11716 





- Length: the length of the protein sequence. 
- Number of predicted TMHs: The number of predicted transmembrane helices. 
- Exp number of AAs in TMHs: The expected number of amino acids intransmembrane 
helices. If this number is larger than 18 it is very likely to be a transmembrane protein 
(OR have a signal peptide). 
- Exp number, first 60 AAs: The expected number of amino acids in transmembrane helices 
in the first 60 amino acids of the protein. If this number more than a few, you should be 
warned that a predicted transmembrane helix in the N-term could be a signal peptide. 
- Total prob of N-in: The total probability that the N-term is on the cytoplasmic side of the 
membrane. 
- POSSIBLE N-term signal sequence: a warning that is produced when "Exp number, first 
60 AAs" is larger than 10. 
 
Supplementary Figure 5 VISTA plot displaying TCF4 gene structure and evolutionary 
conserved regions in a comparison of human, rhesus, dog, mouse and fugu DNA sequences. 
Multi-species conserved sequences  (MCS, in red) is defined as an alignment at least 100-bp long 
and at least 70% identity. The plot used human gene and annotations as reference. The blue 






























Suplementary Figure 6 Expression Pattern of Human element [hs376], 
Position: chr18:53,089,625-53,091,079, Source: Lawrence Berkeley National Laboratory, 

























































Supplementary Figure 8 Expression of the five TCF4 probes in different tissues. Data were 




Supplementary Figure 9 Expression of 212386_at TCF4 probe in different tissues. Data were 
retrieved from BioGPS.  
 
 
 
 
